













This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
 
This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
When referring to this work, full bibliographic details including the author, title, 




Global burden of acute lower respiratory 
infection (ALRI) associated with influenza virus, 
human metapneumovirus, and human 
parainfluenza virus among children under five 
years 
 









Lay summary of thesis 
Influenza virus (IFV), human metapneumovirus (hMPV), and human 
parainfluenza virus (hPIV) are three important viruses causing acute lower 
respiratory infections (ALRI), including pneumonia and bronchiolitis. However, 
global burden estimates of hMPV-associated ALRI and hPIV-associated ALRI 
among young children are unavailable, and there are no licenced vaccines and 
approved antiviral treatment for the two viruses. Influenza virus has been the 
focus for many years. Some attempts have been made to estimate the global 
burden of influenza virus in children under five years using various types of data 
and different models over the past 10 years. The estimates for influenza virus 
vary across these studies, reflecting the methodological heterogeneity between 
studies. This thesis aims to estimate the global number of ALRI cases, 
hospitalisations, and deaths associated with the three viruses (IFV, hMPV, and 
hPIV) in children under five years.  
This thesis uses data on virus–confirmed incidence rates, hospitalisation rates, 
and in–hospital case–fatality ratios (hCFRs) from systematic literature search 
and unpublished datasets shared by collaborators in the Respiratory Virus 
Global Epidemiology Network. This thesis also uses data on pneumonia deaths 
shared by the the Demographic Evaluation of Populations and their Health 
Network and the US Influenza–Associated Pediatric Mortality Surveillance 
System, and data on care–seeking among children with pneumonia as 
measured in Multiple Indicator Cluster Surveys and Demographic and Health 
Surveys.  
This thesis estimates that globally, 9.1 million children under five years had IFV 
related ALRI infections in 2018, resulting in approximately 0.9 million 
hospitalisations and 27,400 deaths worldwide. Globally, 14.6 million children had 
hMPV related ALRI infections, resulting in 0.6 million hospitalisations and 16,100 
deaths worldwide. Approximately 29.5 million children under five years had hPIV 
 
related ALRI infections, resulting in 1.0 million hospitalisations and 53,000 
deaths worldwide. Age–stratified estimates show that infants had higher 
hospitalisation rates than older children, and 45–61% of the hospitalisations 
(varying by viruses) occurred among infants under one year old. Children in 
low– and lower middle–income countries had higher hCFRs than other 
countries.  
These estimates demonstrate that globally, IFV, hMPV, and hPIV contribute to 
7%, 11%, and 21% of ALRI cases and contribute to 3%, 2%, and 7% deaths due 
to ALRI in children under five years. This thesis uses data on cause of child 
ALRI death from Child Health and Mortality Prevention Surveillance Network in 
sensitivity analysis for mortality estimation. Additional data on incidence rates, 
hospitalisation rates, and hCFRs of virus–confirmed ALRI by narrow age groups 
would refine the estimates. Using existing influenza surveillance systems and 
new surveillance systems may help improve the availability of data on hMPV 
and hPIV disease burden (especially hospitalisations) and the activity of the two 
viruses. Virus–ALRI mortality estimates would be refined by improving the viral 
etiologic diagnosis in children who die from ALRI outside hospital inpatient 
services. Ongoing and new post–mortem surveillances would help refine the 
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Abstract  
Introduction 
Acute lower respiratory infection (ALRI) is one of the leading causes of mortality 
in children under five years. Although childhood ALRI mortality has substantially 
reduced over the past 15 years, continued progress will in part depend on 
targeted prevention and treatment against important pathogens in future. 
Influenza virus (IFV), human metapneumovirus (hMPV), and human 
parainfluenza virus (hPIV) are three important viruses causing childhood ALRI. 
However, global burden estimates of hMPV-associated ALRI and hPIV-
associated ALRI among young children are unavailable, and there are no 
licenced vaccines and approved antiviral treatment for the two viruses. Over the 
past 10 years, several studies have estimated the global burden of influenza 
virus in young children using different types of data and different models. The 
estimates varied between these studies, partly reflecting the differences in 
analytical models between studies. This thesis aimed to estimate the global and 
regional ALRI morbidity and mortality associated with the hMPV and hPIV, and 
to update the estimates for global and regional ALRI burden associated with 
IFV.  
Methods 
Systematic reviews were conducted to identify published data on IFV-
associated, hMPV-associated, hPIV-associated ALRI burden among children 
under five years. Relevant data included laboratory-confirmed incidence rates, 
hospitalisation rates, proportion positives, and in-hospital case-fatality ratios 
(hCFRs). Additionally, Respiratory Virus Global Epidemiology Network 
contributed unpublished data by finer age groups from different geographic 
locations, especially from low- and lower middle-income countries experiencing 
high childhood ALRI burden. A modified Newcastle-Ottawa Scale was used to 
assess the risk of bias in included studies. Incidence rates, hospitalisation rates, 
  iv 
proportion positives, and hCFRs of virus-associated ALRI were analysed using a 
generalized linear mixed model. The meta-estimates of incidence rates and 
hospitalisation rates were applied to United Nation 2018 population estimates to 
yield the number of cases and hospitalisations of virus-associated ALRI. The 
point estimates and uncertainty ranges were estimated using Monte Carlo 
simulation. The hospitalisations and hCFRs for virus-ALRI were combined to 
yield the estimates for in-hospital mortality. Analyses were stratified by three age 
groups (0-5 months, 6-11 months, and 12-59 months) and child mortality 
settings (low and high) where available. Data were also stratified by World Bank 
income regions and country development status. The overall virus-associated 
ALRI deaths (including both in-hospital and out-hospital deaths) were estimated 
using in-hospital mortality estimates and multiple types of data due to the 
differences in data availability for the three viruses. These data mainly included 
population-based childhood pneumonia deaths in defined catchment areas, 
care-seeking for child pneumonia, and the US influenza-associated paediatric 
in-hospital deaths and out-hospital deaths. 
Results 
Globally among children under five years, IFV was associated with 9.1 million 
(UR 6.4–13.2) ALRI cases, 854,000 (UR 514,000–1,450,000) hospitalisations, 
27,400 (UR 10,600–100,000) ALRI deaths, accounting for 7% of ALRI cases, 5–
17% of ALRI hospitalisations, and 3% of ALRI deaths. hMPV was associated 
with 14.6 million (UR 10.5-21.0) ALRI cases, 643,000 (UR 425,000–977,000) 
ALRI hospitalisations, 16,100 (UR 5,700–88,000) ALRI deaths, accounting for 
11% of ALRI cases, 4–13% of ALRI hospitalisations, 2% of ALRI deaths. hPIV 
was associated with 29.5 million (UR 19.2–46.7) hPIV–ALRI cases, 1.0 million 
(UR 0.6–1.8) ALRI hospitalisations, and 53,000 (UR 25,300–113,500) ALRI 
deaths, accounting for 21% of ALRI cases, 6–20% of ALRI hospitalisations, 7% 
of ALRI deaths. The three viruses shared several similarities in the burden 
distribution. For the three viruses, infants had higher hospitalisation rates than 
  v 
older children. About 45–61% of the virus–ALRI hospitalisations occurred 
among infants under one year old (varying by viruses). hCFRs varied by income 
regions, and children in low– and lower middle–income countries generally had 
the highest hCFRs. The differences in hCFR meta–estimates of IFV–ALRI and 
hPIV–ALRI between age groups was less obvious than hMPV–ALRI. For 
hMPV–ALRI, the hCFRs were much higher in young infants aged 0–5 months 
than older children.  
Conclusion 
These estimates show that the three viruses are associated with substantial 
burden in children under five years. Infants under one year old and children in 
low– and lower–middle income countries were disproportionately affected by 
severe infections associated with the three viruses. This thesis presented the 
new IFV–associated ALRI morbidity and mortality estimates in the era with the 
circulation of influenza A/H1N1pdm09, and the first global burden estimates of 
hMPV–ALRI and hPIV–ALRI in children under five years, by narrow age groups. 
These global and regional burden estimates should inform the development of 
targeted prevention and treatment and guide further health investment priorities 
and resource allocation. The IFV–associated burden estimates should provide 
new evidence for maternal and paediatric influenza immunisation and should 
inform future immunisation policy particularly in low– and middle–income 
countries as a national influenza immunisation programme has not been 
adopted in most low– and lower middle–income countries. Large data gaps 
exist, especially in the mortality of virus–ALRI. Continued efforts are needed to 
fill and address the data gaps to improve global burden estimates providing 
evidence for developing future prevention and treatment strategies against 
childhood ALRI.   
Global burden of acute lower respiratory infection (ALRI) associated with influenza virus, human 
metapneumovirus, and human parainfluenza virus among children under five years 
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Chapter 1 Background 
1.1. Acute lower respiratory infection 
Acute lower respiratory infections (ALRI), including bronchiolitis and pneumonia, 
are one of the leading causes of morbidity and mortality in children worldwide, 
accounting for 10% of mortality in children under five years in 2017 (WHO 
2018). Globally, there were 68–138 million ALRI cases and 5–16 million ALRI 
hospitalisations in children under five years during 2015–2016 according to 
studies (McAllister et al. 2019, Troeger et al. 2018). Infants, especially neonates, 
are at greater risk of ALRI hospitalisation and mortality compared with older 
children (Nair et al. 2013, Li Liu et al. 2016). Hypoxaemia (oxygen saturation 
below 90%) and general danger signs (i.e., difficulty in breastfeeding or drinking, 
vomiting everything, convulsions, lethargy, or unconsciousness, cyanosis, head 
nodding) are indicators of increased severity and mortality (WHO 2005a, 
Lazzerini et al. 2015). Findings from a systematic review suggest that children 
with oxygen saturation below 90% have a 5.4 fold increase in the risk of death 
from ALRI (Lazzerini et al. 2015). Among children under five years, about 11–
15% of hospitalised ALRI presented hypoxaemia (varying by age), and 25% of 
hospitalised ALRI presented with either danger signs or hypoxaemia (Nair et al. 
2013). As recommended by World Health Organization (WHO) Integrated 
Management of Childhood Illness (IMCI), the presence of a general danger sign 
indicates the need for urgent referral (WHO 2005a). Although screening and 
management of hypoxaemia was not emphasized in the guidelines, evidence 
shows that oxygen therapy and systematic screening for hypoxaemia using 
pulse oximetry can substantially reduce the risk of mortality (Floyd et al. 2015, 
Subhi et al. 2009).  
Viruses are important causes of childhood ALRI, accounting for 61% of 
hospitalised ALRI in children under five years according to one recent 
prospective, multi–country pneumonia case–control study (Pneumonia Etiology 
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Research for Child Health Study Group (PERCH) 2019). Respiratory syncytial 
virus (RSV), influenza virus (IFV), human metapneumovirus (hMPV) and human 
parainfluenza virus (hPIV) are the leading causative viruses of childhood ALRI 
(Shi et al. 2015, Benet et al. 2017, Zar et al. 2016, Pneumonia Etiology 
Research for Child Health Study Group (PERCH) 2019). ALRI caused by 
different viruses have similar symptoms, so are not distinguishable by clinical 
presentation (Ma et al. 2018). The diagnosis of a virus depends on the 
identification of the virus using laboratory tests. The advent of molecular tests 
allows us to identify traditional and emerging viruses, and improves our 
understanding of these viruses (Mahony 2008). Next sections summarise the 
key characteristics of the structure of three viruses – IFV, hMPV, and hPIV, and 
the epidemiology, prevention, and treatment of the infections associated with the 
three viruses.  
1.2. Influenza virus (IFV) 
1.2.1. Basic description of influenza virus 
Influenza viruses (IFV), belonging to Orthomyxoviridae family, are negative–
sense, single–stranded and segmented RNA viruses. There are four types: 
influenza A, B, C, and D. Influenza A and B cause clinically important disease in 
human populations (Ghebrehewet et al. 2016). IFVA are further divided into 
subtypes based on the antigenic differences of the two most important surface 
proteins: hemagglutinin (HA) and neuraminidase (NA). There have been 18 
hemagglutinin subtypes and 11 different neuraminidase subtypes described so 
far (Webster et al. 1992, Bouvier and Palese 2008, US Centers for Disease 
Control and Prevention 2017). Influenza B viruses are divided into two lineages: 
B/Yamagata and B/Victoria (Hay et al. 2001). 
IFV is constantly changing through two mechanisms – antigenic drift and 
antigenic shift (Fukuyama and Kawaoka 2011). The accumulation of mutations 
during genomic replication contributes to the minor and gradual changes in virus 
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proteins (“antigenic drift”). These changes allow the virus to evade pre–existing 
immunity and to cause reinfections and annual epidemics (Bouvier and Palese 
2008, Ghebrehewet et al. 2016). In contrast, the emergence of a new influenza 
A subtype due to a major shift in the surface proteins (“antigenic shift”) causes 
pandemics as most people have no immunity against the new subtype. The 
most recent influenza pandemic in 2009 was caused by a new influenza A 
subtype – A/H1N1pdm09, which is different from the pre–existing seasonal 
A(H1N1) virus. The new subtype has replaced the old subtype and has been 
circulating annually since the 2009 influenza pandemic (WHO 2019). 
IFV mainly spreads by infectious droplets and aerosols and replicates in 
endothelial cells in the respiratory tract (Wagner et al. 2002, US Centers for 
Disease Control and Prevention , WHO , Killingley and Nguyen-Van-Tam 2013). 
A systematic review (Lessler et al. 2009) estimated that the incubation period 
(the time between infection and symptom onset) for IFV ranged from 1 to 4 
days, with the median incubation period of 1.4 days for type A, and 0.6 days for 
type B. Virus shedding generally peaks within the first three days after illness 
onset (Lau et al. 2010). Healthy children can shed virus for up to two weeks after 
illness onset, with viral load decreasing with time. Children with weakened 
immune systems may have a longer shedding time (Carrat et al. 2008, Lau et al. 
2010). 
1.2.2. Epidemiology, prevention, and treatment 
Seasonal influenza epidemics often occur in winter and spring in temperate 
climate regions, while the seasons are less defined in subtropical or tropical 
climate regions. For temperate climate regions, seasonal influenza epidemics 
occur during October–June, with peaks around January and February in 
northern hemisphere; in southern hemisphere, seasonal influenza epidemics 
occur during May–October, with peaks around August (WHO). The circulation of 
influenza is generally low outside seasons in temperate climate regions. In 
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tropical climate regions, influenza may occur throughout a year, with one or 
multiple peaks; the timing of influenza epidemics varies across years and 
regions. The seasonality of influenza is found to be shaped by temperature and 
humidity, though the mechanism remains unclear (Lowen and Steel 2014, 
Jaakkola et al. 2014, Cherry et al. 2009, Li et al. 2019, Broor et al. 2012). The 
activity of influenza virus, especially A(H3N2), is positively associated with low 
temperature and high relative humidity according to one systematic analysis on 
the global pattern of influenza virus (Li et al. 2019). Consistent with this, another 
systematic analysis shows that seasonal influenza epidemics are associated 
with two types of environmental conditions – “cold–dry” and “humid–rainy”. In 
details, influenza activity peaks during the cold-dry season for locations with low 
level average humidity or temperature, while for locations with high level 
average humidity and temperature, the activity peaks during rainy season 
(Tamerius et al. 2013).  
Influenza A has been documented to cause several pandemics (2010, Kilbourne 
2006), and the most recent pandemic was caused by A/H1N1pdm09 during 
2009–2010. It was estimated that the 2009 global pandemic respiratory mortality 
burden in all ages was similar to seasonal influenza (Dawood et al. 2012, 
Simonsen et al. 2013). However, several studies suggest the age distribution of 
A/H1N1pdm09–associated burden differs from that of seasonal influenza. 
Several US studies found that the median age of children who died from 
A/H1N1pdm09 was higher compared with the children who died from seasonal 
influenza (Ruf and Knuf 2014). Similarly, a pooled analysis of data from 19 
countries or regions suggested the risk of hospitalisations due to A/H1N1pdm09 
was the same for 0–4 years and 5–14 years (Van Kerkhove et al. 2011). 
Influenza B viruses are less common in most seasons than influenza A viruses, 
and do not cause pandemics. The virology data from 31 countries showed that 
IFVB accounted for 23% of all influenza infections during 2000–2018, and was 
the dominant virus type in one every seven seasons (Caini et al. 2019).  
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In addition to respiratory illnesses, influenza can also cause many extra–
pulmonary complications, such as myocarditis and encephalitis (Ghebrehewet et 
al. 2016). Recently, emerging evidence shows that influenza infections are 
associated with the occurrence of acute myocardial infarction in older people 
(Steinberg et al. 2012, Barnes et al. 2015, Surtees and DeSousa 2006).  
Influenza vaccination protects people from influenza infections. The protective 
effect of influenza vaccines varies, and depends on the degree of match 
between the vaccine and circulating influenza strains, and individuals’ 
susceptibility to infection and their responses to vaccination (US Centers for 
Disease Control and Prevention). Children aged 6 months–59 months are 
recommended as one of the priority groups for seasonal influenza vaccination. 
According to systematic reviews, the efficacy of trivalent inactive influenza 
vaccine (TIV) can be 58% against laboratory–confirmed influenza infections in 
children aged 6 months to 7 years, and the efficacy can be 83% for the live 
attenuated influenza vaccine (LAIV); the included data were mostly from 
seasons with a good match between the epidemic and the vaccine strain 
(Jefferson et al. 2005, Osterholm et al. 2012, Manzoli et al. 2012). Inactive 
influenza vaccine is recommended for children aged 6 months to 2 years. 
However, the efficacy of TIV is generally low for this age group (Rolfes et al. 
2017, Jefferson et al. 2005). In a randomized trial among children of Germany 
and Finland, the MF59–adjuvant trivalent influenza vaccine (MF59 is an oil-in-
water emulsion adjuvant that arguments the immune responses) showed greater 
efficacy against laboratory–confirmed influenza infections compared with TIV 
[77% (95%CI 37 to 92) versus 11% (95%CI 58 to 89)] in young children aged 6 
months to 2 years during two seasons with a good matching (at least 85% of 
cases were caused by the vaccine-matched strains) (Vesikari et al. 2011). 
Maternal vaccination increases the level of maternal antibodies transferred to 
newborns, thus, protecting infants younger than 6 months from influenza 
infections (Marta C. Nunes and Shabir A. Madhi 2018). Maternal influenza 
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vaccination could prevent 48% of laboratory–confirmed influenza infections and 
72% of laboratory–confirmed hospitalisations in the first 6 months of life 
according to results from four trials (M. C. Nunes and S. A. Madhi 2018). Studies 
in high–income countries have shown similar effects of maternal influenza 
immunisation. Pooled analyses of data from several observational studies from 
US and UK suggested that maternal vaccine could reduce 58% of laboratory–
confirmed influenza infections and 82% of laboratory–confirmed hospitalisations 
in the first six months of life (M. C. Nunes and S. A. Madhi 2018). The degree of 
match between the vaccine and the circulating influenza strains was usually not 
reported in the included studies.  
Neuraminidase inhibitors, including inhaled zanamivir and oral oseltamivir, were 
recommended to treat children with severe infections during the 2009–2010 
influenza pandemic (WHO 2010). However, the policies on the use of 
neuraminidase inhibitors varied across countries (Muthuri et al. 2014). Zanamivir 
is indicated for people aged above five years (WHO 2010). Oseltamivir is 
licensed to treat influenza infections in young children. It is recommended that 
young children, especially those under two years, and those who are at greater 
risk of developing severe complications from pandemic influenza, should be 
treated with oseltamivir as soon as possible in the infection. Oseltamivir can 
reduce the duration of illness and lower the risk of developing otitis media 
(Malosh et al. 2017). Prompt treatment within the first 48 hours of symptom 
onset can reduce over 50% of mortality risk in children who are critically ill with 
influenza (Louie et al. 2013). For young children, vomiting is the only adverse 
effect potentially associated with the use of oseltamivir (Malosh et al. 2017).  
1.3. Human metapneumovirus (hMPV) 
1.3.1. Basic description of hMPV 
Human metapneumovirus (hMPV) was first identified in 2001 in Netherlands 
(Van den Hoogen et al. 2001). Belonging to the Paramyxoviridae family along 
Global burden of acute lower respiratory infection (ALRI) associated with influenza virus, human 
metapneumovirus, and human parainfluenza virus among children under five years 
Background  7 
with RSV, it is an enveloped, single–stranded, negative–sense RNA virus (Kahn 
2006, Schuster and Williams 2013). There are two major genetic subgroups, A 
and B, each with two minor subgroups (A1, A2, B1, and B2) (Van den Hoogen et 
al. 2004, Yang et al. 2009). Cross–protection against different strains may exist, 
but the immunity wanes over time (Principi et al. 2006, Schuster and Williams 
2013). Studies have reported hMPV reinfections in young children, usually with 
a different subgroup; reinfection is usually milder (Williams et al. 2004, Ebihara 
et al. 2004).  
Like other respiratory viruses, hMPV spreads mainly by respiratory droplets and 
secretions. The incubation period ranges from 4 to 6 days for hMPV (Lessler et 
al. 2009). Viral shedding can last one to two weeks after acute illness onset 
(Panda et al. 2014, Sarasini et al. 2006, Nina Moe et al. 2017). 
1.3.2. Epidemiology, prevention, and treatment 
In most temperate climate regions, hMPV epidemics occur in late winter and 
spring, while the timing of epidemics is more diverse in the tropics (Kahn 2006, 
US Centers for Disease Control and Prevention , Li et al. 2019, Owor et al. 
2016, Gardinassi et al. 2012, Do et al. 2011). The activity of hMPV was found to 
be significantly associated with the RSV activity in most temperate climate 
regions, with the epidemics occurring 1–2 months later than RSV (Li et al. 
2019).  The association between hMPV and RSV epidemics have been studied 
in a temporal analysis in UK (Nickbakhsh et al. 2019). This study found a 
positive interaction among hMPV and RSV activity at population level, while was 
unable to assess this interaction at host level due to the small number of hMPV 
cases. Future studies are warranted to improve the understanding of such 
interaction, for example, whether this interaction is the result of viruses’ different 
responses to certain environment conditions, including temperate and humidity, 
or their responses to population immunity dynamics, or both (Nickbakhsh et al. 
2019). The timing of hMPV epidemics can vary by years. One study in the US 
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observed that hMPV epidemics demonstrated a unique biennial pattern of early 
and late seasonal onsets, following RSV seasons (Haynes et al. 2016). Different 
subgroups of hMPV usually co–circulate, with the subgroup A2 and B2 more 
frequently detected (Aberle et al. 2010, Loo et al. 2007). One study among 
Austrian infants hospitalized with acute respiratory infections (ARI) observed a 
periodic change in the predominate subgroup – one dominating hMPV subgroup 
was displaced by another subgroup every 1 to 3 years during 1987–2008. This 
displacement might reflect the dynamics of population immunity against 
heterologous and homologous subgroups (Aberle et al. 2010). A similar finding 
was reported in one study among US children under five years with upper 
respiratory infections (URI) during 1982–2001 (Williams et al. 2006). In contrast, 
one study in Kilifi, Kenya observed that the subgroup A2 dominated solely 
through four years during 2007–2011, with the other subgroups (B2) co–
circulating in lower numbers (Owor et al. 2016). There is no consistent evidence 
about the relationship between hMPV subgroups and disease severity (Wei et 
al. 2013, Panda et al. 2014, Schuster et al. 2015, N. Moe et al. 2017). 
Being closely related to RSV, hMPV shares some similarities in clinical 
symptoms with RSV (Garcia-Garcia et al. 2017, N. Moe et al. 2017, Edwards et 
al. 2013). For example, bronchiolitis and wheezing are more commonly 
associated with hMPV compared to other viruses (Williams et al. 2004, Panda et 
al. 2014, Bosis et al. 2005). However, the age distribution of hMPV infections is 
different from RSV infections. In the community setting, the rate of hMPV 
infections is greater in children aged 6–11 months (Homaira et al. 2012, 
Edwards et al. 2013). In contrast, the age distribution of hMPV infections is more 
variable in hospital settings. The highest hospitalisation rate of hMPV respiratory 
infections was observed among 0–5 months in some studies (Edwards et al. 
2013, Homaira et al. 2016), while among 6–11 months in others (Owor et al. 
2016).  
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Currently there are no approved antiviral treatments or licenced vaccines for 
hMPV infections (Luoto et al. 2016, Panda et al. 2014). Supportive care is 
provided to relieve the symptoms caused by severe infections. Some strategies 
have been tested in vitro and in animal models for the treatment and control of 
hMPV infections, such as antiviral (ribavirin), polyclonal antibody, monoclonal 
antibody, and fusion inhibitors (Panda et al. 2014, Wen and Williams 2015). 
Ribavirin and intravenous immunoglobulin have been administered to patients 
with severe hMPV infections (Wen and Williams 2015). Several types of hMPV 
vaccine candidates have been developed and tested in animal models, such as 
inactivated vaccines, subunit vaccines, and live–attenuated vaccines. 
Inactivated vaccines have been reported to cause enhanced disease after 
hMPV infections. Subunit vaccines can induce immune responses, but the 
responses wane quickly over time (Shafagati and Williams 2018). Live–
attenuated vaccines have showed promise in animal models by inducing high 
titres of neutralizing antibodies that protected against hMPV challenge (Wen and 
Williams 2015). A live–attenuated recombinant hMPV vaccine has been 
assessed in a recent phase I clinical trial, though the results showed that the 
vaccine was over–attenuated for children aged 6–59 months (San Mateo et al. 
2017).  
1.4. Human parainfluenza virus (hPIV) 
1.4.1. Basic description of hPIV 
Human parainfluenza virus (hPIV) was first identified in children in the 1950s 
(Chanock and Parrott 1965). hPIV belongs to the Paramyxoviridae family, 
together with RSV and hMPV (Bennett et al. 2014). There are four predominant 
serotypes (hPIV–1 to hPIV–4) causing disease in human population, divided into 
Respirovirus (hPIV–1 and hPIV–3) and Rubulavirus (hPIV–2 and hPIV–4) 
genera. There are two major subtypes of hPIV–4 (hPIV–4A and hPIV–4B) 
(Henrickson 2003). Parainfluenza virus 5 cause diseases in cattle, but not in the 
Global burden of acute lower respiratory infection (ALRI) associated with influenza virus, human 
metapneumovirus, and human parainfluenza virus among children under five years 
Background  10 
human population (Y. Liu et al. 2015). Like other respiratory viruses, hPIV 
spreads by respiratory droplets. According to a systematic review, the incubation 
period for hPIV ranges from 2 to 6 days, with a median period of 2.6 days 
(Lessler et al. 2009). Infected children can shed virus from 3–4 days before the 
onset of symptoms to 10 days past; the period can be longer for hPIV–3 
(Henrickson 2003). Reinfections have been described in children, reflecting 
waning immunity (Glezen et al. 1984, Henrickson 2003). 
1.4.2. Epidemiology, prevention, and treatment 
HPIV epidemics are mostly in spring and early summer in northern and southern 
hemispheres, with a longer duration (6–7 months) of epidemics than IFV and 
hMPV (Li et al. 2019). The seasonal patterns of hPIV vary by serotypes. HPIV–3 
is the most frequent serotype; increased activity has been seen in spring, 
summer, and autumn. HPIV–1, hPIV–2, and hPIV–4 are less frequent, and their 
seasonality is less defined (Henrickson 2003, US Centers for Disease Control 
and Prevention 2015, Abedi et al. 2016, Liu et al. 2013, Mizuta et al. 2013). In 
tropics, hPIVs can circulate throughout the year (Morgan et al. 2013, Fé et al. 
2008, Khor et al. 2012).  
The age distribution and clinical manifestations vary by hPIV serotypes. HPIV–3 
tends to infect young infants (i.e., under 6 months) while hPIV–1 and hPIV–2 
tend to infect older children (1–3 years). ALRI can be caused by all serotypes, 
but more frequently caused by hPIV–3. HPIV–1 and HPIV–2 are common 
causes of croup (Henrickson 2003, Liu et al. 2013, Weinberg et al. 2009, Abedi 
et al. 2014). It is believed that hPIV–4 usually causes mild illness in children, 
and partly because of this perception, hPIV–4 is rarely included in the routine 
respiratory virus detection (Aguilar et al. 2000, Lau et al. 2005). However, 
several studies from different populations have showed hPIV–4 is more frequent 
than hPIV–2 among children hospitalised with respiratory infections (Maykowski 
et al. 2018, Frost et al. 2014, Xiao et al. 2016, Linster et al. 2018). Inconsistent 
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findings were reported on the association between severity and different hPIV 
serotypes (Maykowski et al. 2018, Frost et al. 2014, Xiao et al. 2016, Linster et 
al. 2018).  
Like hMPV, there are no specific antiviral treatments or licenced vaccines for 
hPIV infections currently. The development of hPIV vaccines has started since 
1960s. Cross protection between different serotypes is minimal and short–lived 
(Branche and Falsey 2016). Currently, most research has been focused on 
hPIV–3 vaccines, which is the predominant serotype and the serotype most 
commonly detected in children with pneumonia. Three hPIV–3 candidate 
vaccines have been assessed or are currently under assessment in phase I and 
phase II clinical trials among children (rHPIV3rcp45, rB/HPIV3, and MEDI–534), 
and two have demonstrated safety and immunogenicity in seronegative children 
older than 6 months (Karron et al. 2011, Bernstein et al. 2011, Bernstein et al. 
2012). Moreover, studies show that a 3 dose–schedule (2 doses administrated 2 
months apart) can increase the antibody levels of recipients following each dose 
(Bernstein et al. 2011, Bernstein et al. 2012). A longer interval between doses (2 
doses administrated 6 months apart) can boost the antibody titres in the 
recipients with a suboptimal response after the prior dose (Englund et al. 2013). 
A few vaccines against hPIV–1 and hPIV–2 infections are now in phase I clinical 
trials in children (Karron et al. 2014, Adderson et al. 2015, Schmidt et al. 2011).  
1.5. Risk factors 
There are a wide range of risk factors associated with greater rates of ALRI, 
increased disease severity, and an increased risk of death from ALRI. Child 
related factors include younger age (under 6 months), prematurity, malnutrition, 
low birthweight, lack of exclusive breastfeeding, and immunodeficiency (Sonego 
et al. 2015, Jackson et al. 2013, Rudan et al. 2008, Rudan et al. 2013). In 
addition, there are socioeconomic, environmental and healthcare–related 
factors, such as low maternal education and low socioeconomic status, 
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crowding, passive smoking, indoor air pollution, incomplete immunization, 
access to care, and quality of care (Sonego et al. 2015, Rudan et al. 2008, 
Jackson et al. 2013). The presence of chronic underlying diseases has also 
been reported to increase the risk of death from ALRI in children (Sonego et al. 
2015).  
For specific pathogens, studies have been focused on the risk factors of RSV– 
and IFV–associated ALRI (T. Shi et al. 2015). Younger age (under 2 years), a 
history of prematurity, immunodeficiency, the presence of specific comorbidities 
(e.g., chronic respiratory disease, chronic cardiac disease, and compromised 
immune status) are  important risk factors related to severe influenza infections 
in children (WHO Strategic Advisory Group of Experts on Immunization 2012, 
Gill et al. 2015). 
Few studies have assessed the risk factors for hMPV– or hPIV–specific 
infections in children. Similar to all–cause ALRI, the presence of underlying 
chronic diseases (e.g., chronic respiratory and cardiac disease) are related to 
greater rates of hMPV– and hPIV–respiratory infections, and increased severity 
among infected children (Hahn et al. 2013, Cohen et al. 2015, Papenburg et al. 
2012, Principi and Esposito 2014, Henrickson 2003, Schuster and Williams 
2013, Madhi et al. 2007, Maykowski et al. 2018, Mullins et al. 2004). Several 
studies show that prematurity is an important risk factor for hMPV infections in 
children. Prematurity is associated with greater hMPV respiratory 
hospitalisations. In a 7–year prospective study of Spanish children hospitalised 
with ALRI, hMPV was more frequently detected in preterm children than in term 
children (P–value <0.05), while the difference was not significant for IFV or RSV 
(Garcia-Garcia et al. 2015). Similar findings were also reported in other 
prospective studies (Edwards et al. 2013, Papenburg et al. 2012). Moreover, 
hMPV–infected children with a history of prematurity are more likely to need 
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supplemental O2, to have subcostal retractions, and to stay longer in hospitals 
compared with those without (Pancham et al. 2016).  
The association of human immunodeficiency virus (HIV) infections and hMPV 
and hPIV infections has been studied in African population. In a prospective 
severe acute respiratory infection (SARI) surveillance in South Africa, the 
hospitalisation rate of hPIV–SARI was 1.5–3.7 times greater in children with HIV 
infections compared with children without (Cohen et al. 2015). Of note, the 
greater rate of hospitalisations for viral infections does not suggest a greater 
contribution of viruses among HIV–infected children. A systematic review among 
African population did not find significant difference in the percent positivity of 
hPIV in ALRI between HIV positive and HIV negative children aged 0–5 years 
[Odds ratio (OR), 1.38 (95%CI 0.73–1.26)] (Kenmoe et al. 2019). In the same 
study, however, hMPV was detected less frequently among HIV positive children 
than HIV negative children [OR, 0.50 (95%CI 0.40–0.60)]. The lower aetiology of 
hMPV in HIV–infected children is consistent with hospitalisation data. Although 
HIV is known to be associated with greater hospitalisation rates of all–cause 
SARI, one study estimated similar hospitalisation rates of hMPV–associated 
SARI in HIV–infected and HIV–uninfected children under five years. The 
association of HIV infections and the severity of hMPV and hPIV infections is 
controversial. According to two studies, HIV–infected children had prolonged 
hospitalisations and an increased risk of death (Madhi et al. 2002, Madhi et al. 
2007). However, this association might be confounded by the greater 
prevalence of bacterial coinfections and underlying diseases in HIV–infected 
children. Another study adjusted for the presence of pneumococcal coinfection 
and other factors (age and hospital site) and did not find the association 
between HIV infections and longer hospital stays or increased risk of deaths 
from hPIV–SARI among children under five years (Cohen et al. 2015). However, 
the small number of outcomes (e.g., deaths) in this study might have limited its 
ability to detect an association.  
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Infants, especially those under six months, are more susceptible to severe 
respiratory infections and deaths from respiratory infections than older children 
(Nair et al. 2013, Zhou et al. 2012, Sachedina and Donaldson 2010, Abedi et al. 
2014, Weinberg et al. 2009, Edwards et al. 2013). The increased susceptibility is 
related to the immaturity of their immune system (Simon et al. 2015). Figure 1–1 
shows the immune response to influenza infections over the lifetime of an 
individual (Simon et al. 2015). As shown in Figure 1–1, new-borns have a 
relatively high level of immune response to influenza at birth because maternal 
antibodies are transferred to the baby across the placenta and through 
breastfeeding, providing protection in early life. However, maternal antibodies 
decay over time in infants and infants are increasingly exposed to infectious 
agents through contact . Human immune system develops gradually and 
reaches adult levels at around the 20th year.  
The duration of protection that maternally acquired antibodies may provide may 
vary depending on viruses. Natural maternal antibodies may only protect against 
influenza infections for less than one week without maternal immunisation (M. D. 
Tapia et al. 2016, Nunes et al. 2016). Similarly, maternal antibodies against 
hMPV and hPIV infections decay in the first several months of life, as shown in 
prospective studies (Fadeela et al. 2003, Sangli et al. 2001).  
Maternal antibody and the immature immune system impede active 
immunization in early life. In the presence of maternal antibodies, the protective 
immune response of young infants (e.g., the antibody response) is inhibited after 
active vaccination; in theory vaccinating infants would only be successful after 
the maternal antibody levels decline below a certain threshold (Niewiesk 2014). 
This gives rise to an important vaccination strategy – maternal immunisation, 
protecting from respiratory infections in early life. Vaccinating pregnant women 
increases the amount of antibodies in both pregnant women and newborns, and 
higher titres of maternal antibodies can protect infants for a longer duration. 
Global burden of acute lower respiratory infection (ALRI) associated with influenza virus, human 
metapneumovirus, and human parainfluenza virus among children under five years 
Background  15 
Maternal influenza immunisation can prevent around 48% of mild influenza 
infections and 20% of all–cause ALRI hospitalisations in the first 6 months of life 
(Omer et al. 2018, M. C. Nunes and S. A. Madhi 2018). The duration of 
protection conferred by maternal influenza vaccination varies between trials. 
Trivalent inactive influenza vaccine (TIV) reduced the risk of influenza infections 
throughout the first four months of life among Mali infants, while the protection 
only lasted for the first eight weeks of life in South African infants. Factors 
affecting the protection duration need to be explored. 
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Figure 1–1. The seven ages of woman and a schematic graph of the different 
arms of the immune response to influenza over the lifetime of an individual 
Upper: seven ages of women; below: different arms of the immune response. Figure from 
(Simon et al. 2015) *.  
1.6. Specimens and diagnostic tests 
Since clinical manifestations of ALRI are nonspecific, it is often difficult to 
differentiate between viral and bacterial ALRI, or to distinguish ALRI caused by 
one virus from other viruses. Thus, an accurate and quick diagnosis depends on 
the identification of a particular virus, and can inform case management in 
clinical settings. Collection of specimens in the early course of illness, collection 
of nasopharyngeal specimens, storage at an appropriate temperature, 
immediate transport to the laboratory, and detecting with a high-accuracy test 
method are critical for producing reliable test results (Ginocchio and McAdam 
2011).  
 
* Unrestricted use of the cited paper was permitted, provided the original author and source are 
credited. 
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There are many tests available for detecting IFV, hMPV, and hPIV, including 
virus culture, immunofluorescence assays, including direct fluorescent antibody 
assay (DFA) and indirect fluorescent antibody assay (IFA), molecular assays 
such as reverse transcription–polymerase chain reaction (RT–PCR), and 
influenza rapid tests. Molecular assays have been considered the best method 
because of their accuracy and rapidity in detecting viruses, and the ability to 
identify subtypes (Templeton et al. 2005, Landry 2011). Compared with 
molecular assays, other tests are less sensitive in detecting viruses, and are 
usually more affected by the specimen quality. Moreover, some tests rely on 
substantial expertise, thus the sensitivities and specificities are variable between 
laboratories (Landry 2011). The sensitivity of a test compared with molecular 
assays can vary by viruses (Mahony 2008, Ginocchio and McAdam 2011). For 
example, DFA is approximately 70–98% sensitive in detecting seasonal IFV, 
47–93% for A/H1N1pdm09, and 38–80% for hMPV compared with molecular 
assays (Jokela et al. 2010, Wolf et al. 2015, Jun et al. 2008, Aslanzadeh et al. 
2008, Landry 2011, Mahony 2008). Similarly, molecular assays are much more 
sensitive in detecting hPIV, especially hPIV–4, than cell culture and IFA (Lau et 
al. 2005, Aguilar et al. 2000).  
Respiratory specimens are usually collected from the upper respiratory tract 
rather than from the infection site (lower respiratory tract) (Ruuskanen et al. 
2011). Upper respiratory specimens, including nasopharyngeal aspirates, 
washes, and swabs are widely used in pneumonia aetiological studies. A 
nasopharyngeal aspirate is generally considered the specimen of choice for 
paediatric patients as it gathers both nasal and nasopharyngeal mucus samples. 
The use of PCR–based tests in combination with nasal–throat swab can yield a 
diagnosis with similar sensitivities to the nasopharyngeal aspirate for IFV, 
hMPV, and hPIV (Do et al. 2011, Lambert et al. 2008). A comparison between 
nasopharyngeal swab (NPS) and oropharyngeal swab (OPS) did not yield a 
consistent result for the three viruses (Kim et al. 2011). The OPS was more 
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sensitive for influenza B, hPIV–2, and hPIV–3, while less sensitive for influenza 
A and A/H1N1pdm09; the two specimens did not differ significantly for hMPV 
and hPIV–1. Lower airway specimens, including sputum, transtracheal aspirate, 
bronchoalveolar lavage, and lung puncture, have the advantage for establishing 
a diagnosis because they are from the infection site. However, there are some 
potential problems with lower respiratory specimens, such as the contamination 
of these specimens and safety issues (Ruuskanen et al. 2011, Turner et al. 
2012, Hammitt et al. 2012). 
1.7. Co–infections and super–infections 
Viral co–infections are common in children, while the clinical significance of viral 
co–infections is unclear. The association between viral co–infections and 
disease severity is unclear. Viral co–infections are not associated with increased 
severity of respiratory infections according to one systematic review of children 
under 18 years with ARI (Scotta et al. 2016). In contrast, viral co–infections 
might increase the mortality risk among children hospitalised with ARI as 
revealed from another systematic review; this finding, however, was based on 
only one study with a high risk of bias (Asner et al. 2014).  
The interaction of viruses and bacteria has been explored in different types of 
studies. These studies include animal models, time–series analyses 
investigating the temporal association between viral and bacterial infections, and 
clinical trials assessing the impact of pneumococcal conjugate vaccine on viral 
respiratory hospitalisations in children (Lee et al. 2016, McCullers 2014, 
Kukavica-Ibrulj et al. 2009, Madhi et al. 2006, Grijalva et al. 2014, Ampofo et al. 
2008, Li et al. 2018, Madhi and Klugman 2004). Primary viral infections can 
increase the susceptibility of secondary bacterial infections through complex 
mechanisms at the host level, such as facilitating the adherence and invasion of 
bacteria and inhibiting host immunity, as well as lead to increased bacterial 
transmission at the population level (McCullers 2014, Mina and Klugman 2014). 
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Super–infections of bacteria, especially Streptococcus pneumoniae, can cause 
severe infections and even deaths (Mina and Klugman 2014, Seki et al. 2014, 
2009, Madhi and Klugman 2004, Madhi et al. 2007, Madhi et al. 2006, Klugman 
et al. 2018, Simonsen et al. 2011).  
1.8. Advantages and general issues of data on laboratory–
confirmed viruses 
Laboratory–confirmed data record the number of cases that are tested positive 
for viruses and are important data sources for burden estimation. However, 
several issues should be considered when analysing and interpreting the data. 
One case–control study of acute respiratory infection in Netherlands found that 
respiratory viruses were detected in 19% of people without respiratory 
symptoms, and no viruses were detected in 50% of people with acute 
respiratory infections (van Gageldonk-Lafeber et al. 2005). This finding 
highlights several issues related to analysing and interpreting data on laboratory 
– confirmed viruses. First, the carriage of pathogens in the upper respiratory 
tract is common in healthy children or in children with mild upper respiratory 
infections, and it is challenging to establish the causality between the pathogen 
identified in the upper respiratory specimens and ALRI. As revealed from recent 
prospective multi–country ALRI case–control studies and a systematic review,  
the presence of IFV, hPIV, and hMPV in upper respiratory specimens was 
significantly associated with ALRI hospitalisation among children under five 
years (Shi et al. 2015, Benet et al. 2017, Pneumonia Etiology Research for Child 
Health Study Group (PERCH) 2019). Results from recent pooled analyses 
suggested that 80–98% and 73–91% of hospitalised IFV– and hMPV–positive 
ALRI cases could be attributed to the two viruses at the population level; the 
aetiological fraction could vary by hPIV serotypes, with 87% for hPIV–1, 62–85% 
for hPIV–3, 43–62% for hPIV–4, unclear for hPIV–2 (Shi et al. 2015, Benet et al. 
2017, Pneumonia Etiology Research for Child Health Study Group (PERCH) 
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2019). Second, the aetiological fraction of each virus is complicated by the 
presence of multiple agents in a specimen. It is hypothesized that some agents 
may be bystander and innocent, while others are the causative pathogens (Shi 
et al. 2015). Consistent with this hypothesis, results from the two multi–country 
pneumonia case–control studies showed that the associations between 
pneumonia and IFV, hMPV, and hPIV appeared to be stronger after adjusting for 
the presence of other agents (viruses and bacteria), with one exception for 
hPIV–2 (Benet et al. 2017, Pneumonia Etiology Research for Child Health Study 
Group (PERCH) 2019). The results reaffirm that the three viruses are important 
causative pathogens of childhood ALRI. Third, the patients in whom no 
pathogen is identified may be caused by some pathogens that are difficult to 
detect, other pathogens that have not been studied, or pathogens that are 
missed (Woodhead 2002). A virus can cause infections while remain not 
detected for some reasons. For example, a virus can be undetectable due to the 
late collection of specimens, the inappropriate quality of specimens, and the 
poor sensitivity of a test method. Additionally, certain viruses, influenza virus for 
example, can expose individuals to secondary bacterial infections; the virus may 
stop shedding and cannot be detected when children receive care. Consistent 
with this, results from trials assessing maternal influenza immunisation reveal 
that influenza is responsible for about 20% of hospitalised ALRI in infants under 
six months, which is much higher than the estimates using laboratory–confirmed 
data (Nunes et al. 2017, Omer et al. 2018). Despite the advantage of using 
vaccine probe studies to quantify both direct and indirect role of a virus in 
causing ALRI, the conduct of these studies relies on the presence of vaccines 
targeting a virus. Burden estimation using vaccine probe studies are only 
feasible for certain pathogens, for which targeted vaccines exist. For other 
pathogens, traditional or emerging ones, burden estimates reply on laboratory–
confirmed data and/or statistical models.  
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1.9. Overview of approaches and models used to estimate global 
burden of viral respiratory infections 
Laboratory–confirmed viral ALRI incidence rate and case–fatality ratio are 
simple and straightforward statistics to derive viral ALRI morbidity and mortality 
burden. Laboratory–confirmed data are mainly from health facilities and are very 
limited in community settings. This is because specimen collection and 
laboratory diagnostic test is rarely performed if patients do not seek care or only 
seek care at certain informal care providers, such as private pharmacies, except 
for in very limited areas where aetiology studies are ongoing to identify cases 
through household visits. Even in health facilities, not all patients with respiratory 
symptoms are sampled and tested, especially deaths (Feikin et al. 2017). There 
are some reasons for the under–detection and under–representation of deaths 
in aetiology studies. Some critically ill children die prior to specimen collection. 
Moreover, critically ill children are usually not enrolled or sampled in aetiology 
studies because of parents’ refusal and the urgent need for treatment. In light of 
the challenge in systematically identifying and diagnosing infections, especially 
deaths, several statistical models have been developed. Table 1–1 summarises 





Global burden of acute lower respiratory infection (ALRI) associated with influenza virus, 
human metapneumovirus, and human parainfluenza virus among children under five years 
Background  25 
1.10. Conclusion 
Reducing mortality among children under five years is prioritised in 
Sustainable Development Goals, and the reduction needs to be accelerated 
to achieve the Sustainable Development Goals by 2030 (United Nations 
2019, Boerma et al. 2018, WHO 2005b). As one of the leading causes of 
deaths, ALRI mortality among children under five years has substantially 
decreased over the past 10 years; continued progress will partly rely on 
targeted prevention and treatment against leading pathogens in the future. 
This work focused on ALRI burden associated with IFV, hMPV, and hPIV as 
the three viruses are three leading causative pathogens of ALRI in children 
under five years. Despite the causative roles, the global burden estimates for 
hMPV–associated and hPIV–associated ALRI are unavailable, and there are 
no licenced vaccines or approved antiviral treatments for the infections. New 
global and regional estimates are of important value in generating an 
overview of the impact of a particular virus. Regular and timely updates allow 
for the assessment of emerging trends, progress, and intervention 
effectiveness; particularly for IFV, regular updates can provide evidence to 
improve pandemic influenza response. Both new and regular updated 
estimates can help guide health investment priorities and resource allocation 
(Boerma and Mathers 2015).  
Unlike hMPV and hPIV, IFV has been the focus of studies for years. Nair and 
colleagues (Nair et al. 2011) previously estimated that IFV was associated 
with 20 million cases of ALRI, one million cases of severe ALRI, and 28,000–
111,000 ALRI deaths in children under five years in 2008. After this study, 
three studies have estimated global burden of IFV–associated or IFV–
attributable ALRI in children under five years using different approaches. The 
approaches are summarised in Table 1–1. Results from two of the three 
studies suggested that IFV was associated with 870,000 ALRI 
hospitalisations, and 45,000 ALRI deaths in children under five years during 
2012–2015 (Lafond et al. 2016, Iuliano et al. 2018). The third study estimated 
about 8 million ALRI cases, 2.2 million ALRI hospitalisations, and 23,400 
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ALRI deaths were attributed to IFV in children under five years in 2017 
(Troeger et al. 2019). The difference in these estimates in part reflects the 
difference in the methodology between studies.  
One major advantage of the current report is the inclusion and analysis of 
laboratory–confirmed viral ALRI burden data, such as incidence rates, 
hospitalisation rates, and case–fatality ratios. Published data are either very 
limited in low– and middle–income countries, or mostly provide estimates for 
broad age groups, especially for case–fatality ratios. However, burden for 
finer age groups is of great relevance to the development of related policies 
and prevention and treatment strategies. The understanding of the challenge 
in data availability in published literature and the importance of the global 
burden estimates has led to important collaborations, allowing for 
improvement in methods and estimates. The Respiratory Virus Global 
Epidemiology Network, as a collaborative network on respiratory viral 
infections, has contributed data by finer age groups and years from different 
geographic locations, especially from low– and middle–income countries 
experiencing high childhood ALRI burden. In combination with the data, the 
incidence rate–based approach and the case–fatality ratio multiplier 
approach were used in the current analysis to derive the global burden of the 
three viruses. Incidence rates can be seen as the combination of two 
matched estimates from the same population: the incidence rate of total ALRI 
and the proportion of a given virus in total ALRI. In contrast, using the 
proportion–based approach, proportion estimates and ALRI burden estimates 
from different locations and time points are usually combined. Thus, the 
proportion–based approach requires an additional assumption that proportion 
data are generalizable to populations where the ALRI burden estimates are 
from, which the incidence–based approach does not require.  
. 
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Chapter 2 Objective 
The overall objective for this report is to estimate the global burden of IFV–
associated, hMPV–associated, and hPIV–associated ALRI in children under 
five years. The specific objectives are as follows.  
1. To estimate the incidence rate and the number of IFV–associated, 
hMPV–associated and hPIV–associated ALRI cases in the community 
setting;  
2. For IFV, to additionally estimate the burden of the whole spectrum of 
respiratory infections (i.e., including mild respiratory infections, severe 
infections, and deaths due to respiratory infections) associated with IFV in 
the community setting.  
3. To estimate the hospitalisation rate and hospitalisations of IFV–
associated, hMPV–associated, and hPIV–associated ALRI.  
4. For hMPV and hPIV, to additionally estimate the proportion of hMPV and 
hPIV in hospitalised ALRI cases, and use these as input data for a 
proportion–based approach to estimate the hospitalisations of hMPV–
associated and hPIV–associated ALRI.  
5. To estimate hospitalised case–fatality ratios (hCFRs) due to IFV–
associated, hMPV–associated, and hPIV–associated ALRI.  
6. To estimate the in-hospital mortality and the overall mortality (including 
both deaths occurring in hospitals and out of hospitals) due to IFV–
associated, hMPV–associated, and hPIV–associated ALRI.  
7. Where available, to estimate the hospitalisation rate and the 
hospitalisations of IFV–associated, hMPV–associated, and hPIV–
associated ALRI cases with hypoxaemia and any danger signs, or 
requiring ICU admission or mechanical ventilation. 
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Chapter 3 Standardised methods 
A standardised methodology and process was followed to estimate the 
burden of IFV, hMPV, and hPIV, from the conduct of the systematic literature 
review, identification and assembly of high–quality unpublished data, use of 
standardised case definitions, risk of bias assessment tool to the statistical 
analysis. The standardised part of the methodology is presented in this 
chapter. The term “virus” in this chapter is used to refer any of IFV, hMPV, or 
hPIV to simplify the expression. Any adaptations in the methodology for a 
particular virus, where applicable, are presented separately in the chapter for 
each virus (Chapter 4–6).  
3.1. Data source 
3.1.1. Systematic review 
Search strategy  
Systematic reviews were conducted for IFV–associated, hMPV–associated 
and hPIV–associated ALRI burden among children under five years. The 
following databases were searched: Medline (Ovid), Embase (Ovid), Global 
Health (Ovid: 1973 onwards), CINAHL, Web of Science, Global Health 
Library, and three Chinese literature databases – CNKI, Wanfang, and 
Chongqing VIP. Search strategies are in appendices (A2 and A3). To search 
the grey literature, the author additionally carried out broad searches for each 
virus through Google search. Since the literature searches were conducted 
separately, the timespan was slightly different, and the details are available in 
the chapter for each virus. No language or publication restrictions were 
applied. At least one additional reviewer did the systematic reviews for each 
virus according to PRISMA guidelines (Moher, 2009). The reviewers carried 
out the search, screened the titles and abstracts for eligibility, and extracted 
data independently. Studies in languages other than Chinese or English were 
translated into English using Google Translate. Disagreements were resolved 
by discussion or an additional reviewer.  
Inclusion and exclusion criteria 
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(1) Studies were included if they 
o reported any of the following data in children under five years: 
• incidence rates of ALRI and more severe infections with 
laboratory–confirmed virus (IFV, hMPV, or hPIV) in the 
community;  
• hospitalisation rates of ALRI and more severe infections with 
laboratory–confirmed virus (IFV, hMPV, or hPIV);  
• hospitalised case–fatality ratios (hCFRs) of ALRI with 
laboratory–confirmed virus (IFV, hMPV, or hPIV);  
• the proportion of a virus (hMPV or hPIV) in hospitalised ALRI 
cases.  
o AND reported data for at least one complete calendar year, or at least 
one full season for a particular virus in temperate climate regions; 
applicable only to incidence and hospitalisation rates. The hCFR data 
for any length of period were included. For proportion data, only data 
for complete calendar years were included.  
o AND used a clearly defined case definition for specimen collection and 
testing. 
(2) The reviewer excluded studies  
o without a clear denominator (limited to the incidence and hospitalisation 
rate data). Both denominator and numerator are required as input data of 
the meta–analysis.  
o in which a virus was not the primary outcome. In detail, studies were 
excluded if they only reported the cases tested negative for other 
pathogens, potentially excluding the co–infections between the studied 
virus and other pathogens. Studies were also excluded if they only 
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reported the co–infections between the studied virus and other 
pathogens.  
o in which the morbidity and mortality estimates were derived from 
modelling techniques (e.g., regression analysis).  
o in which infections were diagnosed based on serology alone. The author 
determined to exclude studies using serological testing alone because it 
has a very strict requirement on the timing of specimen collection (paired 
acute–phase and convalescent–phase serum specimens). Patients can 
seek care a few days after the disease onset, and the acute–phase 
antibodies may have increased at the time of specimen collection. In the 
case, serology yields results with poor sensitivity among young children 
(Sawatwong et al. 2012). 
o Only reporting nosocomial infections. 
o Only including population subgroups with high–risk conditions (e.g., 
chronic underlying diseases).  
Identification of unpublished data 
The Respiratory Virus Global Epidemiology Network has been established 
and has contributed data to the development of global burden estimates of 
ALRI and key respiratory viruses in children under five years, such as global 
burden of ALRI due to respiratory syncytial virus (2010/2015) and seasonal 
influenza virus (2008), and global hospital admissions for severe ALRI (2010) 
(Nair et al. 2013, Nair et al. 2011, Shi et al. 2017, Nair et al. 2010). Since 
2015 this  collaboration network has included more than 70 investigator 
groups working on respiratory viral infections and provided high–quality 
unpublished data to supplement the systematic review (Shi et al. 2017). 
Standardised case definitions were formulated within the network, and data 
were shared through standardised approaches (standardised data collection 
templates and case definitions) to data analysis. Other investigators with 
relevant data were also invited to contribute data and participate in the 
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analysis. The standardised case definitions are in appendices (A4). 
Generally, unpublished data from the collaboration network had a low risk of 
bias in case definition and test method compared with data from published 
literature due to the recommended use of the standardised case definition 
and the use of molecular tests. Data shared by the collaboration network 
were also checked using the eligibility criteria.  
3.2. Definitions 
A “study” was defined as a dataset at one site in one published paper or from 
one research group in the collaboration network. Studies were classified by 
case ascertainment:  
• Community–based studies with active case ascertainment: studies 
where the cases are actively identified and their respiratory specimens 
are collected through regular visits to households. Studies conducted 
in primary care facilities (e.g., outpatient departments or the offices of 
general practitioner) in high–income countries with good access to 
care are also considered as good proxies of community–based 
studies.  
• Hospital–based studies with passive case ascertainment: studies 
where the cases are identified when they are admitted into hospitals.  
We used separate standardised case definitions for community–based 
studies and hospital–based studies (Appendix A4) (Shi et al. 2017). For 
community–based studies, the 2005 WHO Integrated Management of 
Childhood Illnesses (IMCI) case definition for clinical pneumonia was used to 
define ALRI because this definition has been widely employed in most 
community–based studies, and has been widely used as an indication of the 
treatment of pneumonia (WHO 2005a). There are another two severity levels 
for community–based studies: (1) severe ALRI, defined as ALRI with chest 
wall indrawing; (2) very severe ALRI, defined as ALRI with any general 
danger signs according to 2005 WHO IMIC definition (WHO 2005a). For 
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hospital–based studies, hospitalised ALRI was defined as the physician 
diagnosed ALRI who required or was recommended hospitalisation because 
the diagnoses mostly depend on physicians’ clinical judgement. There are 
another two severity levels for hospital–based studies: (1) ALRI with 
hypoxaemia; (2) very severe ALRI cases, defined as hospitalised ALRI with 
any general danger signs according to 2005 WHO IMCI definition (WHO 
2005a), admitted into intensive care units (ICUs), or requiring mechanical 
ventilation (MV). The relationship between outcomes is shown in the figures 
below. In brief, the strata of less severe cases include the strata of more 
severe cases. 
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3.4. Statistical analysis 
Generally, standardised analysis (e.g., data preparation and analysis) was 
conducted for IFV, hMPV, and hPIV, with certain adaptations for each virus due 
to the difference in data availability. The part of standardised analysis is 
presented in this chapter, and any adaptation is presented in Chapter 4–6. A 
simplified process for the burden estimation is presented in Figure 3–2. All 
analyses were done in R version 3.5.2, particularly the metafor package (R Core 
Team 2018, Viechtbauer 2010). The characteristics of individual studies were 
summarised and are available in the Appendix (A19). Results from sensitivity 
analysis are available in the Appendix (A8–12, 14, 16). 
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Figure 3-2. A schematic figure showing the process to estimate global burden of virus–associated ALRI in children 
under five years. 
“Virus” denotes any of influenza virus, human metapneumovirus, and human parainfluenza virus. This figure summarises the approach for 
each outcome, and shows how they relate to each other. Global hospitalisations for virus–ALRI were estimated by applying virus–ALRI 
hospitalisation rates to population estimates. Virus–ALRI in–hospital deaths were developed on hCFRs of virus–ALRI and the virus–ALRI 
hospitalisations. The overall mortality of virus–associated ALRI was modelled through two routes: (1) applying a multiplier (“inflation factor”) 
to the in–hospital mortality; (2) applying the percent of a virus in ALRI deaths to total ALRI mortality. Different approaches and data were 
utilised to yield the results in the two routes. ALRI: acute lower respiratory infection. hCFR: hospitalised case–fatality ratio.  
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3.4.1. Data preparation 
Data validation and exclusion of duplicate records 
A consistency check was performed for unpublished data using information in 
the standardised data collection template. For example, the subtype cases (or 
deaths) should add up to the number of virus–confirmed cases (or deaths) 
unless there are co–infections between subtypes. The reported annual percent 
of virus–confirmed ALRI cases should match with the monthly counts of ALRI 
cases and tested cases. A plausibility check was performed on the number of 
cases between severity levels; by definition, the number of cases in the less 
severe outcome strata should be greater than the number of cases in the more 
severe outcome strata, as the more severe strata is a subset of the less severe 
strata. For example, the number of hospitalised ALRI cases should be greater 
than the number of hospitalised ALRI cases with hypoxaemia. Any issues were 
resolved through discussion with researchers from individual sites who had 
compiled the data.  
Duplicate data were defined as multiple datasets from an identical group of 
population (e.g., in the sense of age, location, time). The procedure to deal with 
duplicate data was to include either the more detailed dataset (e.g., stratified by 
finer age groups) or the more recent version.  
Data scaling 
Not all the eligible cases (e.g., children with ALRI symptom) were sampled or 
tested. To avoid underestimation caused by the under–detection, a commonly 
used method is to scale the case number (numerator) when estimating 
incidence and hospitalisation rates for a certain virus. The adjusted case number 
is equal to the observed case number dividing by the proportion of tested cases 
(Formula 3–1). In this thesis, however, the population at risk (denominator) was 
scaled based on levels of testing, and the adjusted denominator and the 
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observed case number was the input data of the meta-analysis (Formula 3–2). 
Data were not adjusted when data on levels of testing was unavailable. The 
rates derived from the two formula are the same. Formula 3–2 was chosen in 
this thesis because compared with the original denominator, the scaled 
denominator better reflects the size of study sample and the precision of each 
study.  
Formula 3–1 – scaling the case number:  
Rate = (No. of observed cases Proportion of testing⁄ ) Original denominator⁄  
Formula 3–2 – scaling the denominator (used in this thesis): 
Rate = No. of observed cases (Proportion of testing ∗ Original denominator)⁄  
Using Formula 3–1, the original denominator would be the input data of meta–
analysis, while in Formula 3–2, the scaled denominator would be the input data.  
Proportion data or hCFR data were not adjusted. The input data for the analysis 
of proportion were the number of tested cases and the number of laboratory –
confirmed cases; for hCFR, the input data were the number of laboratory-
confirmed cases and laboratory-confirmed deaths.  
3.4.2. The selected age bands and the rationale 
Previous studies suggest that infants aged 0–5 months and 6–11 months tend to 
have higher hospitalisation rates and hCFRs of ALRI compared with children 
aged 12–59 months(Nair et al. 2013, Shi et al. 2017), so one of the priorities of 
this work was to estimate burden stratified by three narrow age bands – 0–5, 6–
11, and 12–59 months. However, for certain outcome it is challenging to perform 
age – stratified analyses due to the lack of data by age groups. In this scenario, 
imputation was performed to allow inclusion of data from as many studies as 
possible and avoid loss of information.  
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3.4.3. Data imputation 
To follow up and expand the preceding paragraph, it is challenging to estimate 
incidence rates by age group in the community because there are very limited 
data, especially age–stratified data, in this setting. Therefore, it was determined 
to analyse and report estimates for 0–59 months as an overall age group (not 
stratified by age) in the community. Several studies reported data for 0–11 
months, 0–23 months, and 0–35 months; to incorporate the information from 
these studies, the missing incidence rate for 0–59 months was imputed based 
on the available data in these age groups.  
The imputation was done at the study level following three steps: (1) imputing 
the denominator; (2) imputing the rate; (3) calculating the case number using the 
denominator and rate. The step (2) and (3) were skipped if the case number was 
available. The reference group referred to the age group with available rate data 
and could be one of 0–35 months, 0–23 months, and 0–11 months. When two or 
more age groups were available, the reference group was chosen in the 
following order: 0–35 months, 0–23 months, to 0–11 months.  
Details of each step of imputation were:   
• The denominator was imputed by country income regions based on the 
probability of dying between age n and n+x (nqx) for both sexes in 2013, 
obtained from WHO life tables (World Health Organization, 2017). The 
proportion of total under–five population that are in the reference age 
group was calculated using the nqx estimates (World Health Organization, 
2017). Using this proportion and the denominator in the reference group, 
the denominator for 0–59 months was estimated. Since the nqx is only 
available for 0–11 months and 12–59 months, one assumption is that the 
probability of dying is the same from 12 to 59 months (this assumption is 
only required when using 0–23 months and 0–35 months as the 
reference group). Another assumption is that the structure of population 
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under five years for each site is similar to the population structure for the 
corresponding country income region.  
• The case number was imputed using a multiple imputation approach 
assuming the rates for 0–59 months were missing at random (Sterne et 
al. 2009). Figure 3–3 shows the process. First, meta–analysis was 
performed to estimate the rate ratios between 0–59 months and any of 0–
11 m, 0–23 m, and 0–35 m (meta–analysis was only done when there 
were three or more studies). Second, the pooled rate ratio was assumed 
to follow a log–normal distribution, and 100 samples of rate ratios were 
simulated. Third, 100 samples of rates for 0–59 months were generated 
based on the rate in the reference group and the corresponding rate 
ratios. Fourth, case numbers were calculated using the denominator and 
imputed rates. Using the method, 100 datasets of imputed case numbers 
were generated. Fifth, meta–analysis was done for each dataset, and the 
meta–estimates were combined together using the Rubin’s rules (Rubin 
1987, Honaker et al. 2011). 
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3.4.4. Meta–analysis 
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3.4.5. For each outcome, the numerator and the denominator were 
extracted from individual studies as they were reported, or were 
calculated using available data. In light of the differences in 
methodology (e.g., the adjustment of healthcare utilisation, case 
definition, sampling strategy, test methods),  population 
epidemiology (e.g., child health condition), access to care and case 
management between studies, heterogeneity between studies was 
anticipated for each outcome, and a generalised linear mixed 
model was used to estimate the incidence rates, hospitalisation 
rates, proportions, and hCFRs of virus–associated ALRI. Compared 
with the classic random–effect model, this model has an advantage 
in analysing small studies and studies with few events, and does 
not require adding a continuity correction in case of zero events 
(Stijnen et al. 2010). Estimates from the generalised linear mixed 
model were compared with the estimates from the classic random–
effect model (Appendix A8). Similar to the classic random–effect 
model, the generalised linear mixed model assumes that the 
observed estimates can vary between studies due to the 
differences in epidemiology and sampling variability (within–study 
error) (Riley et al. 2011). Thus, for each study the observed effect is 
sampled from a distribution of the true effect, and different studies 
are assumed to have different true effects, which all follow a 
distribution. Based on this general concept, the generalised linear 
mixed model accounts for two levels of variance – within studies 
and between studies. The model decomposes the observed 
variance into within–studies and between–studies variance and 
uses them to assign weights to different studies. Since the within–
study variance depends on the study sizes, a larger study would be 
given to a relatively larger weight compared to a smaller study. In 
this way, the model generates a weighted average estimate across 
all studies. Since the study sizes were scaled based on the levels 
of testing in the meta–analysis of incidence rates and 
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hospitalisation rates, so the model takes account of differences in 
testing practice between studies. No other covariant was added in 
the meta–analysis. Stratified analyses were conducted by age 
groups and region groups. Some studies reported data for multiple 
sites, and potential dependency between the estimates from these 
sites might exist due to the use of similar methods. However, the 
limited number of studies and precision do not allow for the use of 
hierarchical analyses (e.g., three–level meta–analyses). Morbidity 
estimation 
Virus–associated morbidity burden  
To estimate the number of virus–associated ALRI cases and hospitalisations, 
the incidence rates and hospitalisation rates of virus–associated ALRI were 
applied to the population estimates. The population estimates for 2018 were 
used (United Nations et al. 2017). The burden and uncertainty range (UR) 
were estimated using the Monte Carlo simulation (Shi et al. 2017). In detail, 
the pooled incidence rates and hospitalisation rates from the meta-analysis 
were assumed to follow log–normal distributions. A set of 10,000 samples 
was simulated from the mean and standard error, and was multiplied by the 
population estimates to yield a new set of samples, which approximated the 
distribution of the number of cases and hospitalisations. The median value of 
the 10,000 samples and the 2.5th and 97.5th percentiles were extracted as 
the point estimate and the 95% UR.  
Stratified analysis was conducted by three non–overlapping age bands (0–5 
months, 6–11 months, and 12–59 months) and by 2018 child mortality 
settings (low; high: the median value of under–five mortality rate as the cut–
off point) for each outcome where available (United Nations Inter-agency 
Group for Child Mortality Estimation 2019). Attempts have been made to 
stratify data into four child mortality settings based on the quantile of country 
under–five mortality rates. But due to the limited number of studies in each 
age– and region–strata, it was determined to classify data into two groups. 
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For the community setting, the incidence rate for 0–59 months was estimated 
due to the small number of studies as mentioned earlier. Data were also 
stratified by country development status according to UNICEF definitions, 
World Bank income regions [low–income countries (LICs), lower–middle 
income countries (LMICs), upper–middle income countries (UMICs), and 
high–income countries (HICs)] (The World Bank). Due to the small number of 
studies in LICs, the LICs and LMICs were combined (as LMICs) when 
reporting estimates. Global results are the sum of age– and region–specific 
estimates. The numbers of cases were rounded to the nearest thousand.  
Virus–attributable morbidity burden 
As mentioned in the background chapter, the detection of a virus in upper 
respiratory specimens does not mean a causal relationship between the virus 
and the condition (i.e., ALRI). The attributable morbidity burden was 
estimated by combining the virus-associated burden estimates and the 
corresponding attributable fraction (AF). The AFs for virus–associated ALRI 
cases were calculated using data from one systematic review and two recent 
multi–country pneumonia case–control studies in children under five years 
(Shi et al. 2015, Pneumonia Etiology Research for Child Health Study Group 
(PERCH) 2019, Benet et al. 2017) .  
Sensitivity analysis 
As mentioned earlier, the global burden estimate was summed by child 
mortality settings as specified a priori in the main analysis. Other strata, such 
as World Bank income regions and country development status, are also 
commonly used when extrapolating available data to countries and regions 
without data. These stratifications, especially World Bank income regions, 
are relevant to the development and implementation of prevention and 
treatment strategy and resource allocation. The morbidity burden for each 
virus was also estimated and reported by these strata. Global burden 
estimates aggregated by these strata were reported in the sensitivity 
analysis, and were compared with the estimates from the main analysis. 
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Changes were considered non-noticeable if the 95% URs of global burden 
estimates completely overlapped, or if the change in the point values was 
10% or less.  
Moreover, available multi–year data were checked to assess how the 
incidence or hospitalisation rates of virus–associated ALRI had changed over 
years and to observe the variation between years. All studies with virus–ALRI 
incidence or hospitalisation rates over more than five consecutive years or 
seasons were eligible for this analysis. The yearly data, which were collected 
using the same methodology at the same geographical location throughout, 
were plotted by studies.  
Potentially influential studies were examined using studentised deleted 
residuals, DFFITS, and Cook’s distance (Viechtbauer and Cheung 2010). As 
summarised in the methodological paper, if the exclusion of a study leads to 
considerable changes in the fitted model, then the study is considered to be 
influential. The goal of this procedure was not to identify the “real” outliers, 
but to examine whether the meta–estimates were dependent on several 
potentially unusual studies (Viechtbauer and Cheung 2010). Any identified 
studies were compared with other studies among similar populations (e.g., 
the same or neighbouring locations) where available. The characteristics that 
might explain the “different” estimates were explored qualitatively.  
3.4.6. Virus–associated mortality estimation 
In–hospital mortality estimation 
The in–hospital deaths of virus–associated ALRI were estimated by 
combining the virus–ALRI hospitalisations and hCFR meta–estimates using 
Monte Carlo simulation (Shi et al. 2017). First, a set of 10,000 samples 
approximating the distribution of hospitalisations was generated. Second, the 
pooled hCFR was assumed to follow log–normal distributions, and 10,000 
samples for each hCFR was simulated from the mean and standard error. 
The samples of hCFR was applied to the 10,000 samples of hospitalisations 
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to yield a new set of 10,000 samples, approximating the distribution of in–
hospital mortality. 
Similar to morbidity burden, sensitivity analysis of mortality was conducted by 
different stratification scenarios. Moreover, available multi–year data were 
checked to assess how the hCFRs of virus–associated ALRI had changed 
over years. The numbers of deaths were rounded to the nearest hundred.  
Overall mortality (in– and out–hospital mortality) estimation 
(1) Main analysis 
The overall virus–associated ALRI mortality can be classified into three broad 
groups: no hospital care seeking deaths, in–hospital deaths, and post–
discharge deaths. The factor between the overall mortality and in–hospital 
mortality was defined as inflation factor in this thesis, as shown in Figure 3–5 
(Nair et al. 2013, Shi et al. 2017). The inflation factor can be associated with 
many factors: the proportion of no–hospital–care–seeking deaths is 
associated with the access to care and care seeking behaviour; the 
proportion of post–discharge deaths is associated with malnutrition and HIV 
infections (Ngari et al. 2017, Chhibber et al. 2015, Chisti et al. 2014).  
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cause ALRI deaths among children under five years. Next section is focused 
on the data source and estimation of the inflation factor and the virus–
associated ALRI overall mortality.  
(2) Main analysis – formula and data source 
Figure 3–6 shows the estimation of the inflation factor and the virus–
associated ALRI overall mortality. The data required in the analysis of the 
inflation factor are: (1) the number of total pneumonia deaths in children 
under five years among a defined population; (2) the number of deaths 
occurring in–hospitals among the same population. The eligible data were 
firstly obtained at six sites from the International Network for the 
Demographic Evaluation of Populations and their Health (INDEPTH) Network 
who had health and demographic surveillance data on defined populations; 
additional eligible data were obtained from two recently published studies 
(Sankoh and Byass 2012, Ferdous et al. 2018, Ahmed et al. 2018). 
Altogether, available data were from eight sites of six countries with high 
child mortality (Mozambique, Kenya, South Africa, Burkina Faso, Ghana, and 
Bangladesh). The median inflation factor was estimated using these data, 
and was applied to the in–hospital mortality in high child mortality settings to 
yield the overall mortality of virus–associated ALRI deaths in the setting.
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The ratio between the case–fatality of the virus–positive and virus–negative 
cases could be estimated using data from hospital–based studies, in which at 
least 90% of cases were tested. The AF in virus–associated ALRI deaths 
was estimated by adjusting accordingly on the basis of the AF in cases using 
the following formulas.  
Formula 3-3  𝐷𝑒𝑎𝑡ℎ𝑠(𝑣𝑖𝑟𝑢𝑠+) = 𝐶𝑎𝑠𝑒𝑠(𝑣𝑖𝑟𝑢𝑠+) ∗ 𝐶𝐹𝑅(𝑣𝑖𝑟𝑢𝑠+) 
Formula 3-4  
𝐷𝑒𝑎𝑡ℎ𝑠(𝑣𝑖𝑟𝑢𝑠_𝑎𝑡𝑡𝑟𝑖) = [𝐶𝑎𝑠𝑒𝑠(𝑣𝑖𝑟𝑢𝑠 +) ∗
𝐴𝐹𝑐𝑎𝑠𝑒(%)
100
] ∗ 𝐶𝐹𝑅(𝑣𝑖𝑟𝑢𝑠_𝑎𝑡𝑡𝑟𝑖) 
The Deaths (virus+) and Cases (virus+) denote the number of ALRI deaths 
and cases positive for a virus; the CFR (virus+) denotes case–fatality ratio for 
virus–positive ALRI cases. Similarly, the Deaths (virus_attri), Cases 
(virus_attri), and CFR (virus_attri) denote the deaths and cases attributed to 
the virus, and the CFRs for virus-attributed ALRI. The AFcase (%) denotes 
the AF (%) for virus–associated ALRI cases. Based on Formula 3–3 and 3–4, 
the AF (%) for virus–associated ALRI deaths could be estimated in Formula 
3–5:  




The ratio of case–fatality of virus–attributable ALRI cases to virus–positive 
cases was estimated using the formulas below (Formula 3–6 and 3–7). The 
relationship between CFR (virus_attri), CFR (virus_non–attri), and CFR 
(virus+) is shown in Formula 3–7:  
Formula 3-6 
 𝐷𝑒𝑎𝑡ℎ𝑠 (𝑣𝑖𝑟𝑢𝑠 +) = 𝐷𝑒𝑎𝑡ℎ𝑠 (𝑣𝑖𝑟𝑢𝑠_𝑎𝑡𝑡𝑟𝑖) +  𝐷𝑒𝑎𝑡ℎ𝑠(𝑣𝑖𝑟𝑢𝑠_𝑛𝑜𝑛 − 𝑎𝑡𝑡𝑟𝑖) 
= [𝐶𝑎𝑠𝑒𝑠(𝑣𝑖𝑟𝑢𝑠 +) ∗
𝐴𝐹𝑐𝑎𝑠𝑒(%)
100
]  ∗ 𝐶𝐹𝑅(𝑣𝑖𝑟𝑢𝑠_𝑎𝑡𝑡𝑟𝑖) + [𝐶𝑎𝑠𝑒𝑠(𝑣𝑖𝑟𝑢𝑠 +) ∗
100−𝐴𝐹𝑐𝑎𝑠𝑒(%)
100
]  ∗ 𝐶𝐹𝑅(𝑣𝑖𝑟𝑢𝑠_𝑛𝑜𝑛 − 𝑎𝑡𝑡𝑟𝑖) 
Formula 3-7 (transformed from Formula 3–6)        
𝐶𝐹𝑅 (𝑣𝑖𝑟𝑢𝑠 +) =
𝐴𝐹𝑐𝑎𝑠𝑒(%)
100




𝐶𝐹𝑅(𝑣𝑖𝑟𝑢𝑠_𝑛𝑜𝑛 − 𝑎𝑡𝑡𝑟𝑖) 
Global burden of acute lower respiratory infection (ALRI) associated with influenza virus, 
human metapneumovirus, and human parainfluenza virus among children under five years 
Standardised methods  52 
In Formula 3–7, the inputs for AFcase (%) were obtained from a previous 
published systematic review and two recent multi–country pooled analyses 
(Benet et al. 2017, Pneumonia Etiology Research for Child Health Study 
Group (PERCH) 2019, Shi et al. 2015). The CFR (virus_non–attri) denotes 
the CFR for the cases that were tested positive for the virus but not attributed 
to the virus. It was assumed that CFR (virus_non–attri) was equal to the CFR 
for virus–negative ALRI cases. The ratio of case–fatality of virus–positive 
cases versus virus–negative cases was estimated using data from hospital–
based studies.  
Sensitivity analysis 
The virus-attributable mortality was also estimated using data from Child 
Health and Mortality Prevention Surveillance (CHAMPS) Network (CHAMPS) 
using another approach. CHAMPS tracks the causes of under-five mortality 
and stillbirths at seven sites in Sub-Saharan Africa and South Asia since 
December 2016. The seven sites are Baliakandi and Faridpur, Bangladesh; 
Bamako, Mali; Kersa and Harar, Ethiopia; Makeni, Sierra Leone; Manhiça, 
Mozambique; Siaya and Kisumu, Kenya; Soweto and Thembelihle, South 
Africa (Salzberg et al. 2019). For the current analysis, the percent of virus-
attributable ALRI was estimated using (1) the number of all-cause ALRI 
deaths where ALRI could be anywhere in the causal pathway (underlying 
cause or condition, immediate cause or condition, co-morbid causes or 
conditions), and (2) the number of virus-ALRI deaths where virus could be 
anywhere in the causal pathway from December 2016 onward (CHAMPS). 
CHAMPS were conducted in high child mortality countries, so the estimated 
percent was applied to ALRI mortality for high child mortality settings. 
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Chapter 4 Global burden of seasonal influenza virus (IFV) 
–associated respiratory infections 
4.1. Summary 
Background 
Seasonal influenza virus (IFV) is a common cause of ALRI in young children. 
A review in 2008 showed that IFV was associated with 20 million ALRI cases 
and one million severe ALRI in children under five years globally. Influenza 
vaccination for children and pregnant women can protect young children from 
influenza infections. However, only a few low– and middle– income countries 
have adopted routine influenza vaccine for children and pregnant women. 
Most of these countries have achieved only low vaccine uptake. Moreover, in 
the 2009 influenza pandemic, a newly emergent influenza strain (i.e., 
influenza A/H1N1pdm09) replaced the pre–existing seasonal influenza A 
subtype H1N1. The influenza burden might have changed due to the 
circulation of this new subtype.  
Standardised analysis 
The regional and global burden of influenza–associated respiratory infections 
in children under five years were estimated using data from a systematic 
review of studies and additional high–quality unpublished studies. A 
generalised linear mixed model was used to combine incidence rates, 
hospitalisation rates, and hCFRs of IFV–ALRI. The IFV–ALRI cases and 
hospitalisations were estimated by applying the pooled incidence and 
hospitalisation rates to 2018 population estimates. The IFV–ALRI in–hospital 
deaths were estimated by combining hospitalisations and pooled hCFRs of 
IFV–ALRI. Analysis was stratified by severity, region, and age. In the main 
analysis, global estimates were the sum of estimates by age and by child 
mortality settings. The IFV–ALRI overall mortality was estimated using the 
in–hospital deaths and a multiplier (“inflation factor”). As presented in 
Chapter 3, in the analysis of the inflation factor in high child mortality settings, 
input data were the number of all–cause pneumonia deaths among children 
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under five years in defined catchment areas by locations of death. Input data 
from low child mortality settings are presented below. Other adaptions to the 
standardised methods are also presented below.  
The IFV–attributable burden were estimated using IFV–associated burden 
estimates and the attributable fraction (AF) for IFV–associated cases, which 
was obtained from one recent systematic review and two recent multi–
country studies, and the AF for IFV–associated deaths, which was modelled 
using the AF for IFV cases and data from the present systematic review. A 
sensitivity analysis for the IFV–attributable burden was conducted using the 
proportion of IFV–attributable ALRI deaths derived using CHAMPS data.  
Objective 
To update estimates of the global number of cases, hospitalisations, and 
deaths from IFV–ALRI in children under five years for 2018.  
4.2. Adaptation in the methods 
4.2.1. Adaptation in data source – systematic review 
(1) Timespan for systematic review of IFV 
The current systematic review of the burden of seasonal IFV–associated 
respiratory infections was conducted to update a previous systematic review 
(Nair et al. 2011). Search strategies similar to the previous search were used 
to identify studies published between 1 January 2009 and 31 December 
2018. Studies in the previous review were included. Chinese databases had 
not been searched in the previous review, so Chinese databases were 
searched to identify studies published between 1 January 1995 and 31 
December 2018.  
(2) Inclusion and exclusion criteria 
• Studies were included if they reported community incidence rates of 
the entire spectrum of respiratory infections (from mild to severe 
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infections, including influenza–like illness, ALRI, and more severe 
infections) with laboratory–confirmed IFV in children under five years.  
• Studies were excluded if they only reported the proportion of IFV 
among hospitalised ALRI cases because this measure has already 
been analysed in another systematic review (Lafond et al. 2016).  
• Studies were excluded if they only reported estimates from the 2009 
pandemic period (the year 2009 or 2009–2010 season). Studies were 
excluded if they reported combined data for the non–pandemic and 
pandemic periods, and data could not be stratified by non–pandemic 
and pandemic periods. 
There were no adaptations in the case definitions, risk of bias assessment 
tool, morbidity estimation, in–hospital mortality estimation, and virus–
attributable burden.  
4.2.2. Overall mortality of IFV–ALRI 
Main analysis 
The inflation factor and overall mortality of IFV–ALRI in countries with high 
child mortality was estimated using the standardised approach in the main 
analysis. For countries with low child mortality, the inflation factor was 
estimated using the IFV–associated mortality data from the US Influenza–
Associated Pediatric Mortality Surveillance System (US Centers for Disease 
Control and Prevention). The system reports data that are most relevant for 
estimating the inflation factor: location–specific deaths with laboratory–
confirmed IFV infections in children aged under 18 years. For our analysis, 
we extracted the number of IFV–associated paediatric deaths occurring in 
communities, emergency departments, and hospitals over 14 years during 
2004–2018 (excluding the pandemic year 2009–2010).  
Sensitivity analysis 
Global burden of acute lower respiratory infection (ALRI) associated with influenza virus, 
human metapneumovirus, and human parainfluenza virus among children under five years 
Global burden of seasonal influenza virus (IFV) –associated respiratory infections
  56 
Another two approaches (Approach IFV 2 and Approach IFV 3) were used to 
estimate the inflation factor and the overall IFV–associated ALRI mortality for 
high child mortality countries in the sensitivity analysis.  
Data required for the analysis included verbal autopsy confirmed pneumonia 
deaths in a defined catchment area and local concurrent influenza circulation 
data from severe acute respiratory infection (SARI) surveillance, both 
reported on a monthly basis. To be eligible, the number of pneumonia deaths 
were required to be at least 60 over three consecutive years. Five sites were 
identified with eligible data, including four sites in the INDEPTH Network, and 
another study conducted in Bangladesh shared by the Respiratory Virus 
Global Epidemiology Network. The estimation of the inflation factor is shown 
in Figure 4–1. 
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• The country–specific IFV–ALRI overall deaths (C in Figure 4–1) were 
estimated by applying the proportion of IFV in ALRI deaths to country 
pneumonia deaths in children under five years.  
• The country IFV–ALRI in–hospital deaths (D in Figure 4–1) were 
estimated using the country population estimate, and location–matched 
hospitalisation rate and hCFR for 0–59 months, where available (site–
matched data in two sites; country–matched data in two sites). Otherwise, 
the meta–estimates for the corresponding region where the site belongs 
to were applied to the country population estimate (one site).  
As shown in Figure 4–1, the major difference between Approach IFV 2 and 
Approach IFV 3 is how the proportion of IFV in ALRI deaths were estimated.  
Approach IFV 2 
Approach IFV 2 was similar to the model used in the previous IFV analysis 
wherein the excess pneumonia deaths during the influenza season 
compared with non–influenza–season months was associated with IFV (Nair 
et al. 2011). IFV (RSV) season was defined as any months with at least 10 
samples tested and at least 10% of tested samples being positive. Whenever 
there was an overlap between IFV and RSV season, the excess pneumonia 
deaths within influenza season were proportionately attributed to the two 
pathogens. Assumptions are (1) the number of pneumonia deaths associated 
with other circulating pathogens and factors are the same within IFV seasons 
and outside seasons (no confounding effect); (2) the degree of association 
between the virus activity and the number of virus–associated pneumonia 
deaths was the same for IFV and RSV. There were no clear influenza 
seasons in two sites in Bangladesh and Kenya, so an inflation factor could 
not be estimated using this approach. The impact of IFV or any pathogens 
varies by year. It is possible to observe negative IFV-associated pneumonia 
deaths in certain years especially in a mild IFV season because of the 
difficulty in differentiating the excess deaths in IFV seasons from the total 
deaths (Li et al. 2017). Although the point estimate of IFV-associated deaths 
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is negative, the uncertainty intervals can be wide and overlap zero. Since the 
objective of this analysis was to estimate the average impact of IFV on 
pneumonia deaths, the negative excess deaths for one particular year were 
not set to zero. 
Approach IFV 3 
The Approach IFV 3 is a new method. The number of IFV–associated ALRI 
deaths is related to the influenza activity (i.e., the proportion of IFV in ALRI 
cases), the risk of mortality from IFV–ALRI compared with the risk of death 
from non–IFV–ALRI, and the number of ALRI deaths. Influenza activity and 
the number of ALRI deaths can vary by months throughout a year. Thus, the 
number of IFV–ALRI deaths were estimated on a monthly basis using 
Formula 4–1. The risk of mortality from IFV–ALRI was considered to be 
constant throughout a year. 
Formula 4–1 
% 𝐼𝐹𝑉 𝑖𝑛 𝐴𝐿𝑅𝐼 𝑑𝑒𝑎𝑡ℎ𝑠 =  
∑ (
PropIFVi ∗ RiskDeathIFV
(PropIFVi ∗ RiskDeathIFV + (1 − PropIFVi) ∗ 1.00







In the formula, MonPNEi denotes the pneumonia deaths for the ith month, 
and PropIFVi denotes the IFV positivity for the ith month (%). The 
RiskDeathIFV denotes the risk of dying from IFV–ALRI compared with non–
IFV–ALRI: the ratio of case–fatality of IFV–ALRI cases versus non–IFV–ALRI 
cases. The hCFR of IFV–ALRI and the hCFR for non–IFV–ALRI were 
estimated using data from hospital–based studies in which at least 90% of 
cases were tested. The risk of dying from IFV compared with non–IFV–ALRI 
(RiskDeathIFV) was estimated using the two hCFRs. 
Global burden of acute lower respiratory infection (ALRI) associated with influenza virus, human 
metapneumovirus, and human parainfluenza virus among children under five years 
Global burden of seasonal influenza virus (IFV) –associated respiratory infections
  60 
4.3. Results 
During 1995–2018, 157 studies (123 new studies) were identified with data on 
community incidence of IFV–associated respiratory infections, hospitalisation 
rates, and hCFRs of IFV–ALRI. Of these studies, 57 were unpublished from the 
collaboration network and 100 were from published literature. By World Bank 
income regions, 14 studies (9%) were from LICs, 48 (31%) from LMICs, 29 
(18%) from UMICs, 62 (39%) from HICs, and four studies from multiple 
countries from mixed World Bank income regions. Figure 4–2 shows the study 
selection for the systematic review on seasonal influenza. A summary of 
included studies for each outcome are in appendix (A18).  Details of included 
studies are in Appendix A19. 
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4.3.1. The burden of IFV–associated respiratory infections in the community 
There were 38 community–based studies with data on incidence rates. These 
studies included 27 studies with data on IFV–episodes (the entire spectrum of 
respiratory infections associated with IFV), 12 studies for IFV–ALRI, 14 studies 
for IFV–severe ALRI, and 4 studies for IFV–very severe ALRI (Appendix A19).  
Incidence rates of IFV–episodes and the number of cases 
After imputation, 18 studies with incidence rates for 0–59 months were included 
in the meta–analysis. These studies were from South Africa, Australia, the US 
(two studies), Japan (two studies), Finland, Senegal (two studies), Switzerland, 
India (two studies), Vietnam, Bangladesh (two studies), Romania, Spain, and 
Nicaragua. Eight studies were from high child mortality settings; eight studies 
were from LMICs, one study from UMICs, and nine studies from HICs. Eight 
studies reported the rates for pre–2010 period. One study was identified with an 
influential incidence rate of IFV–episodes for 0–59 months. A given study is 
considered influential if the exclusion of this study leads to considerable 
changes in the meta–estimates as mentioned in Chapter 3. This study reported 
a very low incidence rate (1.4 per 1,000 children per year) of IFV–associated ILI 
cases presenting to public healthcare facilities across Romania. No other 
studies were identified with data for this outcome in Romania.  
The incidence rate meta–estimate for IFV-episodes was 175.2 (95%CI 101.5–
302.3) per 1,000 children per year for 0–59 months for high child mortality 
settings, and 42.4 (95%CI 17.1–105.0) for low child mortality settings. These 
meta–estimates translated to 88.3 million (UR 49.6–159.2) IFV–episodes 
globally in children under five years (Table 4–1). 
In sensitivity analysis, the global number of IFV–episodes for children under five 
years was 109.5 million (UR 63.1–190.6) in the stratified analysis by country 
development status (Appendix A8). There was only one study in UMICs, so it is 
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impossible to estimate the global number of IFV–episodes in the stratification by 
World Bank income regions.  
Incidence rates of IFV–ALRI and the number of cases 
After imputation, there were 12 studies with data on incidence rates of IFV–ALRI 
among children aged 0–59 months. Studies were from Australia, Finland, 
Germany, the US, India (three studies), Bangladesh (two studies), Nicaragua, 
Pakistan, and South Africa. No potentially influential studies (significantly 
affecting the combined estimates) were identified for this outcome.  
The incidence rate meta–estimate of IFV–ALRI was 15.6 (95%CI 10.3–23.6) for 
0–59 months in high child mortality settings, and 9.3 (95%CI 7.5–11.5) in low 
child mortality settings. In 2018, 9.1 million (UR 6.4 –13.2) IFV–ALRI cases were 
estimated to occur among children aged 0–59 months globally. In sensitivity 
analysis, the global number of IFV–ALRI cases was 10.1 million (UR 6.8–15.1) 
in the stratification by country development status (Appendix A8).   
Incidence rates of IFV–severe ALRI and IFV–very severe ALRI and the 
number of cases 
After imputation, there were seven studies with data on incidence rates of IFV–
severe ALRI for 0–59 months, and four studies for IFV–very severe ALRI. All 
studies were from high child mortality countries. It was estimated that there were 
1.1 million (UR 0.5–2.5) IFV–severe ALRI cases, and 0.3 million (UR 0.1–1.2) 
IFV–very severe ALRI cases among children under five years in high child 
mortality countries (Appendix A8). 
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  LMICs UMICs HICs High child 
mortality 
Low child mortality Global† 
6–11 m Studies 4 1 0 5 ··  
 Incidence 28 (23.6–33.3) ·· ·· 27.6 (23.4–32.6) ··  
 Episodes (*1,000) 1,229 (1,036–1,459) ·· ·· 1,259 (1,068–
1,485) 
·· ·· 
12–59 m Studies 4 1 0 5 ··  
 Incidence 16.7 (8.6–32.3) ·· ·· 15.6 (8.9–27.1) ··  
 Episodes (*1,000) 5,727 (2,966–11,062) ·· ·· 5,563 (3,198–
9,681) 
·· ·· 
0–59 m Studies 7 (3) 1 4 (3) 8 (3) 4 (3)  
 Incidence 14.6 (9.2–23.3) ·· 9.3 (7.5–11.5) 15.6 (10.3–23.6) 9.3 (7.5–11.5)  
 Episodes (*1,000) 6,299 (3,961–10,021) ·· 590 (477–729) 7,001 (4,647–
10,550) 
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Figure 4-3. Forest plot of non-imputed incidence rates of IFV–episodes for children aged 0–59 months by child 
mortality settings.  
Upper: low child mortality settings; below: high child mortality settings. The forest plots did not include imputed data because using the 
multiple imputation method, a group of values were imputed for each study. The pooled incidence rate point estimate in high child mortality 
settings increased after imputation. This was mainly driven by one study in Nicaragua reporting a high rate for 0–23 m (218 per 1,000 
children per year). This study was not included in the forest plot because it did not report data for 0–59 m. After imputation, rates for 0–59 m 
in this study were included in the meta–analysis.  
Global burden of acute lower respiratory infection (ALRI) associated with influenza virus, human metapneumovirus, and human 
parainfluenza virus among children under five years 
Global burden of seasonal influenza virus (IFV) –associated respiratory infections
  67 
 
Figure 4-4. Forest plot of non-imputed incidence rates of IFV–ALRI for children aged 0–59 months for high child 
mortality settings.  
The forest plot did not include imputed data because using the multiple imputation method, a group of values were imputed for each study. 
Data for low child mortality settings were not plotted because there was only one study with data for 0–59 months (non-imputed data). 
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4.3.2. IFV–associated ALRI burden in the hospital setting 
Hospitalisation rates and hospitalisations of IFV–associated ALRI 
There were 96 studies with data on IFV–ALRI hospitalisation rates, including 59 
studies with data by three narrow age bands (i.e., 0–5 months, 6–11 months, or 
12–59 months) (Appendix A19). As shown in Figure 4–5, Figure 4–6, and Figure 
4–7, the hospitalisation rates ranged from 0 to 25.1 (95%CI 21.3–29.5) per 
1,000 children per years for 0–5 months, 0.6 (95%CI 0.2–1.6) to 37.0 (95%CI 
32.7–41.8) per 1,000 children per year for 6–11 months, and 0.1 (95%CI 0–0.5) 
to 27.7 (95%CI 23.4–32.7) per 1,000 children per year for 12–59 months across 
studies. By narrow age groups three studies were identified with potentially 
outlying hospitalisation rates; no influential studies were identified. Two of the 
three studies reported the highest hospitalisation rates by age groups, one 
Chinese study (2010–2012) and one Japanese (2002–2008). Both studies 
included children hospitalised with ARI and fever, and accounted for healthcare 
utilization when estimating rates. The Japanese study used individually recorded 
person-time as the denominator to estimate rates. The third study reported a 
very low hospitalisation rate for 0–5 months (0.2 per 1,000 children per year) in 
Kamalapur, Bangladesh during 2007–2015. The hospitalisation rate of IFV–ALRI 
in children aged 0–59 months in this study were broadly similar with another 
Bangladeshi study (0.7 vs 0.4 per 1,000 children per year).  
The meta-estimate of IFV–ALRI hospitalisation rate was 2–5–fold higher in 
infants (1.5–4.7 per 1,000 children per year) than children aged 12–59 months 
(0.8–1.2 per 1,000 children per year) across World Bank income regions and 
child mortality settings (Table 4–2). There were 854,000 (UR 514,000–
1,450,000) IFV–ALRI hospitalisations among children under five years globally 
according to the analysis by child mortality settings. About 24% and 21% of the 
hospitalisations were in infants aged 0–5 months and 6–11 months, 
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respectively. An estimated 420,000 (UR 261,000–677,000) IFV–ALRI 
hospitalisations occurred in LMICs. 
The estimates of global hospitalisations of IFV–ALRI for children under five 
years ranged from 786,000 to 870,000 across different stratification groups, with 
wide and overlapping uncertainty ranges (Appendix A8).  
Hospitalisation rates and hospitalisations of IFV–associated ALRI with 
hypoxaemia and IFV–associated very severe ALRI 
An estimated 223,000 (UR 116,000–501,000) hospitalisations of IFV–ALRI with 
hypoxaemia occurred among children under five years globally, accounting for 
26% of IFV–ALRI hospitalisations (Table 4–2). For IFV–very severe ALRI, 
87,000 (UR 23,000–538,000) hospitalisations were estimated to occur in 
children under five years globally, accounting for 10% of IFV–ALRI 
hospitalisations (Table 4–2).  
hCFRs of IFV–associated ALRI and in–hospital mortality 
A total of 66 studies reported hCFRs for IFV–ALRI in children under five years, 
including 28 studies with data on three age bands. hCFRs of studies that were 
included in the main analysis are in Table 4–5. Additional details are in Appendix 
A19. The hCFR meta-estimates were highest in high child mortality settings and 
LMICs, ranging from 2.3 to 3.2% by age groups in high child mortality settings 
and from 3.2 to 8.1% by age groups in LMICs (Table 4–3). The hCFR meta-
estimates of IFV–ALRI were lower in low child mortality settings (0.4–0.8% by 
age groups). In the stratified analysis by child mortality settings, 13,000 (UR 
4,900–52,500) IFV–ALRI in–hospital deaths were estimated to occur in children 
under five years globally, with 27% and 22% among infants aged 0–5 months 
and 6–11 months, respectively. About 82% of IFV–ALRI in–hospital deaths 
occurred in LMICs (calculated in the analysis stratified by World Bank income 
regions).  
Global burden of acute lower respiratory infection (ALRI) associated with influenza virus, human 
metapneumovirus, and human parainfluenza virus among children under five years 
Global burden of seasonal influenza virus (IFV) –associated respiratory infections
  70 
In the stratified analysis by country developing status, 15,300 (UR 5,800–
43,800) IFV–ALRI in–hospital deaths were estimated to occur globally in 
children under five years. The estimate was 20,800 (UR 7,800–65,700) in the 
stratified analysis by World Bank income regions (Appendix A8).  
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Figure 4-5. Forest plot of hospitalisation rates of IFV–ALRI for children aged 0–5 months by child mortality settings.   
Upper: low child mortality settings. Below: high child mortality settings. 
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Figure 4-6. Forest plot of hospitalisation rates of IFV–ALRI for children aged 6–11 months by low child mortality 
settings.  
Upper: low child mortality settings. Below: high child mortality settings. 
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Figure 4-7. Forest plot of hospitalisation rates of IFV–ALRI for children aged 6–
11 months by low child mortality settings.  
Upper: low child mortality settings. Below: high child mortality settings.  
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Table 4-3. In–hospital case fatality ratio (hCFR) meta–estimates and in–hospital deaths in children with IFV–ALRI in 
children under five years in 2018, by World Bank income regions and child mortality settings 
  LMICs UMICs HICs Low child mortality High child mortality Global * 
 Studies † 10 11 7  11 17  
0–5 months hCFR (%)‡ 3.2 (0.6–15.4) 2.6 (0.9–7.5) 0.5 (0–4.6) 0.8 (0.1–5.6) 2.7 (1–7.2)  




100 (0–4,100) 900 (100–6500) 2600 (900–7600) 3500 (1000–
14000) 
6–11 months hCFR (%) 8.1 (4.1–15.3) 0.7 (0.1–7.4) 0.8 (0.2–3.2) 0.4 (0–7.6) 3.2 (1.1–8.5)  
 Deaths (B) 5,300 (2,400–
11,600) 
500 (0–4,700) 200 (0–900) 400 (0–16300) 2500 (800–7200) 2900 (900–
23400) 
12–59 months hCFR (%) 3.3 (1.7–6.3) 0.8 (0.3–2.2) 0.4 (0.1–2.1) 0.4 (0.1–1.5) 2.3 (1.3–3.9)  
 Deaths (C) 9,100 (4,000–
20,100) 
900 (200–3,700) 200 (0–1,300) 900 (200–3800) 5800 (2800–11600) 6600 (3000–
15300) 




600 (100–6,200)  2200 (300–26500)  10900 (4600–26200)  13000 (4900–
52500)  
 
* Global estimates were calculated by summing up estimates in three non-overlapping age groups (0–5 m, 6–11 m, and 12-59 m), and in 
developing and industrialised countries according to UNICEF definition.  
† hCFR meta-estimates were based on studies providing data for the three non-overlapping age bands.  
‡ hCFRs were estimated using generalised linear mixed models. 
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4.3.3. Overall mortality of IFV–associated ALRI 
Of the eight sites with data on pneumonia deaths in hospitals and communities 
in high child mortality settings, five sites were from rural areas, and six from 
African countries. The inflation factor ranged from 1.5 to 3.5 across the eight 
sites, with a median value of 2.2. For low child mortality settings, an inflation 
factor of 1∙6 (range 1.3–1.9 across 14 years) was estimated using the US 
paediatric IFV–associated deaths data. Using the two inflation factors, the 
overall IFV–ALRI mortality was estimated to be 27,400 (UR 10,600–100,000) in 
children under five years globally, including 23,900 (UR 10,100–57,600) in high 
child mortality settings, and 3,500 (UR 500–42,500) in low child mortality 
settings (Table 4–4). Using Approach 2 and Approach 3, the inflation factor was 
estimated to be 3.0 and 4.1, respectively (Appendix A12). Using the two 
approaches, the overall mortality point estimate could increase by 36–75%, with 
wide and overlapping uncertainty ranges (Appendix A12).  
4.3.4. IFV–attributable burden estimates 
Based on a median AF of 80% for IFV–ALRI, about 7.3 million (UR 5.1–10.6) 
ALRI cases and 683,000 (UR 411,000–1,160,000) ALRI hospitalisations could 
be attributed to IFV in children under five years (Table 4–6).  
The ratio of case–fatality of IFV–attributable cases to IFV–associated cases was 
0.9 according to eight hospital–based studies. Therefore, the AF for IFV–
associated ALRI deaths was estimated to be 72% (Table 4–5). This suggested 
that 19,700 (UR 7,700–72,000) overall ALRI deaths could be attributed to IFV 
globally, including 17,200 (UR 7,300–41,500) deaths in high child mortality 
countries (Table 4–7).  
Using CHAMPS data, the proportion of IFV–attributable ALRI deaths was 3.0% 
(95%CI 1.1–6.4) in children aged 1–59 months and 1.0% (95%CI 0.2–5.8) for 
neonates (deaths enrolled from December 2016 to December 2019). According 
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to the proportion, 20,100 (UR 8,100–53,700) ALRI deaths could be attributed to 
IFV among children under five years for high child mortality settings (Appendix 
A16).  
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Table 4-6. Estimation of the attributable fraction for IFV–associated ALRI deaths for 0–59 months.* 
Study country 
























A and C)† 
AF for virus–
associated ALRI 
deaths (=AF for 




0 1.5 1.9 (0.5–6.6) 2.8 (1.2–6.5) 1.5 0.9 72% 
South Africa; 





















* Studies were eligible for the analysis if they tested >=90% of cases and reported at least five ALRI deaths (to ensure the precision of 
estimates). 
† Detailed formulas in Chapter 3.  
‡ The AF for IFV–ALRI cases were calculated using odds ratios from one recent systematic reviews and two additional recent multi-country 
studies. The median estimate of odds ratio from the three studies was input to yield the attributable fraction for IFV–ALRI cases (80%).  
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4.4. Conclusion and discussion 
4.4.1. Implications 
The IFV-associated ALRI burden estimates suggest that IFV is associated with 
7% of ALRI cases, 5-17% of ALRI hospitalisations, and 3% ALRI mortality 
among children under five years globally (WHO 2018, McAllister et al. 2019, 
Troeger et al. 2018).  
The hospitalisation rate of IFV-ALRI was much higher in infants than older 
children. A large proportion of IFV-ALRI hospitalisations (45%) and in-hospital 
deaths (49%) occurred during infancy, with 24% of hospitalisations and 27% of 
the in-hospital deaths in infants younger than six months. The estimates of IFV-
ALRI hospitalisations are likely to underestimate the impact of influenza. 
Influenza can cause primary infections or predispose children to severe 
secondary bacterial infections while not being detected at specimen collection. 
Maternal influenza vaccination trials evaluating the vaccine efficiency against 
hospitalised ALRI might help understand the direct and indirect impact of 
influenza in causing ALRI (Nunes et al. 2017, Omer et al. 2018). Most of infant 
data in the analysis were from low- and middle-income countries with either no 
influenza immunisation policy or low influenza vaccine coverage in pregnant 
women during the study periods (Bangladesh, Guatemala, India, Kenya, 
Mozambique, South Africa, and Thailand) (Ropero-Alvarez et al. 2016, 
Kittikraisak et al. 2015, Lu et al. 2013). Findings from two trials in Mali and South 
Africa suggest that maternal influenza immunisation is an effective intervention 
against influenza infections in the first three months of age (Milagritos D. Tapia 
et al. 2016, Nunes et al. 2016). Moreover, maternal influenza immunization 
could reduce the burden of all-cause ALRI substantially due to influenza virus’ 
role in predisposing individuals to secondary bacterial infections leading to 
severe adverse outcomes (Mina and Klugman 2014). In a pooled analysis of 
three maternal influenza immunization trials — conducted in South Africa, Mali, 
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and Nepal — there was a 20% reduction in all-cause severe clinical pneumonia 
in infants under six months (Omer et al. 2018). 
The highest hCFRs were in LMICs, and 82% of the in-hospital deaths occurred 
in these countries. However, only 10% of low- and lower middle-income 
countries have had a national policy for influenza immunisation in children [13% 
for pregnant women] in 2014 (Ortiz et al. 2016). Where present there were 
mostly very low or unknown levels of vaccine coverage (Pan American Health 
Organization 2015, Members of the Western Pacific Region Global Influenza 
Surveillance Response et al. 2013, Palache et al. 2014, Hirve et al. 2016, Pan 
American Health Organization 2016). According to previous evidence, a high 
influenza vaccine coverage (about 70%) can substantially reduce influenza-
associated hospitalisations and deaths in children under five years of age 
(Rolfes et al. 2019).  
4.4.2. Meta-analysis results by different stratification groups 
For all outcomes, the main analysis stratified by child mortality settings yielded 
estimates that were similar or more conservative than other stratification groups. 
The estimated number of IFV-episodes in the main analysis was 29% lower than 
the estimate in the analysis stratified by country development status (88 vs 110 
million). The difference in the two estimates can be explained by the substantial 
variation in incidence rates between settings (e.g., developing versus 
industrialised countries; high child mortality versus low child mortality settings) 
and the different population structures in the two stratification scenarios. The 
global estimates of IFV-ALRI cases and hospitalisations were similar in different 
stratification groups. The estimate of global IFV-ALRI in-hospital deaths in the 
main analysis was broadly similar to the estimate in the stratified analysis by 
country development status, while increased by 60% in the stratified analysis by 
World Bank income regions (Appendix A8). The higher estimate in the analysis 
by World Bank income regions is mainly driven by the high hCFRs in LMICs. 
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4.4.3. Comparison with previous estimates 
As an updated systematic review, the new estimates of incidence rates of IFV–
episodes and IFV–severe ALRI for 0–59 months are generally comparable to 
the previous estimates for 2008 (Nair et al. 2011). However, a lower incidence 
rate of IFV–ALRI was estimated compared with the previous review (16 [95%CI 
10–24] vs 28 [95%CI 18–44] per 1,000 children per year) for 0–59 months in 
developing countries. In the previous review, the incidence rate of IFV–ALRI 
was only based on three studies from two sites. The updated estimate was 
refined by incorporating data from more geographically diverse areas (12 
studies) and new data with larger sample sizes achieved by multiple–season 
observation. Improved influenza vaccine uptake is not likely to be the reason for 
the lower incidence of IFV–ALRI since paediatric influenza immunization policy 
had not been introduced (Bangladesh, India, and Pakistan), or was only 
introduced in children with chronic diseases (Nicaragua); or achieved low 
coverage (South Africa) during the study periods (Ropero-Alvarez et al. 2016). 
The national PCV coverage was above 60% midway in three studies in 
Nicaragua, Pakistan, and South Africa. The increase in PCV uptake might 
contribute to the lower point value of incidence rates (International Vaccine 
Access Center (IVAC) and Johns Hopkins Bloomberg School of Public Health , 
Madhi and Klugman 2004). This explanation needs to be assessed using multi–
year aggregated data in time series analysis or using individual data. The 
reduction in IFV–ALRI incidence rates is consistent with a general decrease in 
the incidence of all–cause ALRI (McAllister et al. 2019). The updated estimate of 
IFV–ALRI hospitalisations was similar to the previous estimate (Nair et al. 2011).  
4.4.4. Long–term trend in IFV estimates, PCV introduction, and variation 
between years 
Five studies reported annual IFV–ALRI hospitalisation rates over five years or 
more with PCV introduced midway in the study period (Appendix A17). The plot 
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showed that the trend in IFV–ALRI hospitalisation rates was inconsistent across 
the five studies. In the main analyses of IFV–ALRI hospitalisations most studies 
were from post–2009 period, and hospitalisation estimates did not change after 
excluding pre–2009 data (Appendix A8). In a pooled regression analysis of the 
five studies, no significant difference in IFV–ALRI hospitalisation rates was 
found between high PCV coverage period (PCV coverage >=60%) and low 
coverage period (<60%). However, this finding needs to be interpreted with 
caution because the five studies had short observation periods (5–8 years).  
The annual IFV–ALRI hospitalisations rates varied across years across studies. 
As shown in Appendix A17, the maximum seasonal variation was 2–7–fold in 
four studies. The other study reported a high rate of IFV–ALRI of 1.4 per 1,000 
children per year in one year while a very low rate of 0.1 per 1,000 children per 
year in another year. Yearly data were aggregated to ensure sufficient study 
sizes for age– and region–stratified analysis. However, the variation between 
years cannot be incorporated in the current analysis, leading to an 
underestimation to the uncertainties in the IFV–associated burden estimates.  
It was difficult to observe or quantify any trends in hCFRs of IFV–ALRI due to 
the small number of IFV–ALRI deaths in multi–year studies (0–7 IFV–ALRI 
deaths over five or more years across nine studies).  
4.4.5. Limitations related to diagnostic tests  
Polymerase chain reaction (PCR) was used in 80% of studies with IFV–
associated hospitalisation rates in the main analysis. Other studies used a mix 
of PCR and other tests (e.g., culture, immunofluorescence assays, and serologic 
test), immunofluorescence assays, influenza rapid test, and time-resolved 
fluoroimmunoassay. Immunofluorescence assays require considerable 
expertise, so the sensitivity can vary substantially between laboratories. The 
sensitivity of direct fluorescent antibody assay (DFA) can be 48–98% sensitive 
in detecting influenza viruses compared with molecular methods according to a 
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review (Landry 2011). Indirect immunofluorescence assay (IFA) can detect IFV 
with moderate sensitivity (70%) and high specificity (94–99%) (Iskander et al. 
2009, Nutter et al. 2012). Similarly, traditional rapid influenza tests have high 
specificity (>90%) while low to moderate sensitivity (60–70%) for detection of 
IFV in children according to a systematic review (Merckx et al. 2017). These 
tests have low to moderate sensitivity but high specificity, thus can produce false 
negative results more frequently than false positive results. Therefore, the IFV–
ALRI hospitalisations could have been underestimated in studies using these 
tests. 
4.4.6. Under–detection of IFV and the adjustment for levels of testing 
Not all ALRI cases were tested for IFV. Incidence and hospitalisation rates of 
IFV–ALRI were adjusted for the levels of testing based on the assumption that 
the percent positivity for IFV was the same in those tested and untested. Studies 
were systematically assessed, and the rates might be biased in some studies. 
For IFV–ALRI hospitalisation studies, rates could have been biased in 30% of 
studies in which less than 90% of cases were tested, and the reasons for not 
testing included cases being tested systematically (17%), refusal and discharge 
(10%), and unknown reasons (3%). Rates could have also been underestimated 
in 20% of studies where data on the proportion tested was unavailable. In the 
remaining 50% of studies, at least 90% of cases were tested. hCFRs of IFV–
ALRI were not adjusted for the under–detection. hCFRs might be 
underestimated because children who were very ill were less likely to be 
sampled and tested, as suggested by the higher hCFRs among untested cases 
than those tested (Appendix A7). 
4.4.7. Limitations related to IFV–ALRI overall mortality estimation 
The IFV–ALRI overall mortality estimate for high child mortality settings was 
estimated using three approaches. Each approach has potential biases, and the 
estimate of inflation factor was based on limited data in three approaches. The 
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inflation factor (2.2) from the main approach (main analysis) was more 
conservative than the estimate from another two approaches (3.0 in Approach 2 
and 4.1 in Approach 3). The estimate of mortality might be biased when 
generalising the results to other regions and countries, though the extrapolation 
was only done among countries with high child mortality. Moreover, the estimate 
of IFV–ALRI mortality might be biased if the percent positivity of IFV is 
associated with the location of child ALRI deaths (inpatient departments versus 
other locations, including outpatient and emergency departments, clinics, on the 
way to care facilities, and at home). One modelling study in South Africa 
estimated that a significantly higher percentage of IFV–attributable deaths 
occurred outside hospitals compared to the percentage of all–cause deaths 
occurring outside hospitals (57% versus 41%) (Cohen et al. 2018). This finding 
suggests that using the inflation factor for all–cause pneumonia deaths might 
cause an underestimation to the IFV–ALRI deaths in the main analysis. Potential 
biases for Approach 2 and 3 are summarised in Appendix A12.  
For low child mortality settings, the inflation factor was estimated using the US 
data on IFV-associated mortality for 0–17 years, and was extrapolated to other 
regions or countries with low child mortality. The inflation factor in the US might 
not be generalisable to other low child mortality countries. Moreover, using data 
for 0–17 years might cause an underestimation if young children (i.e., under five 
years) are more likely to die before being admitted, or an overestimation if young 
children are more likely to be taken to healthcare facilities when they are sick 
(Noordam et al. 2015).  
4.4.8. IFV–attributable burden estimates 
The IFV–attributable burden estimates suggest that IFV can cause 5% of ALRI 
cases, 4–13% of ALRI hospitalisations, 2% of ALRI deaths among children 
under five years globally. The IFV–attributable mortality estimates are developed 
using the AF for IFV–associated deaths (72%), which was modelled by 
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assuming the hCFR for IFV–unattributable cases was equal to the hCFR for 
IFV–negative cases. The assumption might not be true, and the estimates of AF 
and IFV–attributable mortality could be biased. No evidence was identified to 
validate the assumption. The estimate of IFV–attributable deaths in high child 
mortality countries using the “AF” approach was similar to the estimate using the 
proportion of IFV–attributable ALRI deaths derived from CHAMPS data (20,100 
using CHAMPS data versus 19,700 using modelled AF).  
4.4.9. Comparison with estimates from other studies 
Table 4–8 shows recent estimates of global IFV–associated or IFV–attributable 
burden among children under five years in other studies. The number of IFV–
attributable ALRI cases (about 8 million) estimated by the Institute for Health 
Metrics and Evaluation (IHME) is generally comparable to the estimate in the 
main analysis (Troeger et al. 2019).  
Two other studies estimated the global number of IFV–associated or IFV–
attributable ALRI hospitalisations in children under five years using a proportion–
based approach. IHME estimated much greater IFV–attributable ALRI 
hospitalisations for 2017 (about 2,200,000) compared with the estimate in the 
present analysis (Troeger et al. 2019). The difference in the two estimates might 
reflect the difference in analytical methods; data used in the two analytical 
methods were not directly comparable (hospitalisation rate versus proportion). In 
contrast, though using a proportion–based approach, the estimate of 
hospitalisations by Lafond and colleagues was similar to the present estimate 
(Lafond et al. 2016). 
IFV–associated or IFV–attributable overall mortality was estimated in two 
studies recently published. The estimate of IFV–associated ALRI overall 
mortality in the present review was lower than the IFV–associated respiratory 
mortality estimate by Iuliano and colleagues [44,888 (95% credible interval 
9,243–105,690) in 2015] for 92 countries where 92% of respiratory deaths 
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occurred (Iuliano et al. 2018). Iuliano and colleagues performed a time series 
analysis using vital respiratory deaths records and influenza circulation data in 
three countries, and extrapolated to other countries. The different estimates 
reflected the difference in case definitions (respiratory deaths versus ALRI 
deaths) and in statistical models (Li et al. 2017). In this review, the number of 
IFV–ALRI overall deaths was modelled using three different approaches, and 
the most conservative estimate was reported. IHME modelled an estimate of 
IFV–attributable ALRI overall mortality that is broadly similar to the estimate in 
the present analysis (about 23,400 IFV–attributable ALRI deaths in 2017) 
(Troeger et al. 2019). 
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4.4.10. Influenza vaccine use in children and pregnant women 
Influenza vaccine use has substantially increased over the last decade in some 
countries (e.g., the US) (Palache et al. 2014). Inclusion of data from the low 
vaccine-coverage period could cause an overestimation to the estimates of IFV-
ALRI cases and hospitalisations. Influenza vaccine use was not adjusted for 
when estimating IFV-associated burden due to the scarcity of influenza vaccine 
coverage data in most countries. Progress has been made to account for 
influenza vaccine use when estimating influenza burden at the country level 
(Kostova et al. 2013). Adjusting for the vaccine use at global level is challenging 
because the influenza vaccine coverage among children and pregnant women 
remains unknown in many countries, except in high-income countries such as 
the US and UK, and in Latin American countries (Palache et al. 2014, Pan 
American Health Organization 2015, European Centre for Disease Prevention 
and Control 2017). Another challenge is that the protective effect of influenza 
vaccines is dependent on the type of vaccine and the degree of match between 
the vaccine and circulating influenza strains, thus can vary by seasons 
(Osterholm et al. 2012, Manzoli et al. 2012). The coverage and the effect of 
administrated influenza vaccines over different seasons among different 
populations are required to adjust for the vaccine use at the global level. 
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Chapter 5 Global burden of human metapneumovirus 
(hMPV)–associated ALRI 
5.1. Summary  
Background 
hMPV, first identified in 2001, is an important virus in children with ALRI, and the 
attributable fraction ranges from 73% to 91% according to one recent systematic 
review and two multi–country studies. Previous serological studies and 
laboratory–confirmed studies reveal that the almost all children have been 
exposed to or infected with hMPV by the age of five years, and children in this 
age group are most likely to have severe infections. Available pooled analyses 
of data from different populations have focused on broad age groups and 
showed that hMPV is associated with 6.1–6.4% of ALRI among paediatric 
patients under 20 years worldwide. Incidence and mortality of hMPV–ALRI are 
less available in published literature, especially for narrow age groups. No global 
or regional burden estimates have been made for children under five years. 
Standardised analysis 
The regional and global burden of hMPV–associated ALRI in children under five 
years were estimated using data from a systematic review of studies and 
additional high–quality unpublished studies. A generalised linear mixed model 
was used to combine incidence rates, hospitalisation rates, and hCFRs of 
hMPV–ALRI. The hMPV–ALRI cases and hospitalisations were estimated by 
applying the pooled incidence and hospitalisation rates to 2018 population 
estimates. The hMPV–ALRI in–hospital deaths were estimated by combining 
hospitalisations and pooled hCFRs of hMPV–ALRI. Analysis was stratified by 
severity, region, and age. In the main analysis, global estimates were the sum of 
estimates by age and by child mortality settings. The hMPV–ALRI overall 
mortality was estimated using the in–hospital deaths and a multiplier (“inflation 
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factor”). As presented in Chapter 3, to estimate the inflation factor in high child 
mortality settings, input data were the number of all–cause pneumonia deaths 
among children under five years in defined catchment areas by locations of 
death. For low child mortality settings, the input data were the percent of 
children with pneumonia seeking care per country as measured in Demographic 
and Health Surveys, Multiple Indicator Cluster Surveys, and other national 
surveys (as presented in the standardised method chapter). The data are 
available in UNICEF databases (Murray and Newby 2012).  
The hMPV–attributable burden was estimated using hMPV–associated burden 
estimates and the attributable fraction (AF) for hMPV–associated cases, which 
was obtained from one recent systematic review and two recent multi–country 
studies, and the AF for hMPV–associated deaths, which was modelled using the 
AF for hMPV cases and data from the current systematic review. A sensitivity 
analysis for the hMPV–attributable burden was conducted using the proportion 
of hMPV–attributable ALRI deaths derived using CHAMPS data. Any adaptions 
to the standardised methods are presented below.  
Objective 
To estimate the global number of cases, hospitalisations, and deaths from 
hMPV–ALRI in children under five years in 2018. 
5.2. Adaptation in the methods 
5.2.1. Adaptation in data source – systematic review 
The literature search was limited to the time points between 1 January 1995 and 
31 December 2017.  
5.2.2. Adaptation in statistical analysis 
Hospitalisations of hMPV–associated ALRI 
Global burden of acute lower respiratory infection (ALRI) associated with influenza virus, human 
metapneumovirus, and human parainfluenza virus among children under five years 
Global burden of human metapneumovirus (hMPV)–associated ALRI
  96 
In addition to the incidence–based approach, the range of hMPV–associated 
ALRI hospitalisations was estimated using the proportion–based approach: the 
proportion of hMPV–ALRI, which was estimated using data from the systematic 
review, was applied to the hospitalisations of all–cause ALRI among children 
under five years. The global all–cause ALRI hospitalisations for 2015–2016 
ranged from 5,133,000 to 16,400,000 among children under five years, and 
were used in the proportion–based approach (Troeger et al. 2018, McAllister et 
al. 2019). In light of the substantial differences between the two estimates of 
global all–cause ALRI hospitalisations, the proportion–based approach was only 
used to estimate the possible range for hMPV–ALRI hospitalisations (similarly 
for hPIV). 
Overall mortality of hMPV–associated ALRI 
In the main analysis, the standardised approach was used to estimate the 
overall hMPV–ALRI mortality. As mentioned in Chapter 4, mortality associated 
with certain viruses (e.g., IFV and RSV) can be modelled with population–based 
pneumonia deaths and local concurrent virus circulation data. This was, 
however, challenging for hMPV and hPIV as location–matched pneumonia 
mortality data and virus circulation data were more limited for the two viruses 
than for IFV or RSV.  
Therefore, a different approach was developed for hMPV and hPIV, and the 
overall hMPV–ALRI mortality was estimated by applying the percent of hMPV in 
ALRI deaths to the number of overall ALRI deaths for children under five years, 
as shown in Figure 5–1. 
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5.3.1. hMPV-associated ALRI burden in the community 
The incidence rate of hMPV-associated ALRI and the number of cases 
There were 10 studies with data on the incidence of hMPV–ALRI. The incidence 
rates for 0–59 months were available in nine studies after imputation and these 
studies were included in the meta-analysis. The nine studies were from Australia 
(two studies), Bangladesh, India, Nepal, Pakistan, Peru, South Africa, and the 
US. The remaining one study reported an incidence rate of 36.5 per 1,000 
children per year among American Indian children aged 24–59 months in 2009. 
Five studies were from high child mortality settings. By World Bank income 
regions, there were four studies from LMICs, two studies from UMICs, and three 
studies from HICs. Three studies reported the rates for pre-2010 period. For this 
outcome, no potentially influential studies (considerably affecting the combined 
estimates) were identified.  
The hMPV–ALRI incidence rate meta-estimate was 21.2 (95%CI 17.1–26.2) per 
1,000 children per year for 0–59 months in high child mortality settings, and 22.3 
(95%CI 12.3–40.6) for low child mortality settings. The incidence rate in low 
child mortality settings was estimated based on three studies (one from the US 
and the other two from Australia), and the high rate was mainly driven by two 
Australian studies (one for 1996–1999 and the other one for 2010–2014). Based 
on the meta-estimates, 14.6 million (UR 10.5-21.0) hMPV-ALRI cases were 
estimated to occur globally in children under five years (Table 5–1). 
In the sensitivity analysis, hMPV–ALRI incidence rate meta–estimates ranged 
from 17.7 (95%CI 9.9–31.8) to 27.4 (95%CI 14.6–51.3) for 0–59 months when 
stratified by country development status and by World Bank income groups. The 
global number of hMPV–ALRI cases for children under five years was 13.7 
million (UR 10.1–18.9) and 13.7 million (UR 9.4–20.3) in the stratified analysis 
by country development status and by World Bank income groups, respectively 
(Appendix A9).  
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The number of hMPV-associated severe ALRI cases 
Only four studies were identified with data on incidence rates of hMPV–severe 
ALRI (Appendix A9 and A19). The four studies reported incidence rates from 
2011 onwards in four countries with high child mortality (Bangladesh, India, 
Pakistan, and South Africa). Details of the four studies are in Appendix A19. For 
0–59 months, high incidence rates (17–18 per 1,000 children per year) were 
reported in two studies in India and South Africa, while low rates (1–2 per 1,000 
children per year) in the other two studies in Bangladesh and Pakistan. The 
meta–estimate was 5.3 (95%CI 1.6–17.9) per 1,000 children, translating to 2.4 
million (UR 0.7–7.9) hMPV–severe ALRI cases in high child mortality settings 
(Appendix A9). 
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Figure 5-3. Forest plot of non–imputed incidence rates of hMPV–ALRI for children aged 0 – 59 months in high child 
mortality settings.  
Imputed data were not included in this plot because using the multiple imputation method, a group of values were imputed for each study. 
Data for low child mortality settings were not plotted because there was only one study with data for 0–59 months. 
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5.3.2. hMPV-associated ALRI burden in the hospital setting 
Hospitalisation rates of hMPV-ALRI and hospitalisations 
There were 39 studies with data on hMPV–ALRI hospitalisation rates, including 
29 studies with data by three narrow age bands. As shown in Figure 5–5, Figure 
5–6, and Figure 5–7, the hospitalisation rates ranged from 0 to 18.0 (95%CI 
9.4–34.3) per 1,000 children per years for 0–5 months, 0.9 (95%CI 0.2–3.7) to 
10.9 (95%CI 4.9–24.0) for 6–11 months, and 0.1 (95%CI 0–0.6) to 2.1 (95%CI 
1.7–2.5) for 12–59 months across studies. More details of included studies are 
in Appendix A19. When reported by age groups, estimates of two studies (in 
Kenya and South Africa) were potential outliers, but the estimates were not 
influential (significantly affecting the combined estimates). For 12–59 months, 
one such outlier was conducted in two refugee camps in Kenya. Compared with 
two other Kenyan studies with data on hMPV–ALRI hospitalisation rates for 0–
59 months, this study reported a rate between the highest and lowest rate. For 
infants, the other such outlier was conducted in Pearl, South Africa. Some of the 
results from this study have already been published. In this study, individually 
recorded person-time at risk during the follow–up were used to estimate 
hospitalisation rates of hMPV–ALRI. 
The pooled hospitalisation rate point estimate was more than 4–fold higher in 
infants aged 0–5 months and 6–11 months (2.2–3.3 per 1,000 children per year) 
compared to children aged 12–59 months (0.3–0.6 per 1,000 children per year) 
across World Bank income regions and child mortality settings (Table 5–2). The 
analysis stratified by child mortality settings yielded 643,000 (UR 425,000–
977,000) hMPV–ALRI hospitalisations globally among children under five years. 
The global hospitalisations for hMPV–ALRI for children under five years only 
changed marginally, ranging from 626,000 to 650,000 in the stratified analysis 
by World Bank income regions and country development status (Appendix A9).  
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A total of 117 studies were identified with data on proportions of hospitalised 
ALRI cases positive for hMPV, including 78 studies with data for 0–59 months. 
For 0–59 months, the proportions ranged from 0.9 percent (95%CI 0.1–6.3) to 
19.7 percent (95%CI 12.3–30.2) across the 78 studies. Meta-analyses for 
children aged 0–59 months showed that 5.6–6.5% of ALRI was associated with 
hMPV across World Bank income regions (Appendix A11). As mentioned above 
in this chapter, two recent estimates of global all–cause ALRI hospitalisations 
are very different (5,133,000 and 16,400,000), making it difficult to yield a point 
estimate for hMPV–ALRI hospitalisations using the proportion–based approach. 
The global hMPV–ALRI hospitalisations were estimated to range from 298,000 
to 951,000 among children under five years using the proportion–based 
approach.  
Hospitalisations of hMPV–ALRI with hypoxaemia 
There were 11 studies with data on hospitalisation rates for hMPV–ALRI with 
hypoxaemia by three narrow age bands (Appendix A19). Only three studies 
were from the low child mortality setting. In the analysis stratified by child 
mortality settings, 112,000 (UR 29,000–522,000) hospitalisations for hMPV–
ALRI with hypoxaemia were estimated to occur in children under five years 
globally, accounting for 17% of hMPV–ALRI hospitalisations (Table 5–2). 
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Figure 5-4. Forest plot of hospitalisation rates of hMPV–ALRI for children aged 0–5 months by child mortality 
settings.   
Upper: low child mortality settings. Below: high child mortality settings.
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Figure 5-5. Forest plot of hospitalisation rates of hMPV–ALRI for children aged 6–11 months by child mortality 
settings.  
Upper: low child mortality settings. Below: high child mortality settings.
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Figure 5-6. Forest plot of hospitalisation rates of hMPV–ALRI for children aged 12–59 months by child mortality 
settings.   
Upper: low child mortality settings. Below: high child mortality settings.
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hCFRs and in–hospital mortality of hMPV–associated ALRI 
A total of 73 studies reported hCFRs of hMPV–ALRI in children under five years, 
including 28 studies with data stratified by three narrow age bands. Table 5–4 
shows the studies included in the main analysis. More details are in Appendix 
A19. According to the meta-estimates, infants aged 0–5 months from the high 
child mortality setting and LMICs had highest hCFRs [4.5% (95%CI 2.3–8.6) for 
LMICs; 3.3% (95%CI 1.7–6.1) for high child mortality settings] (Table 5–3). The 
hCFRs were lower for children aged 6–59 months and for children in HICs (0.5–
1.1%), with wide confidence intervals. These meta–estimates yielded 7,700 (UR 
2,600–48,800) hMPV–ALRI in–hospital deaths globally in children under five 
years. About 64% of these deaths were in young infants aged 0–5 months 
[4,900 (UR 2,100–19,300)], and 88% [6,800 (UR 2,500–27,100)] occurred in 
countries with high child mortality. An estimated 7,200 (UR 2,600–52,300) in–
hospital deaths occurred in LMICs. The estimate in the main analysis was 
similar to that in the stratified analysis by country development status (7,500). In 
the stratified analysis by World Bank income regions the estimate of global in–
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5.3.3. Overall mortality of hMPV–associated ALRI 
Approach 1 – the “inflation factor” approach 
The inflation factor for hMPV–ALRI deaths in the high child mortality setting was 
estimated using the same data as used for IFV–ALRI deaths (Table 5–4). More 
details of the data are given in Chapter 4. A median inflation factor of 2.2 across 
eight sites was applied to the hMPV–ALRI in–hospital deaths, yielding 14,900 
(UR 5,600–59,700) overall hMPV–ALRI deaths in high child mortality settings. 
Across 28 countries or regions with low child mortality, 22% to 94% of children 
with pneumonia received care from a health provider. Using these data, the 
median inflation factor was estimated to be 1.3 across regions or countries, 
yielding 1,100 (UR 100–28,800) overall hMPV–ALRI deaths among children 
under five years for the low child mortality setting. Altogether, the “inflation 
factor” approach yielded 16,100 (UR 5,700–88,000) overall hMPV–ALRI deaths 
globally among children under five years (Table 5–4).  
Approach 2 – the proportion of hMPV positives in ALRI deaths 
hMPV was identified in 3.2% (95%CI 1.9–5.2) of ALRI deaths (573 ALRI deaths 
in total) for children aged 1–59 months. Details are given in Appendix A14. 
Using this approach, the point value of the overall hMPV–ALRI mortality for the 
high child mortality setting was 30% higher than the “inflation factor” approach, 
with overlapping confidence intervals [19,900 (UR 12,100–33,200) for 1–59 
months] (Appendix A14). The overall deaths in neonates were not estimated 
using this approach because very few neonatal ALRI deaths were reported in 
hospital–based studies, and no hMPV deaths were identified.   
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5.3.4. hMPV–attributable ALRI burden estimates 
Approach 1 – the attributable fraction (AF) approach 
A median AF of 78% for hMPV–ALRI was used to estimate hMPV–attributable 
ALRI cases and hospitalisations (Appendix A15; Table 5–7). Combining the 
hMPV–associated burden estimates and the AF, 11.4 million (UR 8.2–16.4) 
ALRI cases and 502,000 (UR 332,000–762,000) ALRI hospitalisations could be 
attributed to hMPV in children under five years (Table 5–7).  
The ratio of case–fatality of hMPV–unattributable ALRI and hMPV–attributable 
ALRI to that of hMPV–associated cases was estimated to be 1.4 and 0.9, 
respectively, based on 13 hospital–based studies. Details of this analysis are in 
Table 5–6. Using the ratios, the AF for hMPV–associated ALRI deaths was 
estimated to be 70%. This suggested that 5,400 (UR 1,800–34,100) in–hospital 
ALRI deaths and 11,300 (UR 4,000–61,600) overall ALRI deaths could be 
attributed to hMPV globally, including 10,400 (UR 3,900–41,800) for high child 
mortality settings (Table 5–6).  
Approach 2 - proportion of hMPV-attributable ALRI deaths 
The proportion of hMPV–attributable deaths in ALRI deaths was 1.6 (95%CI 
0.3–4.5) in children aged 1–59 months using CHAMPS data from high child 
mortality countries. Accordingly, 9,900 (UR 2,600–39,300) ALRI deaths could be 
attributed to hMPV among children aged 1–59 months for high child mortality 
settings (Appendix A15). The hMPV-attributable deaths in neonates were not 
estimated using this approach because no hMPV-attributable deaths were 
identified among neonates in CHAMPS. 
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Table 5-6. Estimation of the attributable fraction for hMPV–associated ALRI deaths for 0–59 months.* 
































deaths (=AF for 
hMPV–ALRI cases 
* D)‡ 










Gambia; 2012-2013 2 2.8 
Zambia; 2012-2013 7.5 18.8 
Mali; 2012-2014 2.1 16.2 
Kenya; 2011-2013 3.6 4.9 
South Africa; 2011-
2013 
3.4 3.8      
Philippines; 2014-
2016 
0 5      
Mozambique; 2011-
2013 
3.6 1.3      
Philippines; 2012-
2015 
1.8 2.1      
Philippines; 2012-
2016 
0 2.6      
 
* Studies were eligible for the analysis if they tested >=90% of cases and reported at least five ALRI deaths (to ensure the precision of 
estimates). 
† Detailed formulas in Chapter 3.  
‡ The AF for hMPV–ALRI cases was calculated using odds ratios from one recent systematic reviews and two additional recent multi-country 
studies. The median estimate of odds ratio from the three studies was input to yield the attributable fraction for hMPV–ALRI cases (78%).  
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5.4. Conclusion and discussion 
5.4.1. Implications 
The hMPV–associated burden estimates suggest that hMPV is associated with 
11% of ALRI cases, 4–13% of ALRI hospitalisations, and 2% of ALRI deaths 
among children under five years globally (WHO 2018, McAllister et al. 2019, 
Troeger et al. 2018). 
The meta-estimate of hMPV–ALRI incidence rate did not vary much by age 
groups (21–26 per 1,000 children per year across 0–5 months, 6–11 months 
and 12–59 months), indicating that hMPV is associated with ALRI throughout 
early childhood. This result needs to be verified with more data. In contrast, the 
hospitalisation rate was much higher in infants; about 58% of hospitalisations 
(374,000) and 71% of in–hospital deaths (5,500) for 0– 59 months occurred in 
the first year of life. The substantial morbidity and mortality burden during 
infancy might reflect the increased susceptibility of infants to severe respiratory 
infections, due to the immaturity of infant’s immune system (Simon et al. 2015). 
Additionally, the maternal antibodies against hMPV infections decay over the 
first several months of life, leaving infants susceptible to severe infections. 
Consistent with this, a follow–up study among 40 Israeli children found the 
prevalence of anti–hMPV antibodies declined by 50% at seven months of age 
compared with the prevalence at two months (Fadeela et al. 2003). Infants’ 
hMPV–ALRI hospitalisation rate was consistently high across different settings, 
highlighting the need to develop safe and effective vaccines targeting hMPV to 
protect infants against severe hMPV infections.  
The hCFR estimates of hMPV–ALRI show that younger infants aged 0–5 
months are at an increased risk of hMPV–ALRI mortality. In contrast to the 
pattern for the hospitalisation rate, the hCFR for 0–5 months varied by settings. 
The variation of hCFRs by World Bank income regions could reflect the 
difference in hospital care and disease severity at admission. The higher hCFRs 
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among children in low– and lower middle–income countries could be a result of 
multiple factors, including the high prevalence of certain underlying conditions 
which can predispose children to severe infections, no access to care and 
delays in care–seeking which can lead to rapid deterioration, and the poor 
quality of hospital care (McAllister et al. 2019, Pneumonia Etiology Research for 
Child Health Study Group (PERCH) 2019). In this respect, further efforts are 
needed to improve the outcome of hMPV–ALRI in infants in low– and lower 
middle–income countries. 
5.4.2. Meta-analysis results by different stratification groups 
The global estimates for hMPV–ALRI hospitalisations and in–hospital deaths 
were mostly similar when stratified by different groups (Appendix A9), with one 
exception for hMPV-ALRI in–hospital deaths, for which outcome the point 
estimate increased by 18% in the stratified analysis by World Bank income 
regions (9,100 versus 7,700). The hospitalisation estimates (298,000–951,000; 
Appendix A11) derived from the proportion–based approach were broadly 
similar to those using an incidence–based approach. The estimates for hMPV–
ALRI and severe ALRI need to be interpreted with caution due to the limited 
data for this outcome and the substantial variation between studies.  
5.4.3. Long–term trend in hMPV estimates and variation between years 
Five studies provided yearly hospitalisation rates of hMPV–ALRI over five years 
or more for children aged 0–59 months (Appendix A17). The yearly hMPV–ALRI 
hospitalisations rates appeared to follow a cyclical pattern over every 3–5 years 
in three studies.  
No consistent secular trends in hospitalisation rates were observed across the 
five studies. A reduction in the hospitalisation rates was seen in two studies in 
Kenya and South Africa, while an increase was seen in the other three studies in 
South Africa, Vietnam, and Norway. The maximum decrease was seen in the 
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Kenyan study (1.9 per 1,000 children per year during 2007-2009 versus 0.7 
during 2010-2016), while the maximum increase was seen in the Vietnamese 
study (0.4 per 1,000 children per year during 2007-2009 versus 0.7 during 2010-
2014).  
Variation between seasons were observed. The maximum seasonal variation 
was mostly 3–7–fold except in two studies where the number of hMPV–ALRI 
cases was extremely low in certain years and the rates were very imprecise. For 
hCFRs, six studies provided yearly data over five years or more for children 
aged 0–59 months. It was difficult to observe or quantify any trends in hCFRs of 
hMPV–ALRI because there were very few hMPV–ALRI deaths (1–3 deaths) in 
these multi–year studies. Similar to the analysis for IFV, the aggregation of 
yearly data could have caused an underestimation to the uncertainties in the 
hMPV–associated burden estimates.  
5.4.4. Limitations related to diagnostic tests  
In the main analysis, 90% of hospitalisation studies used PCR to detect hMPV. 
The remaining studies used indirect immunofluorescence assay (IFA), a mix of 
PCR and other tests (direct immunofluorescence assay [DFA], culture, and 
serologic test). IFA, DFA, or culture has showed lower sensitivity (38–80% for 
DFA; 73% for IFA; 32% for culture) and similar specificity compared to molecular 
tests (Ebihara et al. 2005, Jokela et al. 2010, Wolf et al. 2015, Mahony 2008). 
As discussed in Chapter 4, the use of these tests might lead to an 
underestimation to hospitalisation rates of hMPV–ALRI.  
5.4.5. Under–detection of hMPV and the adjustment for levels of testing 
Similar to IFV, not all the ALRI cases were tested for hMPV. Incidence rates and 
hospitalisation rates of hMPV were adjusted for the levels of testing based on 
the assumption that the percent positivity for hMPV was the same in those 
tested and untested. The hospitalisations of hMPV–ALRI might be biased in 
31% of studies in which less than 90% of cases were tested mainly due to 
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refusal (17%) and systematic sampling and testing (7%), and for unknown 
reasons (3%). Moreover, rates might be underestimated in another 4% of 
studies in which the proportion tested was unavailable. hCFRs of hMPV–ALRI 
were not adjusted for the under–detection. Since the hCFR of the tested ALRI 
cases was higher than those untested, the hCFR of hMPV–ALRI and in–hospital 
mortality might be underestimated (Appendix A7). 
5.4.6. Limitations for hMPV–ALRI overall mortality estimation 
The inflation factor for high child mortality settings was estimated using the 
same data as used for IFV. Therefore, the hMPV–ALRI overall mortality 
estimate is susceptible to similar limitations as the IFV estimate, including 
limitations related to the scarcity of data, the extrapolation of inflation factor from 
data–existing regions to other regions and the validity of the assumption in the 
estimation of “inflation factor” . Nevertheless, the estimate of overall hMPV–ALRI 
mortality in high child mortality settings derived from the “inflation factor” 
approach is more conservative, and the point value increased by about 30% 
using “the proportion of hMPV in ALRI deaths” approach (Appendix A14).  
For low child mortality countries, the inflation factor, estimated using the 
reciprocal of the percent of children with pneumonia symptoms seeking care, 
were likely to be underestimated. This is because the definition of “care–
seeking” is broader than the definition of “in–hospital” in this thesis: contact with 
primary care is included as “care–seeking” in the surveys (e.g., Multiple Indicator 
Cluster Surveys and Demographic and Health Surveys) but are not included in 
the “in–hospital mortality” estimate in the present work. The US vital statistics 
data show that about 40% of under–five pneumonia deaths occurred in 
outpatient or emergency departments during 2010–2017 (Centers for Disease 
Control and Prevention and National Center for Health Statistics). The estimate 
might also be biased if the case–fatality ratio was different between those 
children who received care and those who did not. The direction of the bias is 
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hard to determine: the cases admitted into hospitals are likely to be more severe 
and have a higher risk of death; but the non–severe cases who do not seek care 
can deteriorate rapidly (Bennett et al. 2015, Najnin et al. 2011, Onyango et al. 
2012). Moreover, such data (i.e., the percent of children with pneumonia seeking 
care) in HICs are not readily available in published reports, and extrapolating 
data from other low child mortality countries to HICs might have biased the 
estimate.  
5.4.7. hMPV–attributable burden estimates 
The hMPV–attributable burden estimates show that hMPV can cause 8% of 
ALRI cases, 3–10% of ALRI hospitalisations, and 1% of ALRI mortality in 
children under five years globally. The assumption of the AF approach is similar 
to the analysis for IFV, which is explicated in Chapter 4. The assumption will be 
discussed in detail in Chapter 7. The estimate in high child mortality countries 
using the AF approach was similar to the estimate derived using the proportion 
of hMPV attributable ALRI deaths from CHAMPS data (10,400 using AF versus 
9,900 using CHAMPS). 
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Chapter 6 Global burden of human parainfluenza virus 
(hPIV)–associated ALRI 
6.1. Summary  
Background 
There are four major hPIV serotypes, from hPIV–1 to hPIV–4, and the 
prevalence and the attributable fraction vary by types. An earlier meta–analysis 
of data in different populations estimated that hPIV was associated with 2.7% of 
hospitalised ALRI in children under five years. This estimate was only based on 
seven studies with a mixture of age strata (e.g., 0–23 months and 0–59 months). 
Over the past decade, there have been an increasing number of hospital–based 
studies worldwide reporting the proportion of hPIVs in childhood ALRI cases. In 
contrast, data on incidence rates, hospitalisation rates, and case–fatality ratios 
of hPIV–ALRI, which are important measures of disease or healthcare burden 
associated with the virus, are less available in published reports. Global burden 
estimates for hPIV–ALRI in children under five years have not been made.  
Standardised analysis 
The regional and global burden of hPIV–associated ALRI in children under five 
years were estimated using data from a systematic review of published literature 
and additional high–quality unpublished studies. As specified in the standardised 
methods, a generalised linear mixed model was used to combine data for each 
outcome. One major adaption for hPIV was that prior to meta–analysis, data 
were adjusted at study levels to account for the non–detection of hPIV4. Then 
adjusted incidence rates and hospitalisation rates and adjusted hCFRs were 
input to yield the number of hPIV–ALRI cases, hospitalisations, and in–hospital 
deaths. Details of the adaptions are presented in this chapter.  
Analysis was stratified by severity, region, and age. In the main analysis, global 
estimates were the sum of estimates by age and by child mortality settings. The 
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hPIV–ALRI overall mortality was estimated using the in–hospital deaths and a 
multiplier (“inflation factor”). As presented in Chapter 3, to estimate the inflation 
factor in high child mortality settings, input data were the number of all–cause 
pneumonia deaths among children under five years in defined catchment areas 
by locations of death. For low child mortality settings, the input data were the 
percent of children with pneumonia seeking care per country as measured in 
Multiple Indicator Cluster Surveys, Demographic and Health Surveys, and other 
national surveys (data are available in UNICEF databases) (Murray and Newby 
2012).  
The hPIV–attributable burden was estimated using hPIV–associated burden 
estimates and the attributable fraction (AF) for hPIV–associated cases, which 
was estimated based on two recent multi–country studies, and the AF for hPIV–
associated deaths, which was modelled using the AF for hPIV cases and data 
from the present systematic review. A sensitivity analysis for the hPIV–
attributable burden was conducted using the proportion of hPIV–attributable 
ALRI deaths derived from CHAMPS data. Any adaptions to the standardised 
methods are presented below in this chapter.  
Objective 
To estimate the global number of cases, hospitalisations, and deaths from 
hPIV–ALRI in children under five years in 2018. 
6.2. Adaptation in the methods 
6.2.1. Adaptation in data source – systematic review 
The literature search was limited to the time points between 1 January 1995 and 
31 December 2017.  
6.1.2. Adaptation in statistical analysis 

Global burden of acute lower respiratory infection (ALRI) associated with influenza virus, human 
metapneumovirus, and human parainfluenza virus among children under five years 
Global burden of human parainfluenza virus (hPIV)–associated ALRI
  126 
type were eligible for this analysis. The analysis was restricted to hospital–based 
studies because the majority of the hPIV type data were from hospital-based 
studies. For the type analysis, the numerator was the number of cases positive 
for each hPIV type as they were reported. The denominator was the number of 
all hPIV cases as they were reported where available, otherwise was calculated 
accordingly in different scenarios. The primary aim was to estimate the percent 
of four hPIV types (especially hPIV–4) among children under five years; age–
stratified analysis was not performed due to the relatively small sizes of most 
studies. However, age distributions could differ between types. Thus, only the 
four–type data for children aged 0–59 months were included in the analysis.  
Adjusted hCFRs and in–hospital deaths of hPIV–associated ALRI – 
accounting for missing hPIV–4 
Not all hCFR studies detected hPIV–4, so the hCFRs were adjusted at the study 
level to account for missing hPIV–4 hospitalisations and deaths using the type–
specific prevalence and type–specific hCFRs. The adjustment is shown in 
Figure 6–2. The adjusted hCFRs (and adjusted hospitalisations) were used as 
input data to yield the adjusted hPIV–associated ALRI in–hospital deaths. 

Global burden of acute lower respiratory infection (ALRI) associated with influenza virus, human 
metapneumovirus, and human parainfluenza virus among children under five years 
Global burden of human parainfluenza virus (hPIV)–associated ALRI
  128 
The hPIV–attributable ALRI mortality 
Approach 1 – the “attributable fraction (AF)” approach 
As mentioned in the standardised method, the hPIV–attributable burden was 
estimated by applying the AF to the adjusted hPIV–associated morbidity and 
mortality estimates. Pooled analyses of multi–country data show that the AF for 
hPIV–associated ALRI cases varies by type (Pneumonia Etiology Research for 
Child Health Study Group (PERCH) 2019, Benet et al. 2017), so the average AF 
in hPIV cases was estimated using type–specific AF and type–specific 
prevalence (Formula 6–1).  
Formula 6–1: 𝐴𝐹𝐸𝑎𝑣𝑒𝑟𝑎𝑔𝑒 = ∑ % ℎ𝑃𝐼𝑉𝑖 ∗ 𝐴𝐹𝑖4𝑖  
In the formula, %hPIVi denote the prevalence of hPIV–1 to hPIV–4; AFi denote 
the AF for each type. Input data and final estimates are listed in Appendix A15. 
Similar to IFV and hMPV, the AF in deaths for hPIV was estimated using the 
following formula: 




The AFdeaths and AFcases denote the attributable fraction for hPIV–associated 
ALRI cases and deaths, respectively; the average AF in cases was the input for 
AFcases. The ratio of case–fatality of hPIV–attributable [CFR (hPIVattributable)] 
and hPIV–associated ALRI [CFR (hPIVassociated)] were calculated using data 
from 12 hospital–based studies. Data were eligible for this analysis if at least 
90% of ALRI cases were tested, at least five ALRI deaths were reported, and 
four hPIV types were detected. More details are in Appendix A15.  
Approach 2 – the proportion of hPIV–attributable ALRI deaths 
As mentioned in the standardised method, the hPIV–attributable mortality was 
also estimated using the proportion of hPIV–attributable ALRI deaths based on 
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CHAMPS data (CHAMPS). Four hPIV types are detected in CHAMPS (Diaz et 
al. 2019).  
6.2. Results 
Figure 6–3 shows the study selection for hPIV. A total of 190 studies were 
identified with data on hPIV–ALRI community incidence (12 studies), 
hospitalisation rates (35 studies), hospitalised proportion positives (160 studies), 
and hCFRs (56 studies). There were 41 studies from the collaboration network 
and 149 studies from published literature. By World Bank income regions, 7 
studies were from LICs, 35 from LMICs, 102 from UMICs, and 46 from HICs. 
Figure 6–4 shows the location of included studies. A summary of included 
studies for each outcome are in appendix (A18).  Details of included studies are 
in Appendix A19. 
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6.2.1. hPIV–associated burden in the community 
The number of hPIV–associated ALRI cases 
There were 12 studies with data on incidence rates of hPIV–ALRI cases, 
including 11 studies with data for 0–59 months (including imputed data). Seven 
studies were from high child mortality countries, including five from South–East 
Asia and the other one from South Africa. Four studies were from low child 
mortality countries, including two from Australia, one from Spain, and one from 
the US. Six studies reported the rates for pre–2010 period. One study detected 
four hPIV types, one study only detected hPIV–3, and other studies detected 
hPIV–1 to hPIV–3. Four older studies used test methods that are less sensitive 
than PCR: ELISA, DFA, conventional culture, and culture with IFA. No influential 
studies (significantly affecting the combined estimates) were found for this 
outcome. 
The adjusted hPIV–ALRI incidence rate meta–estimate was 42.5 (95%CI 31.2–
57.8) per 1,000 children per year for 0–59 months for high child mortality 
settings, and 45.5 (95%CI 22.7–91.0) for low child mortality settings. The high 
incidence rate in low child mortality settings was mainly driven by two Australian 
studies (one for 1996–1999 and the other for 2010–2014). Based on the meta–
estimates, 29.5 million (UR 19.2–46.7) hPIV–ALRI cases were estimated to 
occur globally in children under five years (Table 6–1). Similar hPIV–ALRI 
incidence rate meta–estimates for 0–59 months (42–46 per 1,000 children per 
year) were estimated by country development status, by World Bank income 
regions, and by child mortality settings. The number of hPIV–ALRI cases were 
not estimated in UMICs because there was only one study. In the stratified 
analyses by country development status, 29.0 (UR 20.6–41.4) million hPIV–
ALRI cases were estimated to occur globally among children under five years 
(Appendix A10).   
The number of hPIV–associated severe ALRI cases 
Global burden of acute lower respiratory infection (ALRI) associated with influenza virus, human 
metapneumovirus, and human parainfluenza virus among children under five years 
Global burden of human parainfluenza virus (hPIV)–associated ALRI
  132 
There were only five studies with data on incidence rates of hPIV–associated 
severe ALRI cases, all of which were from high child mortality countries. For 
children aged 0–59 months, the unadjusted rate of hPIV–severe ALRI ranged 
from 2 to 30 per 1,000 children per year for 0–59 months across five studies. 
The lowest rate was reported in a Bangladeshi study and the highest rate in a 
South African study. The meta–estimate was 9.3 (3.5–24.9) per 1,000 children 
per year, yielding 4.2 (UR 1.6–11.1) hPIV–severe ALRI cases in high child 
mortality settings (Appendix A10).
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Table 6-1. Estimates of the adjusted incidence (per 1,000 children per year) and adjusted number of hPIV–associated ALRI 
cases in the community in children under five years in 2018, by World Bank income regions and child mortality settings* 






0–5 m Study† 4 1 0 0 5  




Cases (*1,000) 1240 (493–3123) ·· ·· ·· 1694 (747–
3843) 
·· 
6–11 m Study 4 1 0 0 5  
 
Rate 82.9 (66.6–102.7) ·· ·· ·· 80 (66.4–96.1)  
 
Cases (*1,000) 3639 (2934–4514) ·· ·· ·· 3651 (3038–
4388) 
·· 
12–59 m Study 3 1 0 0 4  
 
Rate 34.4 (17.8–65.4) ·· ·· ·· 32.9 (20–53.6)  
 
Cases (*1,000) 11797 (6177–22539) ·· ·· ·· 11733 (7188–
19161) 
·· 
0–59 m Study 6 (3) 1 4 (3) 4 (3) 7 (3)  
 













* The incidence rate was adjusted to account for the missing hPIV–4 (in 9 studies). In one study only the hPIV–3 rate was available, so the rate was 
adjusted to account for the missing hPIV–1, hPIV–2, and hPIV–4. For the remaining one study, four types were detected so the rate was not adjusted.   
† No of studies. The number in the parentheses were the number of imputed studies. Rates were imputed using multiple imputation method.  
Global burden of acute lower respiratory infection (ALRI) associated with influenza virus, human metapneumovirus, and human parainfluenza virus 
among children under five years 
Global burden of human parainfluenza virus (hPIV)–associated ALRI  134 
 
Figure 6-4. Forest plot of incidence rates of hPIV–ALRI for children aged 0–59 months in high child mortality settings.   
Imputed data were not included in this plot because a group of values were imputed for each study using the multiple imputation approach. Data from 
low child mortality settings were not plotted because there was only one study with data (non-imputed) for 0–59 months. The pooed incidence rate point 
estimate in high child mortality settings increased after imputation. This rate was mainly driven by three studies in Bangladesh (39.5 per 1,000 children 
per year for 0–59 m), South Africa (43.1 per 1,000 children per year for 0–59 m), and Nepal (48 per 1,000 children per year for 0–23 m) reporting high 
rates. The three studies had the largest sample sizes. After imputation, the rates for 0–59 m in the Nepali study were included in the meta–analysis.  
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6.2.2. hPIV–associated burden in the hospital setting 
Adjusted hospitalisations of hPIV–ALRI 
There were 35 studies with hPIV–ALRI hospitalisation rates, including 26 studies 
reporting data by three narrow age groups. Only 9 studies detected four hPIV 
types. More details of included studies are in Appendix A19. hPIV-4 accounted 
for 12% of all hPIV cases among children under five years (Appendix A13). After 
adjusting for missing hPIV-4 at the study level, as shown in Figure 6–5, Figure 
6–6, and Figure 6–7 (Above), the hospitalisation rates of hPIV–ALRI ranged 
from 0.8 to 30.1 (95%CI 18.2–49.3) per 1,000 children per years for 0–5 months, 
0.6 (95%CI 0.4–0.8) to 18.1 (95%CI 9.8–33.4) for 6–11 months, and 0 to 6.8 
(5.3–8.7) for 12–59 months across studies. The adjusted hospitalisation rate 
meta–estimate was 2–8–fold higher in infants aged 0–5 months and 6–11 
months (2.0–5.8 per 1,000 children per year) compared to children aged 12–59 
months (0.7–0.8 per 1,000 children per year) across World Bank income regions 
and child mortality settings (Table 6–2). In the analysis by child mortality 
settings, 1.0 million (UR 0.6–1.8) hPIV–ALRI hospitalisations were estimated to 
occur globally in children under five years. The global hospitalisations of hPIV–
ALRI in children under five years ranged from 969,000 to 1.0 million across 
different stratification groups (Appendix A10).  
There were 160 studies with data on proportions of hospitalised ALRI cases 
positive for hPIV, including 91 studies with data for 0–59 months. hPIV was 
positive in 8.7% of hospitalised ALRI in children aged 0–59 months, ranging 
from 6.7% to 11.1% across World Bank income regions (Appendix A11). Using 
the proportion–based approach, 447,000–1,427,000 ALRI hospitalisations were 
associated with hPIVs among children under five years globally. As discussed in 
Chapter 5, it was difficult to give a point estimate using the proportion–based 
approach because of the substantial differences between the two input 
estimates for global all–cause ALRI hospitalisations.  
Global burden of acute lower respiratory infection (ALRI) associated with influenza virus, human 
metapneumovirus, and human parainfluenza virus among children under five years 
Global burden of human parainfluenza virus (hPIV)–associated ALRI
  136 
Adjusted hospitalisations of hPIV–ALRI with hypoxaemia  
There were 13 studies with data on hospitalisation rates for hPIV–ALRI with 
hypoxaemia by age strata. Five studies did not detect hPIV–4. In the analysis 
stratified by child mortality settings, 166,000 (UR 94,000–795,000) 
hospitalisations (adjusted) for hPIV–ALRI with hypoxaemia were estimated to 
occur in children aged 0–59 months globally, accounting for 16.5% of the hPIV–
ALRI hospitalisations.
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 Rate (/1,000) 0.1 (0.1–0.2) 0.1 (0–1.3) ·· 0.1 (0–4.8) 0.1 (0.1–0.2)  
 Hospitalisations (*1,000) 34 (24–48) 15 (1–232) ·· 18 (1–558) 36 (25–50) 54 (26–608) 
0–59 m (D+E+F) Hospitalisations (*1,000) 65 (10–560) 44 (9–291) ·· 25 (5–569) 141 (89–226) 166 (94–
795) 
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Figure 6-5. Forest plot of adjusted hospitalisation rates of hPIV–ALRI for children aged 0–5 months by child mortality 
settings.  
Upper: low child mortality settings. Below: high child mortality settings. 
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Figure 6-6. Forest plot of adjusted hospitalisation rates of hPIV–ALRI for children aged 6–11 months by child 
mortality settings.   
Upper: low child mortality settings. Below: high child mortality settings. 
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Figure 6-7. Forest plot of adjusted hospitalisation rates of hPIV–ALRI for children aged 12–59 months by child 
mortality settings.   
Upper: low child mortality settings. Below: high child mortality settings. 
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Adjusted hCFRs and in–hospital mortality of hPIV–associated ALRI 
There were 56 studies with data on hCFRs for hPIV–ALRI in children under five 
years, including 27 studies with data stratified by three narrow age bands. In 
eight studies hPIV–4 was not detected. Table 6–4 shows the age–stratified 
hCFR estimates. More details are in Appendix A19. A 1–2–fold difference was 
found in the hCFR meta-estimates between age groups for each setting. 
Children in high child mortality countries and those in LMICs generally had the 
highest hCFRs (2.3–3.6% across three age groups for high child mortality 
settings; 2.0–3.9% for LMICs) (Table 6–3). Based on these meta–estimates, 
25,700 (UR 12,000–56,500) hPIV–ALRI in–hospital deaths were estimated to 
occur among children under five years. About 42%, 24%, and 34% of these 
deaths were in children aged 0–5 months, 6–11 months, and 12–59 months, 
respectively. In LMICs, there were 19,400 (UR 7,800–50,800) hPIV–ALRI in–
hospital deaths among children under five years. In the stratified analysis by 
World Bank income regions, the global in–hospital deaths were estimated to be 
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6.2.3. Overall mortality of hPIV–associated ALRI 
The hPIV–ALRI overall mortality was estimated using the same inflation factors 
as used in the analysis for hMPV: an inflation factor of 2.2 was used for high 
child mortality settings and 1.3 for low child mortality settings. Details of the 
estimation of inflation factors are in Chapter 5 – 5.2 Adaptions in the methods. 
Using the “inflation factor” approach, 53,000 (UR 25,300–113,500) overall hPIV–
ALRI deaths were estimated to occur globally in children under five years, 
including 47,600 (UR 23,400–97,100) deaths in high child mortality settings and 
5,300 (UR 1,800–16,200) in low child mortality settings (Table 6–4). In the 
sensitivity analysis for high child mortality settings, hPIV was positive in 7.3% 
(95%CI 4.6–11.3) of ALRI deaths (584 ALRI deaths in total) for 0–59 months. 
Based on this percent, 56,100 (UR 36,500–87,400) overall hPIV–ALRI deaths 
were estimated to occur in children under five years in high child mortality 
settings (Appendix A14).  
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6.2.4. hPIV–attributable burden estimates 
Based on type-specific prevalence and AF, an average AF of 73% was 
estimated for hPIV–associated ALRI cases and 66% for hPIV–associated ALRI 
deaths among children under five years (Appendix A15; Table 6–6). Based on 
the AFs and hPIV–associated burden estimates, 21.5 million (UR 14.0–34.1) 
ALRI cases, 735,000 (UR 439,000–1,277,000) ALRI hospitalisations, 17,000 
(UR 7,900–37,300) in–hospital ALRI deaths, and 35,000 (UR 16,700–74,900) 
could be attributed to hPIV in children under five years globally (Table 6–6). 
Based on CHAMPS data, hPIVs were detected in 2.2% (95%CI 0.3–7.7) of ALRI 
deaths in neonates and 6.8% (95%CI 3.7–11.4) for 1–59 months. Applying the 
proportions to the estimates of all–cause ALRI mortality, 45,500 (UR 24,900–
91,700) ALRI deaths could be attributed to hPIV among children under five 
years in high child mortality settings (Appendix A16).
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Table 6-6. Estimation of the attributable fraction for hPIV–associated ALRI deaths for 0–59 months. * 
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cases * D)‡ 
Philippines; 2014–
2016 










Gambia; 2012–2013 2.3 2.9 




Kenya; 2011 – 2011 2.8 5.1 
Mali; 2012 –2014 11 15.9      
Morocco; 2010 2011 3.8 3.7      
Mozambique; 2011–
2014 
0 2.8      
Philippines; 2008– 
2015 
7.6 5.9      
 
* Studies were eligible for the analysis if they tested >=90% of cases and reported at least five ALRI deaths (to ensure the precision of 
estimates). 
† Detailed formulas in Chapter 3.  
‡ Firstly, type–specific AFs for hPIV–ALRI cases were calculated using the median of type–specific odds ratios from two recent multi-country 
studies. The estimated AFs for each hPIV type and the prevalence of four hPIV types were input to yield the average AF for hPIV–ALRI 
cases (73%).  
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6.3. Conclusion and discussion 
6.3.1. Implications 
The estimates suggest that hPIVs are associated with about 21% of ALRI cases, 
6–20% of ALRI hospitalisations, and 7% of ALRI mortality, indicating the 
importance of developing effective targeted prevention and treatment among 
children under five years. Infants are disproportionately affected by hPIV–ALRI 
morbidity and mortality burden, reflecting their immature immunity and the decay 
of maternal antibodies (Simon et al. 2015, Sangli et al. 2001). 
The reduction in hCFRs with age was less marked than the reduction in 
hospitalisation rates with age. Children aged 12–59 months in low– and lower 
middle–income countries had a relatively high hCFR. This might reflect the 
virulence of hPIV and would have implications for prevention and treatment 
strategies – strategies only targeting infants are likely to be insufficient. Similar 
to IFV and hMPV, children hospitalised with hPIV–ALRI in low– and lower 
middle–income countries had the highest hCFRs, warranting continued efforts to 
improve the outcome of hPIV–ALRI in low– and lower middle–income countries.  
6.3.2. Meta–analysis results by different stratification groups 
The global estimates for hPIV–ALRI hospitalisations and in–hospital deaths 
were similar in different stratification groups (Appendix A10). The range of 
hospitalisations (447,000–1,427,000; Appendix A11) derived from the 
proportion–based approach was also broadly similar with the estimates using 
the incidence–based approach.  
6.3.3. Long–term trend in hPIV burden estimates and variation between years 
There were five studies with annual hospitalisation rates of hPIV–ALRI over five 
years or more for 0–59 months (Appendix A17). As shown in Figure A17–3 
(Appendix A17), hospitalisation rates varied across years in each study. The 
maximum seasonal variation was mostly 3–5–fold, and in one study the 
seasonal variation could be as large as 12–fold. As aforementioned, the 
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uncertainties in the hPIV–associated burden estimates could have been 
underestimated due to the aggregation of yearly data.  
No consistent secular trends were observed in the hospitalisation rates across 
the five studies: rates changed by 20% or less in three studies in Argentina and 
South Africa; rates increased substantially in the study in Thailand (0.4 per 
1,000 children per year pre–2010 vs 1.1 after 2010) while decreased in the 
study in Kenya (2.0 per 1,000 children per year pre–2010 vs 0.9 since 2010). 
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6.3.4. Non–detection of hPIV–4 and adjustment for missing hPIV–4 
The estimation of hPIV–associated ALRI burden was complicated by the co–
existence of three–type (hPIV–1 to 3) and four–type data (hPIV–1 to 4). The 
ALRI burden associated with four hPIV types were modelled on two key 
parameters. One parameter was the prevalence of hPIV–4, which was 
estimated in a pooled analysis of hospital–based studies (Appendix A13). This 
prevalence was extrapolated to community–based studies. By doing this, the 
number of hPIV–ALRI cases might have been underestimated because hPIV–4 
accounted for about 20% of all hPIVs during 2012–2017 in one community–
based study detecting four hPIV types. The prevalence in total hospitalised ALRI 
was extrapolated to hospitalised ALRI with hypoxemia. It was impossible to 
assess how the extrapolation affected burden estimates because the information 
of serotype was unavailable in hypoxemic cases. The second parameter – 
hCFRs for four hPIV types – were estimated using very limited data (five 
studies) from high child mortality countries (Appendix A13). The type–specific 
hCFRs had wide and overlapping confidence intervals, especially for hPIV–2 
and hPIV–4, reflecting the substantial variation across five studies and the 
limited precision. Additional relevant hPIV type–specific hCFR data are needed 
to refine the estimate.  
6.3.5. Limitations related to diagnostic tests  
PCR was used in 69% of hospitalisation studies in the main analysis for 
detection for hPIV. The remaining 31% studies used indirect 
immunofluorescence assay (IFA), culture, and a mix of PCR and other tests 
(culture and serologic test). IFA or culture shows lower sensitivity (about 50%) 
and similar specificity compared to molecular tests (Kuypers et al. 2006, Druce 
et al. 2005). Therefore, hospitalisation rates of hPIV–ALRI could have been 
underestimated due to the use of these tests.  
6.3.6. Under–detection of hPIV and adjustment for the levels of testing 
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Similar to IFV and hMPV, incidence rates and hospitalisation rates of hPIV were 
adjusted for the levels of testing based on the assumption that the percent 
positivity for hPIV was the same in those tested and untested. hPIV–ALRI 
hospitalisation rates could have been biased in 23% of studies in which less 
than 90% of cases were tested due to refusal or cases being transferred or 
discharged (8%), cases being systematically sampled (8%), and unknown 
reasons (8%). In the remaining 77% of hospitalisation rate studies, at least 90% 
of cases were tested for hPIV. The under–detection might also cause an 
underestimation to the estimates of hCFR and in-hospital mortality as very 
severe cases and deaths are usually less likely to be tested (Feikin et al. 2017). 
Consistent with this, data from the current systematic review showed that hCFR 
in those tested was higher compared to those untested (Appendix A7). 
6.3.7. Limitations for hPIV–ALRI overall mortality 
The estimate of overall hPIV–associated ALRI mortality was modelled using two 
approaches (“inflation factor” and “the proportion positives of hPIV–ALRI 
deaths”). The analyses were susceptible to the limitations similar to the analysis 
for hMPV, which are explicated in Chapter 4 and 5. The assumptions and 
limitations will be discussed in detail in Chapter 7. The estimates for high child 
mortality settings were broadly similar in the two approaches.  
6.3.8. hPIV–attributable burden estimates 
The hPIV attributable burden estimates suggest that hPIV can cause about 16% 
of ALRI cases, 4–14% ALRI hospitalisations, and 4% of ALRI mortality in 
children under five years (McAllister et al. 2019, WHO 2018, Troeger et al. 
2018). The assumption for the analysis of hPIV–attributable ALRI deaths is 
similar to the analysis for IFV and hMPV. The assumption will be discussed in 
detail in Chapter 7. The point estimate of hPIV–attributable mortality in high child 
mortality countries increased by 30% in another approach using the proportion 
of hPIV-attributable ALRI deaths based on data from CHAMPS (Appendix A16).   
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Chapter 7 Overall findings, strengths and limitations 
7.1. Overall findings 
Table 7–1 shows an overview of the estimated faction of influenza virus, human 
metapneumovirus and human parainfluenza virus in child ALRI cases, 
hospitalisations, and deaths in this thesis. In general, hPIV appears to account 
for a higher proportion of ALRI morbidity and mortality in children under five 
years, followed by IFV and hMPV. Compared with IFV, hMPV accounts for a 
lower proportion of ALRI hospitalisations and deaths, while a higher proportion 
of ALRI cases. Estimation of hMPV and hPIV burden are preliminary based on 
fewer datapoints than IFV, so can be refined when data are more available in 
future. For example, future additional studies are needed to assess and verify 
whether the higher proportion of hMPV in ALRI cases indicates the “true” larger 
impact of hMPV in non–severe ALRI cases than IFV in young children or it is 
due to an overestimation to the number of hMPV–ALRI cases. Overall, the 
burden estimates of the three viruses are likely to be conservative because 
some cases might have been missed as many factors can influence test results 
and cause a false negative diagnosis. Vaccine probe studies can help better 
understand the true impact of hMPV and hPIV with the availability of effective 
vaccines against the two viruses. Additionally, the true number of cases 
requiring hospitalisation is likely to be higher than the estimates, especially in 
regions with limited healthcare capacity and poor access to care.  
On the other hand, as presented in Chapter 1, the carriage of respiratory viruses 
in upper respiratory tract of healthy children and children with mild infections is 
common, and the detection of a virus does not necessarily suggest causal 
association between the detected virus and ALRI. Thus, this thesis incorporates 
the attributable fractions for the three viruses into analyses and makes attempts 
to quantify the true role of the three viruses in causing ALRI morbidity and 
mortality.  
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According to a recent multi–country analysis, viruses cause about two times as 
many ALRI hospitalisations as bacteria among children under five years in low–
income and low middle–income settings with widespread uptake of Haemophilus 
influenzae type b (Hib) vaccine and pneumococcal conjugate vaccine 
(PCV)(Pneumonia Etiology Research for Child Health Study Group (PERCH) 
2019). Respiratory syncytial virus, IFV, hMPV, and hPIV are found to be the 
leading causative viral pathogens of childhood ALRI, accounting for a large 
fraction of the cases. The substantial burden associated with hMPV and hPIV in 
the present work highlights the potential benefit of targeted vaccines and 
treatment in reducing ALRI morbidity and mortality due to the two viruses, 
especially hPIV, in young children. The availability of such interventions and 
increased uptake of influenza immunisation for young children and pregnant 
women will facilitate and accelerate the progress towards meeting the 
Sustainable Development Goal 3 of reducing one–third of under–five mortality 
between 2017 and 2030 (United Nations 2019). 
For all three viruses, age stratified estimates highlight the importance of 
developing targeted interventions for infants, including maternal immunisation, 
active immunisation, and antiviral drugs. High hCFR estimates in low– and lower 
middle–income countries warrant continued efforts and investment to reduce 
ALRI mortality by improving child health condition (e.g., nutrition), immunisation, 
access to care, testing capacity and practice, and the quality of care in these 
countries. 
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7.2. Strengths 
As summarised in Chapter 1, one of the major strengths of this work is the 
incorporation of unpublished data on the incidence, hospitalisations, hCFRs of 
virus–specific ALRI from different geographic locations, especially from low– and 
lower middle–income countries. The incidence rate–based approach requires 
fewer assumptions compared to proportion–based approach. The inflation factor 
approach is straightforward. The assumptions related to the inflation factor 
approach mostly arise from the input data. Assumptions and limitations that 
have been presented in Chapter 4–6 will be discussed in this chapter. Additional 
assumptions and limitations will also be discussed in detail.  
The detailed datasets shared from the collaboration network also allow for the 
estimation of several parameters that are difficult to obtain from published 
literature. These estimates include (1) “the proportion of virus–associated ALRI 
deaths”, (2) “the hCFR for each hPIV type” (mainly estimated using data from 
PERCH), and (3) “the attributable fraction (AF) for virus–associated deaths”. The 
first estimate leads to the development of an alternative approach (in sensitivity 
analysis) for overall mortality of virus–specific ALRI. A mixture of different 
approaches was used to triangulate the mortality estimates. The hPIV type–
specific CFRs allow for the adjustment for missing hPIV–4 in three type hCFR 
studies, helping refine the estimation of mortality associated with four hPIV 
types. While the mere presence of respiratory viruses in a child dying from ALRI 
may not indicate causal association, the AF estimates assist in reporting virus–
attributable mortality, in order to derive estimates which may be closer to the 
true role in ALRI mortality than the virus–associated mortality.  
7.3. Limitations 
To summarise, the uncertainty ranges of estimates of the three viruses are all 
very wide, reflecting the paucity of data and differences between studies, 
including differences in viral epidemiology between populations and differences 
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in methodology. This thesis presents the first estimates of global burden of 
hMPV– and hPIV–ALRI among young children. In light of the paucity of data at 
regional levels for hMPV and hPIV, the estimates for hMPV and hPIV should be 
viewed as preliminary estimates. Additional studies reporting burden estimates 
are needed to improve the estimates for the two viruses. Next section is focused 
on specific limitations. 
7.3.1. Heterogeneity between studies 
A high level of between–study heterogeneity was observed in forest plots, 
indicating the substantial differences in estimates from different studies. 
Heterogeneity is usually broadly classified as epidemiological differences and 
methodological differences. One recommended approach is to incorporate the 
epidemiological heterogeneity into a meta–analysis model (e.g., classical 
random effect model and generalised linear mixed model) (Schroll et al. 2011). 
Such model assumes that the effects from different studies are not identical but 
follow some distribution (normal distribution are commonly used). As a result, 
the combined estimate from such model can only be interpreted as the average 
effect across all studies rather than the “true” effect estimated in a fixed effect 
model as “true” effects can vary (Higgins JPT 2011, Riley et al. 2011). 
Methodological heterogeneity is dealt with in the same way as epidemiological 
heterogeneity because it is challenging to distinguish them. However, the 
presence of methodological differences usually lead to overestimation or 
underestimation in the combined estimate.  
Heterogeneity in methodology was systematically assessed in all studies and 
was found for each outcome, which would indicate the presence of biases and 
affect the estimates in included studies. Certain biases could be dealt with 
statistically. For example, the testing practice was different between studies; 
incidence and hospitalisation rates were adjusted for different levels of testing to 
account for the extents of under–detection. This adjustment, however, could 
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have biased estimates in certain studies as discussed in the chapter 4–6. To 
summarise, when adjusting for the under–detection of viruses, it was assumed 
that the percent positivity for a given virus (any of IFV, hMPV, and hPIV) was the 
same in those tested and untested. The reasons for not testing were unavailable 
in a few studies, and it is suspected that rates in these studies are likely to be 
biased after the adjustment. Even in studies with relevant information, certain 
reason for not testing (i.e., not testing because of refusal) provided little 
information on how the adjustment could affect rates. Moreover, it was 
impossible to adjust for under–detection in studies where the level of testing was 
unavailable, and in these studies rates could have been underestimated. 
Available data from hospital–based studies show that children who were not 
tested for the three viruses tended to have a higher case–fatality ratio than those 
who were tested. The findings are consistent with the observation and 
understanding that patients with severe infections and fatal cases are usually 
under–detected (Feikin et al. 2017). This suggests that the estimates of hCFRs 
and mortality of virus–ALRI might have been underestimated. One recent multi–
country analysis showed that the detection of hPIV was negatively associated 
with disease severity in children under five years; the differences for IFV and 
hMPV were less obvious (Pneumonia Etiology Research for Child Health Study 
Group (PERCH) 2019). Thus, a higher level of severity among untested patients 
might indicate an overestimation to hPIV hospitalisation rates after adjusting for 
the under–detection of hPIV.   
For other biases arising from methods, the magnitude is difficult to quantify 
because different estimates between studies could reflect both the 
methodological heterogeneity between studies and the inherent difference in a 
given virus’ epidemiology between populations. Meta–regression analysis has 
been used to identify characteristics affecting the estimates of interest and to 
quantify their impact. This, however, is inappropriate in the present work 
because the “real” difference between populations and seasons could confound 
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and blur the true association between methodological characteristics and 
estimates. Several key methodological factors can affect burden estimates, but 
their influences were not dealt with statistically in this thesis. One of the key 
factors is the test method. Heterogeneity mainly came from differences in the 
sensitivities and specificities of various test methods. Since the sensitivity of a 
given test may vary by viruses, the potential bias regarding this issue has been 
discussed separately for each virus (in Chapter 4–6). To summarise, traditional 
test methods usually have lower sensitivities and similar specificities compared 
to molecular tests, producing false negative test results more commonly than 
false positive test results. Thus, numbers of virus–positive cases and infection 
rates could have been underestimated in studies using these test methods. 
Other factors are summarised below.  
Case ascertainment 
There are two types of case ascertainment: active ascertainment (active studies) 
and passive ascertainment (passive studies). In active studies, cases were 
identified actively through regular household visits, while in passive studies, 
cases were only identified when patients sought care in healthcare facilities. By 
viruses, 9–21% community–based studies were conducted in clinics, offices of 
general practice, and outpatient departments in high–income countries. Other 
community–based studies are active household studies. The identification of 
cases in active studies does not rely on care–seeking, so active studies are 
likely to provide estimates closer to the “true” virus–ALRI burden in a defined 
catchment area. However, active studies are extremely rare because the 
establishment and follow–up is resource–intensive.  
All the hospital–based studies included in the analysis are passive studies. 
Passive studies are efficient in identifying severe viral respiratory infections 
requiring hospital care. However, in addition to the perceived severity of 
illnesses, whether a patient presents to or is admitted to hospitals is often 
related to geographic accessibility, healthcare cost, and healthcare services. In 
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addition to hospitals, patients may go to traditional healers, drug sellers, or 
choose not to seek any care (Webair and Bin-Gouth 2013). Therefore, the 
potential number of severe cases requiring hospitalisation is likely to be higher 
than the current estimate in resource–limited regions. Care–seeking can vary 
substantially within and between countries, which makes it difficult to quantify 
the underestimation in the estimate of global hospitalisations (Deutscher et al. 
2012, Jordan et al. 2009, Breiman et al. 2011, Wong et al. 2018). Pneumonia 
care–seeking data in UNICEF show that an average of 62% of children with 
pneumonia symptoms did not seek formal health care in 86 high child mortality 
regions or countries, indicating the estimates of hospitalisations could have been 
considerably underestimated in high child mortality countries (UNICEF 2016).  
Population denominator 
In addition to case ascertainment, infection rates can also be affected by the 
denominator. Ideally, individually recorded person–time at risk should be the 
most accurate denominator for estimating infection rates. However, more than 
80% of hospital–based studies used official population estimates (e.g., the mid–
year population for a given catchment area). Using official population estimates 
has an advantage of saving efforts and resources. The disadvantage is that the 
official population estimates are not necessarily available for the defined 
catchment area served by the study hospitals. Sometimes the official estimates 
may be only available for a broader or a smaller area than the study hospitals 
provide care for. Hospital–based studies in the main analysis could be classified 
into: (1) the official population estimates were available for the exact catchment 
area (or similar area) that the study hospitals served; (2) the original official 
population estimates were available for a broader area, but were adjusted to 
deduct the non–catchment population, who were not served by the study 
hospitals. The adjustment can improve estimates of hospitalisation rates by 
avoiding the overestimation of denominators. However, relevant information is 
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lacking in nine studies with data on IFV hospitalisation rates, and it is uncertain 
whether the denominator was overestimated or not.  
Study design 
In ALRI aetiology studies, specimens are usually collected when children 
present to or are admitted to health facilities. Therefore, included studies are all 
cross–sectional in terms of the sequence of exposure (viral infections) and 
outcome (ALRI). Nevertheless, included studies could still be divided into two 
types according to whether the cases were identified prospectively (according a 
pre–specified method) or retrospectively. By viruses and outcomes, 0–25% of 
studies were retrospective (Appendix A18). These studies mostly identified 
cases using retrospective records, such as hospital discharge records, and 
provided little information on the case enrolment or sampling. It is suspected that 
estimates from these retrospective studies are more likely to be biased than 
prospective studies.   
Patient groups excluded 
By outcomes, 0–14% of studies in the main analysis excluded children with 
certain high–risk conditions. These conditions include heart disease, chronic 
lung disease, metabolic and genetic diseases, immunosuppression, and 
prematurity. As summarised in Chapter 1, excluding patients with underlying 
conditions might lead to an underestimation to the rates of virus–ALRI and the 
risk of mortality due to these infections.  
By outcomes, 10–33% of studies in the main analysis excluded neonatal data 
(neonatal hospitalisation rates or hCFRs). To assess the impact, hospitalisations 
of hMPV–ALRI for 0–5 months were estimated by summing up the estimates for 
neonates and for 1–5 months; the estimate was comparable to the estimate for 
0–5 months as an overall group. In studies reporting neonatal hCFRs, most 
studies had a very small number of all–cause ALRI deaths (less than five 
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deaths) for neonates. A subgroup analysis for neonates was not performed due 
to the limited precision and the small number of studies. The estimates of 
mortality might be biased due to the exclusion of neonates in several hCFR 
studies.  
Case definition 
For most outcomes, less than 30% of studies used case definitions different 
from the standardised case definition (Appendix A18). The proportion is higher 
(about 40–50%) for IFV–ALRI hospitalisation rate and the proportion of hMPV 
and hPIV in hospitalised ALRI cases. The non-standardised case definitions 
used in hospital–based studies were generally similar for the three viruses. 
These definitions include hospitalised ARI, hospitalised ARI or fever, 
hospitalised ARI with fever, hospitalised ALRI or croup (for hPIV), and 
hospitalised with respiratory and non-respiratory diseases associated with IFV 
(limited to IFV). Using definitions that are broader than the standardised case 
definition, such as hospitalised ARI, hospitalised ARI or fever, and hospitalised 
ALRI or croup (for hPIV) can capture not only the hospitalised virus–ALRI cases, 
but also hospitalised virus–acute upper respiratory infections (AURI). Therefore, 
using these broader definitions could have caused an overestimation to the 
hospitalisations of virus–ALRI. Using “hospitalised ARI with fever” is likely to 
identify a broader group of cases than “hospitalised ALRI” as fever is reported to 
lower the sensitivity of ALRI only marginally, while ARI increases the sensitivity 
(Cardoso et al. 2011). Even in studies using the standardised case definition, 
heterogeneity could also exist because the physician’s judgement could vary 
between facilities. 
Most of the hCFR studies (85–93%, varying by the three viruses) in the main 
analysis used the standardised case definition. Other studies used “hospitalised 
ARI” and “hospitalised due to respiratory and non-respiratory diseases 
associated with IFV”. However, it is uncertain how these definitions affected the 
Global burden of acute lower respiratory infection (ALRI) associated with influenza virus, human 
metapneumovirus, and human parainfluenza virus among children under five years 
Overall findings, strengths and limitations  165 
hCFR estimates. The cases, though not defined as ALRI, were severe enough 
to require hospital admission, which might indicate similar disease severity.  
7.3.2. Precision of estimates 
hCFR studies had relatively small sample sizes (i.e., small numbers of virus–
confirmed ALRI cases), so hCFR estimates were less precise compared with 
other measures. The median study size was 52 (IQR 31–120) for IFV, 45 (IQR 
14–109) for hMPV, and 55 (IQR 28–109) for hPIV. The precision of individual 
studies decreased as data were further stratified by age groups. Small studies 
were not excluded for two reasons. First, excluding small studies could lead to 
the loss of information. Second, the precision of estimates in individual studies 
were incorporated into the combined estimates in the meta–analysis. A meta–
analysis yields a weighted average by combining individual studies, and smaller 
studies tend to have smaller weights.  
Yearly data on incidence rates, hospitalisation rates, and hCFRs were 
aggregated to ensure the precision of estimates in the age– and region–
stratified analysis. However, the variation in these estimates between seasons 
were not accounted for (Appendix A17). Therefore, the true uncertainty of 
burden estimates is likely to be broader.  
7.3.3. Lack of viral respiratory infection burden data 
Incidence, hospitalisations and in–hospital deaths 
The generalisation of meta–estimates is limited because data on virus–ALRI 
incidence, hospitalisations and hCFRs were only available for limited sites and 
time points. For example, for hMPV and hPIV, there were very few data from 
Eastern Mediterranean and European region. This also leads to one of the 
limitations that this work is unable to develop country–specific burden estimates, 
which is relevant to national policy. However, this work intends to estimate the 
overall impact of the three viruses, especially hMPV and hPIV, for which global 
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burden estimates in young children have not been made, informing future new 
public health research and surveillances on the viruses. The availability of local 
research and surveillances in future will facilitate the estimation of country–
specific burden.  
7.3.4. Data from all time points (from 1990’s to 2010’s) were aggregated 
together in the present meta–analysis. A key assumption is that the global 
burden of virus–ALRI did not change over time. Multi–year data suggest 
that the trend in hospitalisation rates of virus–ALRI can be different 
between sites. The rate can remain unchanged at some sites, while 
increase or decrease at other sites (Appendix A17). These multi–year 
studies, however, constitute only a small fraction of included studies. In 
another sensitivity analysis, the estimate of IFV-associated hospitalisations 
remained similar after excluding data prior to 2010 (Appendix A8). For 
hMPV and hPIV, fewer data were available compared to IFV, which did not 
allow for such analysis. It was more challenging to assess how incidence 
rates and hCFRs changed over time due to the scarcity of multi–year 
incidence rates and the small number of virus–ALRI deaths.The estimation 
of overall virus–ALRI deaths 
Current results suggest that over 50% of ALRI deaths occur in the community, 
for which specific viral diagnosis is usually unavailable. Different analytical 
models were used to estimate the virus–specific ALRI mortality, and potential 
biases and limitations for each model are summarised in Chapter 4 and 5. In 
addition to those specific biases, several limitations that are common to all 
models should be noted. First, data were limited in all the models, and additional 
data from diverse geographical regions could improve the mortality estimates. 
Second, the overall mortality of virus–ALRI was estimated using multiple 
approaches in this thesis. Due to the scarcity of virology testing in the 
community setting, especially for ALRI deaths, it was difficult to obtain the “ideal” 
data for each model. Several types of data were used as proxies of the “ideal” 
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data, varying by different settings and different viruses. Table 7–2 shows a 
summary of input data and assumptions in the main analysis. However, no 
evidence validating the assumption regarding using these data as proxies were 
identified. Violations of this assumption could bias the estimates of virus–ALRI 
overall mortality. Post–mortem studies may provide information that helps test 
the assumptions and improves the understanding of the causes of child ALRI 
deaths (Turner et al. 2012, CHAMPS). However, it should be noted that post–
mortem studies are susceptible to several biases caused by the low 
acceptability, microbiological contamination and pathogen degradation (Turner 
et al. 2012).
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7.3.5. The estimation of virus–attributable ALRI mortality 
In this thesis, attempts were made to estimate the virus–specific attributable 
ALRI mortality using two approaches – “the attributable fraction (AF) for virus–
associated ALRI deaths” and “the percent of virus–specific attributable ALRI 
deaths”. For the first approach, the AF for virus–specific associated ALRI 
deaths, which are not readily available in published reports, was modelled by 
assuming that the hCFR for virus–unattributable cases was equal to the hCFR 
for virus–negative cases. A wide range of pathogens, including viruses and 
bacteria, which co–exist with IFV, hMPV and hPIV, are possible causes of the 
unattributable ALRI (Panda et al. 2014, Zhong et al. 2019, Nolan et al. 2017). 
Therefore, virus–negative cases, caused by a mix of pathogens (including 
viruses and bacteria) except for the virus of interest, were used to resemble the 
spectrum of causative pathogens of unattributable cases. The lower hCFRs for 
virus–attributable cases compared with virus–unattributable cases, as derived 
from the model, is generally consistent with the understanding that bacterial–
viral co–infections are associated with increased severity (Ruuskanen et al. 
2011, Brealey et al. 2015). However, no direct evidence was found to validate 
this assumption. Violations of this assumption could bias the estimates of virus–
attributable ALRI mortality. 
The second approach was developed with CHAMPS data. The cause of ALRI 
deaths is ascertained based on the test result of post-mortem specimens and 
other individual information, including laboratory, histopathology and verbal 
autopsy, following a standardised procedure (CHAMPS , Blau et al. 2019). 
Although CHAMPS provides valuable data that improves the understanding of 
causes of ALRI deaths, several potential limitations should be noted as 
discussed in a recently published paper (Salzberg et al. 2019). First, some 
deaths at the sites may be missed. The findings among captured deaths might 
differ from missed deaths. Second, CHAMPS network includes seven sites in 
Sub–Saharan Africa and South Asia, the estimated viral attribution of these sites 
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might not be generalizable to other regions and countries with high child 
mortality (e.g., the region of Americas). Third, although CHAMPS has conducted 
community–based and facility–based surveillance, the majority of the enrolled 
deaths during the initial phase of the surveillance were identified through health 
facilities. Fourth, CHAMPS provide site–combined data. Differences between 
sites could not be accounted for when analysing the combined dataset, thus the 
uncertainty of virus–attributable mortality estimates could have been 
underestimated.  
7.3.6. Potential limitations in data from UN and WHO 
The burden estimates in this work were dependent on the estimates from UN 
Inter-Agency Group on Mortality Estimation on the under–five mortality rates in 
several ways. First, the burden estimates were calculated using UN Population 
estimates, which were estimated using the UN mortality rate estimates. Second, 
meta–analyses were stratified into two groups based on the UN mortality rate 
estimates. Third, in the sensitivity analysis, the overall hMPV– and hPIV–ALRI 
mortality estimates for high child mortality settings were developed using WHO 
child ALRI mortality estimates. Since the WHO child ALRI mortality estimates 
were modelled on the UN mortality rate estimates and data on cause-of-death, 
the hMPV– and hPIV–ALRI mortality estimates for high child mortality settings 
(in sensitivity analyses) were also partially dependent on the validity of UN 
mortality rate estimates.  
The UN population and mortality estimates were chosen in current analyses to 
promote global consistency and to allow for comparison between the updated 
IFV burden estimates and the previous estimates (McAllister et al. 2019). 
However, a recently published study compared 2017 UN child mortality rate 
estimates with IHME estimates and found a relative difference greater than 10% 
in the under–five mortality rate estimates in 32 countries (Hug et al. 2019). The 
largest differences were found in certain African countries and Asian countries 
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with different input data and countries with conflicts or civil unrest and high HIV 
prevalence (Alkema and You 2012). The uncertainty of under–five mortality rate 
estimates in these countries could have affected our global and regional burden 
estimates of IFV, hMPV and hPIV.  
Chapter 8 In sensitivity analyses, WHO under–five ALRI mortality estimates 
for high child mortality settings were used to derive the hMPV– and hPIV–ALRI 
mortality estimates for this setting. There has been a debase about the 
differences between WHO under–five ALRI mortality estimates and the 
estimates modelled by IHME. The 2017 WHO estimates are generally similar to 
IHME estimates in African region and region of Americas (less than 10% of 
difference), and slightly different in Eastern Mediterranean region (27%) and 
South-East Asia region (20%), with the largest difference observed in European 
region (about 50%) (WHO 2018, Institute for Health Metrics and Evaluation 
(IHME) 2020). Thus, for high–child mortality settings which do not include the 
European countries, the WHO ALRI mortality estimates were generally 
consistent with the IHME estimates. However, there are still uncertainties in 
WHO ALRI mortality estimates associated with model uncertainty and quality of 
data on cause-of-death, especially in countries without adequate vital 
registration systems (Li Liu et al. 2015). These uncertainties could have affected 
the hMPV– and hPIV– ALRI mortality estimates for high child mortality settings. 
Proposals for improving future burden estimates and 
implications for immunisation 
8.1. Proposals for improving future burden estimates 
The discussion in the foregoing paragraphs and chapters have revealed the 
gaps that existed in data and analysis. One general issue is that data on virus–
associated ALRI incidence, hospitalisations, and mortality are not available for 
most parts of the world, and where the data are available, data are only 
available for certain years or seasons. Studies initiated in regions with no / 
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limited data should be encouraged because they can provide valuable 
information for local policy makers and help refine the global burden estimates. 
Countries, especially those with high child mortality, can expand existing 
influenza sentinel surveillances or undertake new sentinel surveillances to 
quantify the local public health impact of hMPV and hPIV (e.g., hospitalisations), 
which in turn would help refine the global burden estimates.   
Of all outcomes, incidence rates in the community is one of the scarcest type of 
data. In high–income countries with good care seeking, records from outpatient 
and general practitioner offices offers an opportunity to estimate the virus–
associated incidence. Efforts should be made to increase the availability of data 
by publishing them in papers or on webpages. For example, linking clinical care 
patient level data to virology dataset allows for the estimation of virus–
associated burden in community and hospital settings in some regions (Simpson 
et al. 2015). In other regions with poor care seeking, the incidence can be only 
estimated in community–based studies with household level follow-up, which 
requires considerable funding and resources to initiate and to maintain.  
With the availability of maternal and paediatric influenza vaccines, vaccine probe 
studies provide an alternative option for quantifying the contribution of influenza 
in causing ALRI among young children. Since vaccine probe studies do not 
require viral diagnosis, they have the advantage of accounting for infections that 
are undetectable at specimen collection and accounting for influenza virus’ 
contribution in predisposing children to substantial bacterial infections. Despite 
of the advantages, results from vaccine probe studies can be affected by the 
efficacy of influenza vaccines that are used, which can vary by seasons. Trials 
using maternal influenza vaccine as the probe have estimated the proportion of 
ALRI hospitalisations attributable to influenza among infants under 6 months 
(Omer et al. 2018).  
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Global Influenza Surveillance and Response System (GISRS) provides data on 
influenza activity across many countries, which have been used to estimate 
influenza associated disease burden at the global level (World health 
Organization 2020, Simonsen et al. 2013, Iuliano et al. 2018). The system can 
be expanded to include the detection of hMPV and hPIV providing detailed 
virology data, which may be used to estimate hMPV and hPIV disease burden 
and inform potential upcoming immunisation strategies.  
The virus–associated ALRI overall mortality estimates were modelled on in–
hospital deaths. The estimation of in–hospital mortality can be improved by 
incorporating post–mortem tests to improve the viral diagnosis in children who 
die before specimen collection. Moreover, since post–discharge mortality 
accounts for a substantial fraction of mortality, especially in high child mortality 
countries, hospital–based studies are encouraged to follow up children who are 
discharged from hospitals (for several weeks) to identify children who deteriorate 
or die following discharge (Pneumonia Etiology Research for Child Health Study 
Group (PERCH) 2019, Wiens et al. 2013). The establishment of high–quality 
regional and national health information systems can capture and record virus–
confirmed cases and deaths, which can improve the quality and precision of the 
mortality estimates.  
For the estimation of overall virus–ALRI deaths, estimates can be refined by 
increasing the availability of several types of data with the presence of multiple 
models.  
• The number of ALRI deaths occurring in hospital settings (i.e., deaths in 
inpatient departments) and the number of ALRI deaths occurring in 
community settings (i.e., deaths at home, on the way to health facilities, in 
outpatient departments and emergency departments) within a defined 
catchment area. In some regions, especially high–income countries, 
relevant data may have been collected, while not readily available in 
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public reports. For example, relevant data were identified in vital statistics 
in the US (Centers for Disease Control and Prevention and National 
Center for Health Statistics). The collection of relevant high–quality data 
in resource–limited regions is dependent on the development of death 
registration systems like Health and Demographic Surveillance System 
(HDSS) and INDEPTH Network and the use of tools (e.g., verbal autopsy) 
for establishing the cause of death (Ye et al. 2012). In addition, the 
estimation of future estimates requires new data because care seeking 
may change over time. For IFV, the generalisation of inflation factor in low 
child mortality settings can be improved when location–specific IFV–
associated ALRI deaths are readily available in more regions.  
• The proportion of virus–associated ALRI deaths in total ALRI deaths 
among children under five years. Relevant data should be more available 
in healthcare facilities than in the community because of the availability of 
virology tests. The collection of community mortality data and a full 
understanding of the aetiology of child ALRI deaths in both healthcare 
facilities and communities rely on the establishment of post–mortem 
surveillances like the CHAMPS Network. Regression models have also 
been used to estimate the impact of certain viruses. Compared to 
regression models, using observational data (i.e., the proportion of virus–
associated ALRI deaths) does not require advanced model techniques 
and regression related assumptions. However, observational data are 
likely to underestimate the impact of a virus because the virus may be 
undetectable at specimen collection. Moreover, it is challenging to 
quantify the burden of cardiovascular or all–cause mortality associated 
with a virus (e.g., IFV) using observational data because children with 
non–respiratory infections are less likely to be tested.  
• Similar to IFV, it may be possible to estimate the burden associated with 
hMPV and hPIV in regression models using the weekly or monthly 
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number of deaths and the concurrent virus activity data within a defined 
catchment area. But in the present work, it is impossible to develop such 
models due to the unavailability of data. Relevant data can be collected 
within existing influenza surveillance systems in future to develop 
regression models.  
In addition to the above, for IFV, the adjustment of influenza vaccination in future 
estimates requires vaccine coverage data among young children and pregnant 
women and the vaccine effectiveness by seasons. The adjustment will become 
increasingly necessary as maternal and paediatric influenza vaccine strategy is 
likely to be adopted in more countries in future. Studies assessing the global 
distribution of influenza vaccine doses found that despite the overall increase in 
the number of distributed doses between 2004 and 2011, the distribution of 
influenza vaccine was highly uneven in and across WHO regions with 95% of 
doses being distributed to three WHO regions – the region of Americas, 
European region and Western Pacific region, and only 5% of doses being 
distributed to 50% of the world’s population (Palache et al. 2017). WHO and 
UNICEF have been monitoring and evaluating national influenza immunisation 
policies and uptake in WHO member states (Ortiz et al. 2016). However, 
available global reports only focused on the national influenza coverage in 
general population, with no information regarding influenza uptake for specific 
subgroup population (e.g., in young children and pregnant women). Influenza 
coverage for children and pregnant women have not been readily available in 
most parts of the world, except in some European countries and in the region of 
Americas (Palache et al. 2014, Pan American Health Organization 2015, 
European Centre for Disease Prevention and Control 2017). By reporting 
influenza vaccine coverage in subgroup population, WHO and UNICEF can 
improve influenza vaccination monitoring, especially in high–risk groups, and 
facilitate improvement on global and national influenza burden estimation in 
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future. To improve the global hPIV burden estimates, hPIV–4 should be tested 
more often as is being done for hPIV–1 to hPIV–3.  
8.2. Implications for immunisation 
Vaccination is the most effective way to prevent influenza infections and severe 
outcomes related to the infections. Although it is recommended that young 
children and pregnant women be prioritised for influenza immunisation, only a 
small fraction of low– and middle–income countries have adopted national 
maternal or paediatric influenza vaccination programs (M. C. Nunes and S. A. 
Madhi 2018). The substantial IFV–associated burden estimates in low– and 
lower middle–income countries indicate the importance to adopt national 
maternal and paediatric influenza immunisation programmes in these countries. 
Moreover, evidence suggests that vaccinating children can provide substantial 
benefits for non-vaccinated population through herd immunity effect, especially 
vulnerable population (e.g., older population) (Ropero-Alvarez et al. 2016). This 
strategy is of great significance in view of the limited effect of influenza vaccines 
for older people (Kim 2014). To achieve better and longer protection, many 
factors, such as the vaccination timing and the number of influenza vaccine 
doses administrated per year, should be considered in immunisation strategies 
(Young et al. 2018, Grohskopf et al. 2019).  
Progress has been made in the development of hMPV and hPIV vaccines. As 
summarised in Chapter 1, several types of vaccines against hMPV and hPIVs 
are under investigation. One live–attenuated recombinant hMPV vaccine has 
recently been evaluated in a recent phase I clinical trial, and several hPIV–3 
candidate vaccines have been evaluated or are under evaluation in phase I and 
II clinical trials (San Mateo et al. 2017, Karron et al. 2011, Bernstein et al. 2011, 
Bernstein et al. 2012). It has been shown that three–dose hPIV vaccines can 
substantially increase antibody levels of vaccine recipients (Bernstein et al. 
2011). The vaccine development is currently focused on children older than 6 
months and adults, while little is known about vaccines for young infants under 6 
Global burden of acute lower respiratory infection (ALRI) associated with influenza virus, human 
metapneumovirus, and human parainfluenza virus among children under five years 
In sensitivity analyses, WHO under–five ALRI mortality estimates for high child mortality settings 
were used to derive the hMPV– and hPIV–ALRI mortality estimates for this setting. There has 
been a debase about the differences between WHO under–five ALRI m
  177 
months. Additional efforts and investment should be encouraged to accelerate 
the development of hMPV and hPIV vaccines in the future.
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Chapter 9 Conclusions 
This thesis shows that IFV is associated with 7% of ALRI cases, 5–17% of ALRI 
hospitalisations, and 3% of ALRI deaths among children under five years. hMPV 
is associated with 11% of ALRI cases, 4–13% of ALRI hospitalisations, and 2% 
of ALRI deaths. hPIV is associated with 21% of ALRI cases, 6-20% of ALRI 
hospitalisations, and 7% of ALRI deaths. Future progress in reducing ALRI 
morbidity and mortality requires targeting prevention and treatment for young 
children, especially infants. Additional efforts are needed to improve the 
outcome of children in low– and lower middle–income countries who are 
infected with the three viruses.    
Several challenges remain to be addressed to improve the estimation of global 
burden of virus–ALRI. First, the availability of data on virus–ALRI incidence, 
hospitalisations, and mortality is limited to a very small fraction of regions and 
discrete seasons. Existing influenza sentinel surveillances can be expanded to 
include the detection of other important respiratory viruses (e.g., RSV, hMPV 
and hPIV) to improve the availability of data on virus–ALRI burden, especially 
hospitalisations. Second, the identification of post–discharge mortality and the 
presence of good health service information systems with complete records of 
virus–confirmed deaths would substantially improve the mortality estimates. 
Third, the availability of simple and rapid viral diagnostic tests with good 
sensitivity and specificity would contribute to the identification of virus–
associated infections and deaths in primary care facilities (Merckx et al. 2017). 
Post-mortem testing would assist in addressing the gaps existing in the cause of 
child ALRI death and improving virus–specific mortality estimates. Additionally, 
refinement of mortality estimates at national and global level is impossible 
without complete death registration systems and sample–based mortality 
surveillance systems (e.g., in China and India), and valid methods to establish 
the cause of death (e.g., medical certificate of cause of death and verbal 
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autopsy) (Shiwei Liu et al. 2016, Liu et al. 2019). These challenges need to be 
addressed to develop and improve national and global disease burden 
estimation.
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Chapter 10 Appendices 
A1. Glossary 
Abbreviation Full name 
AF attributable fraction 
AFR African region 
AMR Region of the Americas 
ALRI acute lower respiratory infection 
APAAP alkaline phosphatase and monoclonal anti–alkaline phosphatase 
ARI acute respiratory infection 
BAL bronchoalveolar lavage 
CI confidence interval 
CHAMPS Child Health and Mortality Prevention Surveillance 
d day(s) 
DFA Direct fluorescent antibody test 
DHS Demographic and Health Survey 
ELISA enzyme-linked immunosorbent assay 
EIA EIA: enzyme immunoassay. 
EMR Eastern Mediterranean region 
ETA endotracheal aspirate 
EUR European region 
HI hemagglutination-inhibition assay 
HICs high income countries 
hMPV human metapneumovirus 
hMPV–ALRI human metapneumovirus–associated ALRI 
hPIV human parainfluenza virus 
hPIV–ALRI human parainfluenza virus–associated ALRI 
ICU Intensive care unit 
IF immunofluorescence 
IFA indirect immunofluorescence assay 
IFV influenza virus 
IFV–ALRI Influenza–associated ALRI 
IHME the Institute for Health Metrics and Evaluation 
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Abbreviation Full name 
ILI influenza–like illness 
INDEPTH the International Network for the Demographic Evaluation of 
Populations and their Health 
IVAC International Vaccine Access Center 
LICs Low income countries 
IMCI Integrated Management of Childhood Illness 
LMICs Lower middle income countries  
m month(s) 
MICS Multiple Indicator Cluster Survey 
MN micro-neutralization assay 
MV mechanical ventilation 
NA Not applicable 
NPA nasopharyngeal aspirate 
NPS nasopharyngeal swab 
NPW nasopharyngeal wash 
NS nasal swab 
NW Nasal wash 
OP oropharyngeal 
OPS oropharyngeal swab 
PAHO Pan American Health Organization 
PCR polymerase chain reaction 
PCV pneumococcal conjugate vaccine 
PERCH Pneumonia Etiology Research for Child Health Study Group 
PNE Pneumonia 
pSBI Possible severe bacterial infections. 
RIDT Rapid influenza diagnostic test 
RSV respiratory syncytial virus 
SARI severe acute respiratory infection 
sALRI Severe acute lower respiratory infection 
SEAR South–East Asia 
SPIA Solid-phase immunoassay 
SpO2 Oxygen saturation 
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Abbreviation Full name 
TRFIA time-resolved fluoroimmunoassay 
TS throat swab 
UK United Kingdom 
UMICs Upper middle income countries  
UNICEF United Nations Children's Fund 
UR Uncertainty range 
US United States of America 
vsALRI Very severe acute lower respiratory infection 
WHO World Health Organization 
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A2. Search Strategy of IFV 
Medline (Ovid) 
1. exp Influenza, Human/ 
2. exp Influenzavirus B/ or exp Influenzavirus A/ or exp Influenzavirus C/ 
3. *Influenza Vaccines/ or *Influenza A virus/ or *Influenza, Human/ or *Respiratory Tract 




7. exp Bronchiolitis/ or exp Bronchiolitis, Viral/ 
8. exp Respiratory Tract Diseases/ 
9. exp Respiratory Tract Infections/ or acute respiratory infections.mp. or Influenza, Human/ 
10. exp Pneumonia, Viral/ or *Pneumonia/ or acute lower respiratory infections.mp. 
11. exp Incidence/ 
12. exp Prevalence/ 
13. exp Morbidity/ 
14. exp Child Mortality/ or exp Infant Mortality/ or *Hospital Mortality/ or exp Mortality/ 
15. exp Death/ or exp "Cause of Death"/ 
16. pediatric mortality.mp 
17. paediatric mortality.mp 
18. pediatric death.mp. 
19. paediatric death.mp. 
20. burden.mp. 
21. (1 or 2 or 3 or 4 or 5 or 6) and (7 or 8 or 9 or 10) and (11 or 12 or 13 or 14 or 15 or 16 or 
17 or 18 or 19 or 20) 
22. animals 
23. 21 not 22 




1. exp Influenza virus A/ or exp influenza/ or exp Influenza virus A H3N2/ or exp Influenza 
virus/ or exp Influenza virus A H1N1/ or exp Influenza virus B/ 
2. exp pandemic influenza/ or exp pandemic 
3. influenza outbreak*.mp 
4. exp 2009 H1N1 influenza/ or 2009 H1N1.mp 
5. H1N1pdm.mp 
6. pH1N1.mp 
7. exp respiratory tract infection/ 
8. exp lower respiratory tract infection/ 
9. exp virus pneumonia/ or exp pneumonia/ 
10. exp bronchiolitis/ or exp viral bronchiolitis/ 
11. exp incidence/ 
12. exp prevalence/ 
13. exp morbidity/ 
14. exp mortality/ or exp childhood mortality/ or exp infant mortality/ 
15. exp death/ or exp child death/ 
16. paediatric mortality.mp. 
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17. paediatric mortality.mp. 
18. paediatric death.mp. 
19. paediatric death.mp. 
20. burden.mp. 
21. (1 or 2 or 3 or 4 or 5 or 6) and (7 or 8 or 9 or 10) and (11 or 12 or 13 or 14 or 15 or 16 or 
17 or 18 or 19 or 20) 
22. animals 
23. 21 not 22 
24. Limit 23 to (yr="2009 –2018" and (infant or preschool child <1 to 6 years>)) 
 
Global Health (Ovid) 
1. exp influenza A/ or exp Influenza A virus/ or exp Influenza B virus/ or exp influenza viruses/ 
or exp swine influenza A viruses/ or exp swine influenza viruses/ or exp influenza B/ or exp 
influenza/ 
2. pandemic influenza.mp 
3. 2009 H1N1.mp 
4. H1N1pdm.mp 
5. pH1N1.mp 
6. influenza outbreak*.mp 
7. (respiratory diseases or lower respiratory tract infections).sh. 
8. exp pneumonia/ 
9. bronchiolitis.mp. 
10. exp incidence/ 
11. burden.mp. 
12. exp morbidity/ 
13. exp infant mortality/ or exp mortality/ 
14. exp death/ or exp "causes of death"/ 
15. paediatric mortality.mp. 
16. paediatric mortality.mp. 
17. paediatric death.mp. 
18. paediatric death.mp. 
19. (1 or 2 or 3 or 4 or 5 or 6) and (7 or 8 or 9) and (10 or 11 or 12 or 13 or 14 or 15 or 16 or 
17 or 18) 
20. Limit 19 to yr="2009–2018" 
 
CINAHL 
1. (MH “Influenza, Humans+”) OR (MH “Influenzavirus B+”) OR (MH “Influenzavirus A+”) OR 
(MM “Influenza, Pamdemic (h1N1)2009”)) 
2. (MM “Bronchiolitis”) OR (MM “Community–Acquired Pneumonia”) OR (MM “Pneumonia, 
Viral”) OR (MM “Influenza, Human”) 
3. “children” 
4. 1 AND 2 AND 3 
Limiters: 2009–2018 
 
Web of Science 
TOPIC: influenza or 2009 H1N1 or H1N1pdm or pH1N1 AND TOPIC: children AND TOPIC: 
acute respiratory infection or pneumonia 
Time span= 2009–2018 
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Global Health Library  
tw:((tw:(influenza) OR tw:(ph1n1) OR tw:(h1n1pdm) OR tw:(2009 h1n1)) AND (tw:(children))) 
AND (db:("WPRIM" OR "LILACS" OR "IMSEAR" OR "IMEMR" OR "WHOLIS") AND 
year_cluster:("2009" OR "2010" OR "2011" OR "2012" OR "2013" OR "2014" OR "2015" OR 
"2016" OR "2017" OR"2018" )) 
 
Google 
children acute respiratory infections influenza 




CNKI (China Knowledge Resource Integrated Database) 
Topic: respiratory infection or respiratory tract infection or pneumonia or bronchiolitis  
AND Topic: influenza virus or H1N1 or pandemic influenza 
AND Topic: morbidity or mortality or disease burden or hospitalization 
AND Topic: children or infant 
From 1995 to Dec 31 2018. 
 
Wanfang Data 
Topic: respiratory infection or respiratory tract infection or pneumonia or bronchiolitis 
AND topic: influenza virus or H1N1 or pandemic influenza 
AND Topic: morbidity or mortality or disease burden or hospitalization 
AND Topic: children or infant 
From 1995 to Dec 31 2018. 
Chongqing VIP 
Title or key words: (children or infant) 
AND (morbidity and mortality or mortality cases or hospitalization or disease burden) 
AND (influenza virus or H1N1 or pandemic influenza) 
AND (respiratory tract infection or respiratory infection or pneumonia or bronchiolitis or lung 
infection or severe pneumonia or infectious bronchiolitis) 
AND (Jan 1 1995 to Dec 31 2018). 
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A3. Search strategy of hMPV and hPIV 
Medline (Ovid) 
1. exp Parainfluenza Virus 1, Human/ or exp Parainfluenza Virus 2, Human/ or exp 
Parainfluenza Virus 3, Human/ or exp Parainfluenza Virus 4, Human/ or exp Parainfluenza 
virus infection/ or infection, parainfluenza virus.mp. or infections, parainfluenza virus.mp. or 
virus infection, parainfluenza.mp. or virus infections, parainfluenza.mp. or parainfluenza 
vaccine.mp. or exp Parainfluenza Vaccines/ or PIV.mp. or HPIV.mp. or Parainfluenza.mp. 
2. metapneumovirus.mp. or exp Metapneumovirus/ or hMPV.mp. or HMPV.mp. 
3. Bronchiolitis.mp. or Bronchiolitis/ or Bronchiolitis, Viral/  
4. exp Respiratory Tract Diseases/  
5. exp Respiratory Tract Infections/  
6. acute respiratory infections.mp.  
7. exp Pneumonia, Viral/ or *Pneumonia/  
8. exp Pneumonia, Viral/ or exp Pneumonia/ or Pneumonia.mp.  
9. acute lower respiratory infections.mp.  
10. exp Incidence/ or exp Prevalence/ or proportion.mp. or Morbidity/ or exp Child Mortality/ or 
exp Infant Mortality/ or exp Hospital Mortality/ or *Hospital Mortality/ or hospitalization 
rate.mp. or hospitalisation rate.mp. or exp Death/ or exp "Cause of Death"/  or 
burden.mp.  
11. 1 or 2  
12. 3 or 4 or 5 or 6 or 7 or 8 or 9 
13. 10 and 11 and 12 
14. limit 13 to (humans and ("all infant (birth to 23 months)" or "newborn infant (birth to 1 
month)" or "infant (1 to 23 months)" or "preschool child (2 to 5 years)")) 
15. limit 14 to yr="1995 –2017" 
 
Embase (Ovid)  
1. exp parainfluenza vaccine/ or exp parainfluenza virus infection/ or para influenza virus.mp. 
or Parainfluenza virus.mp. or parainfluenza viruses.mp. or Parainfluenzavirus.mp. or 
virus,parainfluenza.mp. or PIV.mp. or hpiv.mp. or exp Paramyxovirinae/ 
2. exp metapneumovirus/ or exp Metapneumovirus infection/ or mpv.mp. or hmpv.mp.  
3. exp respiratory tract infection/ or exp pneumonia/ or exp bronchiolitis/ or exp viral 
bronchiolitis/  
4. exp incidence/ or exp prevalence/ or proportion.mp. or exp morbidity/ or hospitalization 
rate.mp. or hospitalisation rate.mp. or exp hospital mortality/ or exp mortality/ or exp childhood 
mortality/ or exp infant mortality/ or exp death/ or exp child death/ or burden.mp. 
5. 1 and 3 and 4 
6. 2 and 3 and 4 
7. limit 5 to (human and (infant <to one year> or preschool child <1 to 6 years>))  
8. limit 6 to (human and (infant <to one year> or preschool child <1 to 6 years>))  
9. 7 or 8 
10. limit 9 to yr="1995 –2017" 
 
Global Health (Ovid)  
1. exp parainfluenza/ or exp parainfluenza viruses/ or exp human parainfluenza virus 1/ or exp 
human parainfluenza virus 2/ or exp human parainfluenza virus 3/ or exp human 
parainfluenza virus 4/ or HPIV.mp. or PIV.mp.  
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2. exp metapneumovirus/ or exp human metapneumovirus/ or human metapneumovirus.mp. 
or metapneumovirus.mp.  
3. exp respiratory diseases/ or exp bronchiolitis/ or exp lower respiratory tract infections/ or 
exp pneumonia/ or (respiratory diseases or lower respiratory tract infections).sh. or exp 
pneumonia/ or pneumonia.mp. or exp bronchiolitis/ or bronchiolitis.mp.  
4. exp incidence/ or proportion.mp. or exp morbidity/ or hospitalization rate.mp. or 
hospitalisation rate.mp. or exp infant mortality/ or exp neonatal mortality/ or exp mortality/ or 
exp death/ or exp "causes of death"/  
5. 1 or 2 
6. 5 and 3 and 4  
7. limit 6 to yr="1995 –2017" 
 
CINAHL  
TI parainfluenza OR TI HPIV  
TI metapneumovirus OR TI HMPV 
AND TI acute respiratory infection 
AND TI children 
1995–2017 
 
Global Health Library 
(tw:(parainfluenza)) OR (tw:(piv)) OR (tw:(hpiv)) OR (tw:(metapneumovirus)) OR (tw:(mpv)) 




Web of Science 
TITLE: (parainfluenza) OR TITLE: (HPIV) OR TITLE: (metapneumovirus) OR TITLE: (HMPV)  
AND Title= (Acute Respiratory Infections) OR Title= (Pneumonia) 




Topic: respiratory infections or pneumonia or bronchiolitis  
And topic: parainfluenza virus or metapneumovirus  
And topic: prevalence or deaths or incidence or disease burden or hospitalisation 




Topic: respiratory infections or pneumonia or bronchiolitis  
And topic: parainfluenza virus or metapneumovirus  
And topic: prevalence or deaths or incidence or disease burden or hospitalisation rate 




Any field: parainfluenza virus or metapneumovirus 
AND title or key words: respiratory infection or respiratory tract infection or pneumonia or lung 
infection or severe pneumonia or bronchiolitis 
Global burden of acute lower respiratory infection (ALRI) associated with influenza virus, human 
metapneumovirus, and human parainfluenza virus among children under five years 
Appendices  218 
AND title or key words: incidence or prevalence or death or hospitalisation or burden of 
disease 
AND title or key words: children or infant. 
1995–2017 
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A4. Case definitions 
Virus refers to any of IFV, hMPV, and hPIV.  
For community–based studies: 
❖ Virus–associated ALRI: cough or difficulty breathing with increased respiratory rate 
for age (cut–offs same as in WHO IMCI case definition) AND laboratory confirmed 
virus. 
❖ Virus–associated severe ALRI:  
➢ For 2–59 months: cough or difficulty in breathing with chest wall indrawing AND 
laboratory confirmed virus; 
➢ For 0–1 months: increased respiratory rate (over 60 breaths per minute) OR 
chest wall indrawing AND laboratory confirmed virus.  
❖ Virus–associated very severe ALRI: cough or difficulty breathing with any danger 
signs (cyanosis, difficulty breastfeeding or drinking, vomiting everything, 
convulsions, lethargy, or unconsciousness, head nodding) AND laboratory confirmed 
virus. 
For hospital–based studies:  
❖ Hospitalised virus–associated ALRI: physician confirmed diagnosis of ALRI 
(pneumonia or bronchiolitis) that are hospitalised, or being recommended 
hospitalisation AND laboratory confirmed virus. 
❖ Hypoxaemia: 
➢ at altitude <=2500 meters, SpO2 <90% in children aged 1–59 months and <88% 
for neonates (at sea level);  
➢ at altitude >2500 meters, SpO2 <87% in children aged 1–59 months and <85% 
for neonates. 
❖ Hospitalised virus–associated ALRI with hypoxaemia: hospitalised ALRI with 
hypoxaemia (as defined above) AND laboratory confirmed virus. 
❖ Hospitalised virus–associated very severe ALRI: hospitalised ALRI with any danger 
signs (cyanosis, difficulty in breastfeeding or drinking, vomiting everything, 
convulsions, lethargy, or unconsciousness, head nodding) OR proxies for very 
severe disease – requiring mechanical ventilation OR ICU admission AND 
laboratory confirmed virus.  
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A5. Assessment tool for risk of bias 
Assessment tool for community–based studies 
Category Description Risk of bias 
Study design Studies where the cases were prospectively 
enrolled 
Low 
Other studies High 
Patient groups 
excluded 
No exclusions that may affect estimates Low 
Any of the following:  
1. Not including very young children (e.g., 
neonates). 
2. Excluding children with high–risk conditions. 
3. Other exclusions that may affect estimates 
High 
Case definition Using standardised case definitions Low 




The proportion of testing is available AND 
either of the following:  
1. At least 90% of eligible cases were tested.  
2. Testing a systematic sample of patients. 
Low 
Less than 90% of eligible cases were tested  
OR  
The proportion of testing is unavailable. 
High 
Diagnostic test PCR;  
Or using other diagnostic tests, but confirming 
negative samples with PCR 
Low 
1. Other diagnostic tests, e.g., culture, IFA, 
DFA.  
2. No mention of diagnostic tests 
High 
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Assessment tool for hospital–based studies 
Category Description Risk of bias 
Study design Studies where the cases were 
prospectively enrolled 
Low 







Either of the following:  
1. Including all hospitals or main 
hospitals;  
2. Adjusting for proportion of patients of 
the catchment area seeking care in 
other hospitals.  
Low 
No related information AND no 
adjustment for the proportion of patients 





No exclusions that may affect estimates Low 
Any of the following:  
1. Not including very young children 
(e.g., neonates). 
2. Excluding children with high–risk 
conditions. 
3. Other exclusions that may affect 
estimates 
High 
Case definition Using standardised definitions Low 
Using non–standardised definitions High 
Sampling strategy The proportion of testing is available 
AND either of the following:  
1. At least 90% of eligible patients were 
tested.  
2. Testing a systematic sample of 
patients. 
Low 
Less than 90% of eligible cases were 
tested  
OR  
The proportion of testing is unavailable. 
High 




Or using other diagnostic tests, but 
confirming negative samples with PCR 
Low 
1. Other diagnostic tests, e.g., culture, 
IFA, DFA.  




for studies with 
hypoxaemia data) 
SpO2 was recorded for all virus–
confirmed cases 
Low 
SpO2 was recorded for a proportion of 
virus–confirmed cases.  
High 
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OR 
No related information. 
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A6. Data imputation – sensitivity analysis 
Details of data imputation is presented in Chapter 2. In the previous analysis for IFV, missing 
rates were imputed using median rate ratios (Nair et al. 2011). Briefly, rates were imputed 
based on median rate ratios and the data in the reference age group. Unlike the multiple 
imputation approach, there was one imputed number (one imputed data point) for one study. 
The results from the median rate ratio approach and the multiple imputation approach are in 
Table A6–1.  
Table A6–1: Pooled incidence rates of IFV–associated respiratory infections for 0–59 months 
in the community setting using two imputation approaches. * 
 Excluding imputed 
data 
 Including imputed data 











 8 (3) 135.5 (84–211.3)  175.2 (101.5–
302.3)§ 








3 0.7 (0.1–3.9)  4 (1) 0.7 (0.2–2.9)  0.7 (0.2–2.7) 
 
 
* Rates in high child mortality countries 
† No: number of studies. Data in parentheses was the number of imputed studies.  
‡ Rate: per 1,000 children per year. Incidence rate for community-based studies.  
§ A higher rate ratio was estimated between 0–59 m and 0-11 m (or 0–23 m) using the 
multiple imputation approach compared with the median rate ratio approach. This was 
mainly driven by one large study in Bangladesh in which the incidence rates of IFV-episodes 
increased with age. Unlike the median rate ratio, the rate ratio from a meta-analysis was 
influenced by the sizes of individual studies. Then the higher rate ratio translated to the 
higher incidence rates after imputation. 
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Table A6–2. Pooled incidence rates of hMPV–ALRI for 0–59 months including and excluding 
imputed data* 
 Pooled rates with imputed data  Pooled rates without imputed 
data 
 No of studies Rate  No of studies Rate 
Low child mortality 4 (3) 22.3 (12.3–
40.6) 
 1 17.5† 
High child mortality 5 (1) 21.2 (17.1–
26.2) 
 4 23.0 (19.6–
26.9) 
 
Table A6–3. Pooled incidence rates of hPIV–ALRI for 0–59 months including and excluding 
imputed data‡ 
 Pooled rates with imputed data  Pooled rates without imputed 
data 
 No of studies Rate  No of studies Rate 
Low child mortality  4 (3) 45.5 (22.7–
91.0) 
 1 18.8§ 
High child mortality 7 (3) 42.5 (31.2–
57.8) 
 4 33.4 (25.4–
43.8) 
 
* Using multiple imputation method.  
† Only one study reported data for 0-59 months in low child mortality settings. 
‡ Using multiple imputation method.  
§ Only one study reported data for 0-59 months in low child mortality settings.  
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hCFRs were not adjusted for the under–detection; only tested cases and deaths were 
included in the analysis. For the three viruses, the hCFR of tested ALRI cases was higher 
than the hCFR of untested ALRI cases (Table A7–2, A7–3, and A7–4).  
Table A7–2. Testing for IFV – the hCFR for tested ALRI cases and the hCFR for untested 

























1156 21 502 21 1.8 6.6 
Togo; 2011–
2013; 2014–2015 
155 2 10 2 1.3 20 
South Africa; 
1998 to 2005 
2602 138 119 138 5.3 26.9 
Mozambique; 
2011–2014 
411 11 11 11 2.7 18.2 
Kenya; 2007–
2016 
2994 102 1102 102 3.4 7.6 
Viet Nam; 2008–
2013 
422 0 0 0 0 NA 
Germany; 2010–
2014 
2630 9 0 9 0.3 NA 
Gambia; 2011–
2013 
626 17 12 17 2.7 41.7 
Thailand; 2005–
2011 
7895 16 21618 16 0.2 0.4 
Panama; 2012–
2014 
912 5 3175 5 0.5 0.8 
Argentina; 
2008–2010 
25 0 0 0 0 NA 
South Africa; 
2012–2016 
206 2 33 2 1 3 
Guatemala; 
2010–2016 
1753 49 405 49 2.8 0.2 
Guatemala; 
2010–2016 
1499 56 289 56 3.7 0.3 
Argentina; 
2009–2016 
4666 59 265 59 1.3 0.4 
South Africa; 
2015–2017 
4400 18 5329 18 0.4 4.6 
Morocco; 2010–
2011 
789 30 0 30 3.8 NA 
Zambia; 2011–
2013 
603 108 14 108 17.9 64.3 
South Africa; 
2011–2013 
917 37 3 37 4 0 
Chile; 2012–
2013 
464 2 17 2 0.4 0 
Chile; 2012–
2013 
679 3 4 3 0.4 0 
Meta–estimates     1.3 (0.8–2.1) 3.4 (1.2–
9.3) 
 
* NA: not applicable.  
Global burden of acute lower respiratory infection (ALRI) associated with influenza virus, 
human metapneumovirus, and human parainfluenza virus among children under five years 
Appendices  227 
Table A7–3. Testing for hMPV – the hCFR for tested ALRI cases and the hCFR for untested 





























Lusaka, Zambia 2012–2013 590 105 16 9 17.8 56.3 
Bamako, Mali 2012–2014 659 100 1 0 15.2 0 
Kilifi, Kenya 2011–2013 566 27 2 2 4.8 100 
Soweto, South Africa 2011–2013 866 33 8 0 3.8 0 
Manhiça, 
Mozambique 
2011–2013 477 6 15 7 1.3 46.7 
Soweto, South Africa 2000–2002 1409 66 235 25 4.7 10.6 
Kilifi, Kenya 2007–2011; 
2013–2016 
2758 93 803 79 3.4 6.2 
Berlin, Germany 2010–2014 2516 9 9 0 0.4 0 
Klerksdorp, South 
Africa 
2010–2015 1259 31 45 2 2.5 4.4 
Pietermaritzburg, 
South Africa 
2010–2015 2164 18 52 1 0.8 1.9 
Aurora, Colorado, 
USA 
2010–2016 6424 60 9261 18 0.9 0.2 
Basse, Gambia 2012–2013 623 17 12 5 2.7 41.7 





* Studies with small number of ALRI deaths (<5 ALRI deaths) were excluded in this analysis. 
The hCFRs in these studies were very imprecise. Also, very few hMPV-deaths would be 
missed due to under-detection.  
† Studies were not included if all ALRI cases were tested. 
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Table A7–4. Testing for hPIV – the hCFR for tested ALRI cases and the hCFR for untested 


































93 1270 79 3.4 6.2 
Basse, Gambia 2012–2013 623 17 12 5 2.7 41.7 
Lusaka, Zambia 2011–2014 590 105 16 9 17.8 56.2 
Soweto, South Africa 2011–2013 866 33 8 0 3.8 0 
Kilifi, Kenya 2011–2013 566 27 2 2 4.8 100 
Bamako, Mali 2012–2014 659 100 1 0 15.2 0 





227 1626 25 1.8 1.5 
Manhiça, Mozambique 2011–2014 478 12 14 2 2.5 14.3 
Soweto, South Africa 1998–2005 260
2 










18 52 1 0.8 1.9 
Colorado, United 
States of America 
2010–2016 642
4 
60 9261 18 0.9 0.2 
Berlin, Germany 2010–2014 251
2 
9 13 0 0.4 0 





* Studies with small number of ALRI deaths (<5 ALRI deaths) were excluded in this analysis. 
The hCFRs in these studies were very imprecise. Also, very few hPIV-deaths would be 
missed due to under-detection.  
† Studies were not included if all ALRI cases were tested.  
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A8. IFV –sensitivity analysis of morbidity and in–hospital mortality in different 
stratification groups 
Table A8–1 shows the IFV–ALRI hospitalisations in the stratified analysis by World Bank 
income regions and country development status where available.  
Table A8–2 shows the IFV–ALRI in–hospital deaths in the stratified analysis by World Bank 
income regions and country development status where available. 
Table A8–3 shows the IFV–ALRI hospitalisations and in–hospital deaths after excluding pre–
2009 data.  
Table A8–4 shows the number of IFV–episodes and IFV–ALRI cases in the stratified 
analysis by country development status.  
Table A8–5 shows the incidence of IFV-severe ALRI and IFV-very severe ALRI and the 
number of cases by child mortality settings. 
Table A8–6 shows the hospitalisation rates of IFV–ALRI using the classical random–effect 
model. 
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Table A8–1. Hospitalisation rates (per 1,000 children per year) and hospitalisations for IFV–ALRI by World Bank income regions and country 
development status.* 




Developing Industrialised Global estimates by 
development status 
0–5 m (A) No. of studies 13 9 13  24 11  
 Hospitalisation rate 
(/1,000) 




 2.8 (1.8–4.3) 3.7 (2.7–5.3)  
 Hospitalisations 
(*1,000) 
80 (48–133) 68 (34–138) 28 (20–
40) 
176 (101–311) 174 (113–268) 26 (18–36) 200 (131–304) 
6–11 m (B) No. of studies 11 8 9  21 7  
 Hospitalisation rate 
(/1,000) 




 2.7 (1.7–4.3) 2.6 (0.9–7.6)  
 Hospitalisations 
(*1,000) 
66 (43–102) 70 (32–154) 22 (9–55) 158 (83–311) 166 (105–264) 18 (6–52) 185 (111–317) 
12–59 m 
(C) 
No. of studies 17 11 20  35 13  
 Hospitalisation rate 
(/1,000) 
0.8 (0.5–1.3) 0.8 (0.3–2) 1.2 (0.6–
2.2) 
 0.9 (0.6–1.5) 0.9 (0.4–1.8)  
 Hospitalisations 
(*1,000) 

















94 (48–194) 870 (543–1,415) 
 
* Hospitalisation rates from meta-analysis. Global estimates were the sum of estimates by age and regions.  
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Region 0–5 m  6–11 m  12–59 m 
 No‡  Rate §  No Rate  No Rate 
HICs 13 4.4 (2.6-7.5)  9 3.6 (1.1–
11.1) 
 20 1.2 (0.6–
2.6) 
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A9. hMPV –sensitivity analysis of morbidity and in–hospital mortality in 
different stratification groups 
Table A9–1 shows the hMPV–ALRI hospitalisations in the stratified analysis by World Bank 
income region and country development status where available.  
Table A9–2 shows the hMPV–ALRI in–hospital deaths in the stratified analysis by World 
Bank income region and country development status where available. 
Table A9–3 shows the hMPV–ALRI in–hospital deaths for 2010. Data were included in the 
analysis if they were from the time points before 2010; or part of the data were from the time 
points before 2010 (only for studies in which the data were not stratified by years).  
Table A9–4 shows the number of hMPV–ALRI cases by country development status.  
Table A9–5 shows the number of hMPV–severe ALRI cases in high child mortality settings. 
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Table A9–2. The hCFRs (%) and in–hospital deaths of hMPV–ALRI by World Bank income regions and country development status*  




Global by country 
development 
status 
 No. of studies 15 6 7  23 5  
0–5 m (A) hCFR (%) 4.5 (2.3–8.6) 1.7 (0.6–5.1) 0.4 (0–8.6)  3.2 (1.7–6) 0.4 (0–8.5)  
 Deaths 4300 (2000–
9200) 




100 (0–3500) 5000 (2300–13700) 
6–11 m (B) hCFR (%) 0.7 (0–9)  ..† 0.6 (0.1–3.9)  0.2 (0–7) 0.6 (0.1–4)  
 Deaths 900 (0–37800) NA 100 (0–700) 1000 (0–38500) 300 (0–12400) 100 (0–700) 500 (0–13100) 
12–59 m (C) hCFR (%) 0.9 (0.3–2.8) 1.1 (0.1–9.1) 0.5 (0–7)  0.8 (0.2–3.6) 0.3 (0–3)  















300 (0–5900) 7500 (2800–36800) 
 
* hCFRs from meta-analysis. Global estimates were the sum of estimates by age and regions.  
† All studies reported no MPV-ALRI deaths, so it was impossible to compute hCFR and the number of deaths.  
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Table A9–3. The hCFRs (%) and in–hospital deaths of hMPV–ALRI for 2010 by the child mortality setting.*† 
Age  Low child mortality High child mortality 
Global estimates by child 
mortality settings 
0–5 m (A) No. of studies 6 4  
 hCFR (%) 0.9 (0.2–3.5) 2.9 (0.9–8.5)  
 Deaths 600 (100–2600) 6100 (1700–21200) 6600 (1800–23800) 
6–11 m (B) No. of studies 6 4  
 hCFR (%) 2.2 (0.5–8.2) ..‡  
 Deaths 1300 (300–5000) NA 1300 (300–5000) 
12–59 m (C) No. of studies 9 4  
 hCFR (%) 0.9 (0.3–2.8) 0.3 (0.0–2.4)  
 Deaths 900 (100–7400) 700 (0–15600) 1600 (100–22900) 
0–59 m 
(A+B+C) 
Deaths 2800 (500–15100) 6800 (1700–36800) 9600 (2300–51200) 
 
Table A9–4. The incidence and number of hMPV–ALRI cases for 0–59 months by World Bank income regions and country development status. § 





Global by country 
development status 
No. of studies 4 (1) 2 (1) 3 (2)  6 (2) 3 (2)  






 19.5 (15–25.3) 27.4 (14.6–51.3)  














* Only the hospitalisation rate and hCFR data before 2010 (or partly before 2010) were included in this analysis. The population estimates for 2010 were 
used.  
† hCFR from meta-analysis. Global estimates were the sum of estimates by age and regions.  
‡ All studies reported zero MPV-ALRI death for this strata, so it was impossible to compute hCFR and the number of deaths.  
§ Incidence rates from meta-analysis. Global estimates were the sum of estimates by regions.  
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A10. hPIV –sensitivity analysis of morbidity and in–hospital 
mortality in different stratification scenarios 
Table A10–1 shows the hPIV–ALRI hospitalisations in the stratified analysis by World Bank 
income regions and country development status where available.  
Table A10–2 shows the hPIV–ALRI in–hospital deaths in the stratified analysis by World 
Bank income regions and country development status where available. 
Table A10–3 shows the incidence and number of hPIV-ALRI cases for 0–59 months by 
country development status.  
Table A10–4 shows the incidence and number of hPIV–severe ALRI cases in high child 
mortality settings. 
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Table A10–2. The hCFRs (%) and in–hospital deaths of hPIV–ALRI by World Bank income regions and country development status.* 





Global by country 
development 
status 
 No. of studies 15 8 4  25 2  
0–5 m (A) hCFR (%) 3.9 (2.1–7.3) 2.4 (1.3–4.6) 0.9 (0.2–3.6)  3.2 (2.0–5.0) 1.0 (0.3–3.9)  














hCFR (%) 3.5 (2.2–5.6) 1.9 (0.8–4.1) 0.9 (0.4–1.9)  2.6 (1.2–5.8) 1.3 (0.3–4.9)  














hCFR (%) 2 (0.5–7.4) 3.8 (2.2–6.6) 1.2 (0.3–4.7)  2.7 (1.8–4.1) 0.9 (0.4–2.0)  

























* hCFRs from meta-analysis. Global estimates were the sum of estimates by age and regions.  
† There was only one study with hPIV-ALRI hospitalisation rates, thus it was impossible to estimate the hPIV-ALRI hospitalisations and in-hospital 
deaths.  
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A11. Estimating hospitalisations of hMPV–ALRI and hPIV–ALRI 
using the proportion–based approach 
Table A11–1. The proportion of hospitalised hMPV–ALRI for 0–59 months by World Bank 




Proportion (%) for 0–59 m 
All studies with data for 0–59 months 78 5.8 (5.0–6.6) 
By World Bank income regions   
Low income 4 6.5 (5.3–7.9) 
Middle income 59 5.6 (4.8–6.5) 
High income 15 6.2 (4.5–8.5) 
 
Table A11–2. The proportion of hospitalised hPIV–ALRI for 0–59 months by World Bank 




Proportion (%) for 0–59 m 
All studies with data for 0–59 months 91 8.7 (7.5–10.2) 
By World Bank income regions   
Low income 4 11.1 (6.1–19.3) 
Middle income 70 9.1 (7.5–10.9) 
High income 17 6.7 (5.3–8.5) 
 





Proportion (%) of 
virus–ALRI for 0–59 m 
Hospitalisation




hMPV 78 5.8 (5.0–6.6) 5,133–16,400 
(McAllister et al. 
2018, Troeger 
et al. 2018) 
298 – 951 




* Estimated by applying the point proportion of virus–ALRI to the ranges of hospitalisations of 
ALRI.  
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Table A12–1. Estimating the IFV–ALRI overall mortality using Approach IFV 2. * 







































2010-2015 South Africa 4.6 125 3.7 7105 264 98 2.7 
2012-2016 Mozambique 4.5 151 3.0 11769 351 104 3.4 
2008; 2010-2015 Kenya (Nairobi) -13.5 244 -- 10584 -- 142 -- 
2010-2016 Kenya (Siaya) 50.1 1261 4.0 10584 421 142 3.0 
The IFV–ALRI in–hospital deaths for a given country (f) were estimated using the location–matched hospitalisation rate and hCFR data (site–matched 
data in Siaya, Kenya and Manhiça, Mozambique; country–matched data in South Africa). For Bangladesh, we used the hCFR meta–estimate in 
developing countries because site– or country–matched data were unavailable (Table A12–2). Estimation was done as shown in the following formula: 
Country IFV–ALRI in–hospital deaths = U5 population ∗ U5 Hos Rate ∗ U5 hCFR 
Table A12–2: In–hospital deaths data and population–based pneumonia deaths data by site 
Site and period (population–based pneumonia deaths and IFV 
activity) 
Site and period (in–hospital IFV–ALRI deaths) (f) 
Nairobi (Kenya), 2008, 2010–2015 Siaya (Kenya), 2010–2014 
Siaya (Kenya), 2010–2016 Siaya (Kenya), 2010–2014 
Bangladesh, 2010–2012 Meta–estimates in developing countries 
Manhiça, Mozambique, 2012–2016‡(Nguenha et al. 2018) Manhiça, Mozambique, 2011–2014 
Agincourt, South Africa, 2010–2015 Paarl, Soweto, Klerksdorp, Pietermaritzburg, 2010–; Soweto, 1998–2005 
 
* PNE: pneumonia. IFV: influenza virus. U5: children under five years.  
† Estimated by summing up overall mortality in developing (inflation factor = 3.0) and industrialised countries (inflation factor = 1.6) 
‡ Local IFV and RSV activity data in Manhiça, Mozambique were available during Jan 2012-June 2014, but unavailable during July 2014-Dec 2016. For 
IFV, we used the data in neighbouring areas (distance <100 kilometres). For RSV, the average proportions of RSV during Jan 2012-Dec 2013 were 
extrapolated to Jan-Dec 2014.  
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Step (1) of Approach IFV 3: the proportion of virus–ALRI deaths in total ALRI deaths 
The proportion of IFV–ALRI deaths in total ALRI deaths was estimated using the following 
formula: 
% 𝐼𝐹𝑉 𝑖𝑛 𝐴𝐿𝑅𝐼 𝑑𝑒𝑎𝑡ℎ𝑠 =  
∑ (
PropIFVi ∗ RiskDeathIFV
(PropIFVi ∗ RiskDeathIFV + (1 − PropIFVi) ∗ 1.00







Using Approach IFV 3, the CFR for IFV–ALRI was considered to be constant throughout a 
year. The samples at data–existing sites were mostly from children under five years with 
severe acute respiratory infections; the proportion of IFV in these samples considered a 
proxy of that in ALRI cases. The risk of death from IFV compared with non–IFV–ALRI was 
0.56 (1.9/3.4) according to (1) the hCFR of IFV–ALRI versus the hCFR of non–IFV–ALRI 
using data from eight hospital–based studies in low– and middle–income countries (1.9 
[95%CI 0.5–6.6)] vs 3.4 [95%CI 1.6–7.3], Table A12–4 and Table A12–5). For this approach, 
the bias mainly came from the ratio of case–fatality of IFV–ALRI to non–IFV–ALRI. 
Alternative estimates of this ratio were not identified in published reports. The variation in 
observed influenza activity between months was assumed to be generalisable to children 
who were not tested. Moreover, it was assumed that the testing practice remained stable 
throughout a year. Other details of the estimation using Approach IFV 3 is in Table A12–3. 
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Table A12–3. Estimating the overall IFV–ALRI mortality using Approach IFV 3* 







































2010-2015 South Africa 5.4 125 4.3 7105 307 98 3.1 
2012-2016 Mozambique 5.9 151 3.9 11769 460 104 4.4 
2008; 2010-2015 Kenya (Nairobi) 14.6 244 6.0 10584 633 142 4.5 
2010-2016 Kenya (Siaya) 69.8 1261 5.5 10584 586 142 4.1 
 
Table A12–4. hCFR meta–estimates for IFV–positive ALRI cases, IFV–negative ALRI, and for untested ALRI cases. ‡ 
 hCFR in IFV cases (%) hCFR in IFV negative 
cases (%) 
hCFR in non–test 
cases (%) 
hCFR in all non–IFV cases 
(%) 
0–5 m 1.1 (0.1–19.4) 5.0 (2.5–10.0) 10.4 (1.9–41.1) 5.5 (2.8–10.5) 
6–11 m 3.1 (0.8–11.0) 3.1 (1.2–8.1) 11.1 (0.9–62.9) 3.7 (1.6–8.5) 
12–59 m 1.4 (0.4–5.6) 1.4 (0.5–3.9) 16.4 (2.5–59.9) 2.0 (0.8–4.8) 
0–59 m 1.9 (0.5–6.6) 2.8 (1.2–6.5) 13.5 (3.1–43.7) 3.4 (1.6–7.3) 
 
* PNE: pneumonia. IFV: influenza virus. U5: children under five years.  
† Estimated by summing up overall mortality in developing (inflation factor = 3.4) and industrialised countries (inflation factor = 1.6) 
‡ Meta-estimates were based on the data in eight studies in low- and middle-income countries providing relevant data by three age bands and 
testing >=90% of eligible ALRI cases.  
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Table A12–5. Tested/untested hospitalised ALRI cases/deaths in eight studies in low– and middle–income countries with available data.* 












Gambia; 2011–2013 0–5 m 0 17 5 239 0 3 
Morocco; 2010–2011 0–5 m 0 3 14 125 0 0 
Mozambique; 2011–2014 0–5 m 0 5 5 108 0 1 
South Africa; 1998 to 2005 0–5 m 1 28 92 934 17 42 
South Africa; 2011–2013 0–5 m 0 18 17 437 0 3 
Thailand; 2005–2011 0–5 m 0 34 5 669 26 1961 
Togo; 2011–2013; 2014–2015 0–5 m 0 1 2 33 1 5 
Zambia; 2011–2013 0–5 m 3 11 58 310 4 6 
Gambia; 2011–2013 6–11 m 0 4 5 135 2 5 
Morocco; 2010–2011 6–11 m 0 9 8 126 0 0 
Mozambique; 2011–2014 6–11 m 1 7 2 90 0 4 
South Africa; 1998 to 2005 6–11 m 2 20 24 585 5 21 
South Africa; 2011–2013 6–11 m 1 15 13 211 0 0 
Thailand; 2005–2011 6–11 m 0 110 3 1437 22 3846 
Togo; 2011–2013; 2014–2015 6–11 m 0 5 0 18 0 2 
Zambia; 2011–2013 6–11 m 1 7 28 139 3 3 
Gambia; 2011–2013 12–59 m 0 12 7 219 3 4 
Morocco; 2010–2011 12–59 m 1 16 7 510 0 0 
Mozambique; 2011–2014 12–59 m 0 11 3 190 2 6 
South Africa; 1998 to 2005 12–59 m 1 50 18 985 10 56 
South Africa; 2011–2013 12–59 m 1 21 5 239 0 0 
Thailand; 2005–2011 12–59 m 1 559 7 5086 30 15811 
Togo; 2011–2013; 2014–2015 12–59 m 0 14 0 84 1 3 
Zambia; 2011–2013 12–59 m 2 13 21 144 2 5 
 
* Only including studies testing >=90% of ALRI cases.  
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A13. Adjustment for missing hPIV–4. 
Since a mix of three–type (hPIV–1 to hPIV–3) and four–type (hPIV–1 to hPIV–4) data were 
included, incidence rates, hospitalisation rates, proportions, and hCFRs were adjusted to 
account for the missing hPIV–4 at study levels as presented in Chapter 6. Two key 
parameters used in the adjustment were estimated in Table A13–1 and Table A13–2. Table 
A13–3 shows the unadjusted estimates and the adjusted estimates for each outcome.  
Table A13–1. The prevalence of each hPIV type for children aged 0–59 months.* 
 High child mortality Low child mortality All studies 
No. of studies 16 9 25 
Prevalence of hPIV–1 (%) 29.1 (23.7–35) 21.0 (14.4–29.6) 26.1 (21.6–
31.2) 
Prevalence of hPIV–2 (%) 10.7 (7.5–14.9) 6.3 (2.8–13.5) 8.9 (6.2–12.6) 
Prevalence of hPIV–3 (%) 47.2 (40.3–54.1) 57.3 (46.5–67.5) 50.6 (44.4–
56.8) 
Prevalence of hPIV–4 (%) 12.3 (7.3–19.8) 11.8 (7.3–18.4) 12.2 (8.5–17.2) 
Table A13–2. The prevalence of each hPIV type in hPIV–ALRI deaths for children aged 0–59 
months.† 
 Prevalence in 
cases (%) 
hCFR (%) Prevalence in 
deaths (%) 
hPIV–1 26.1 9.4 (5.4–15.8) 35.7 
hPIV–2 8.9 9.1 (3.8–20.1) 11.4 
hPIV–3 50.6 6.0 (3.4–10.3) 47.1 
hPIV–4 12.2 3.7 (0.6–19.1) 5.7 
 
Based on the prevalence of four hPIV types and the ratio of case–fatality of hPIV–4 to the 
other three types, hPIV–4 was estimated to account for about 6% of hPIV–associated ALRI 
deaths, and hPIV–1 to hPIV–3 for 94% of hPIV–associated ALRI deaths.  
Table A13–3. The unadjusted and adjusted burden estimates of hPIV–ALRI for children 
under five years by outcome.‡  




Global hPIV–ALRI cases in the community 
(*1,000) 
25,649 (UR 18,284–38,000) 29,478 (UR 19,240–
46,714) 
Global hPIV–ALRI hospitalisations (*1,000) 
  
Using the incidence–based approach 947 (UR 561–1,644) 1,007 (UR 601–1,750) 
Using the proportion–based approach 411–1,312 447–1,427 
Global hPIV–ALRI in–hospital deaths 26,400 (UR 12,300–58,300) 25,700 (UR 12,000–
56,500) 
 
* Data were from hospital-based studies; data were eligible if there were at least five hPIV-
ALRI cases, and four hPIV types were detected.  
† Data were from five hospital-based studies where at least 90% of cases were tested, and 
there were at least five hPIV-positive ALRI deaths. Data were from Zambia, South Africa, 
Mali, Morocco, Philippines.  
‡ Data were adjusted to account for missing hPIV–4 in incidence rates, hospitalisation rates 
and hCFRs.  
Global burden of acute lower respiratory infection (ALRI) associated with influenza virus, 
human metapneumovirus, and human parainfluenza virus among children under five years 
Appendices  250 
A14. Sensitivity analysis of hMPV–associated and hPIV–
associated ALRI overall mortality in high child mortality settings 
In sensitivity analysis, overall hMPV– and hPIV–ALRI mortality in high child mortality settings 
were estimated using the following formula:  
Overall virus_ALRI mortality = %𝑣𝑖𝑟𝑢𝑠 𝑖𝑛 𝐴𝐿𝑅𝐼 𝑑𝑒𝑎𝑡ℎ𝑠 ∗ 𝐴𝐿𝑅𝐼 𝑑𝑒𝑎𝑡ℎ𝑠 
hMPV–ALRI overall deaths 
The proportion of hMPV in ALRI deaths was estimated using data from 13 hospital–based 
studies (including five PERCH sites) from the high mortality setting, in which at least 90% of 
ALRI cases were tested and at least five ALRI deaths were enrolled during the study period. 
Although 19% ALRI deaths occurred among neonates, no hMPV deaths were reported in 
hospital–based studies. Thus, the percent of hMPV in ALRI deaths was only estimated for 1–
59 months, and applied to the number of ALRI deaths for the corresponding age band (i.e., 
1–59 m).  
hPIV–ALRI overall deaths 
The proportion of hPIV positives in ALRI deaths was estimated using data from 12 hospital–
based studies (including five PERCH sites) from high mortality settings in which at least 90% 
of ALRI cases were tested and at least five ALRI deaths were identified. All the 12 studies 
detected four hPIV types. In these studies, neonatal hPIV–ALRI deaths were identified. The 
percent of hPIV was estimated for the overall age band (i.e., 0–59 months) as the data were 
insufficient to allow disaggregation by narrower age bands (e.g., 0–27 d and 1–59 m).  
 
Table A14–1. Estimating the overall virus–associated ALRI mortality in high child mortality 








% of virus 
in ALRI 
deaths (C) 
2017 ALRI deaths 




deaths for high child 
mortality settings 
(E=C*D) 
hMPV*† 18 573 3.2% 
(95%CI 1.9–
5.2) 
622,742 for 1–59 m 19,900 (UR 12,100–
33,200) for 1–59 m 
hPIV‡ 42 584 7.3% 
(95%CI 4.6–
11.3) 
769,712 for 0–59 m 56,100 (UR 36,500–
87,400) for 0–59 m 
 
* A meta–analysis was conducted to combine data from 13 studies from Morocco, 
Philippines, Bangladesh, Gambia, Zambia, Mali, Kenya, South Africa, and Mozambique. The 
percent was 3.4% (95%CI 1.8–6.1) when pooling five PERCH sites in Gambia, Zambia, Mali, 
Kenya, and South Africa.  
† The percent of hMPV was estimated for 1–59 m, and only used to yield the hMPV–ALRI 
deaths for 1–59 m.  
‡ A meta–analysis was performed to combine data from 12 studies from Philippines, 
Bangladesh, Gambia, Zambia, Mali, Kenya, South Africa, and Mozambique. The pooled 
percent was 9.4% (95%CI 6.6–13.3) when only pooling five PERCH sites in Gambia, 
Zambia, Mali, Kenya, and South Africa.  
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A15. Estimating the attributable fraction for virus–associated 
ALRI cases 
Table A15–1. The odds ratios for virus and virus–associated ALRI cases and the 
corresponding attributable fraction (AF).  
 Odds ratios (ORs) Attributable fraction [AF% = (OR–1) 
*100/OR]* 
IFV 5.1 (Shi et al. 2015); 2.8–3.3 (Pneumonia 
Etiology Research for Child Health Study 
Group (PERCH) 2019); 55.2 for IFVA and 3.3 
for IFVB (Benet et al. 2017) 
80% 
hMPV 3.8 (Shi et al. 2015); 4.6 (Pneumonia Etiology 
Research for Child Health Study Group 
(PERCH) 2019); 11.0 (Benet et al. 2017) 
78% 
hPIV 3.4 (Shi et al. 2015) 71% 
hPIV–1 7.5 (Pneumonia Etiology Research for Child 
Health Study Group (PERCH) 2019, Benet et 
al. 2017) 
87% 
hPIV–2 Not significant (1.0–2.0) (Pneumonia Etiology 
Research for Child Health Study Group 
(PERCH) 2019, Benet et al. 2017) 
25% 
hPIV–3 2.6 (Pneumonia Etiology Research for Child 
Health Study Group (PERCH) 2019); 6.7 
(Benet et al. 2017) 
79% 
hPIV–4 1.7 (Pneumonia Etiology Research for Child 
Health Study Group (PERCH) 2019); 2.6 
(Benet et al. 2017) 
55% 
 
Table A15–2. Estimating the average attributable fraction (AF) for hPIV–ALRI.  
 AFi (%)† Prevalence of hPIVi‡ 
Average AF (%) = 
∑ % 𝒉𝑷𝑰𝑽𝒊 ∗ 𝑨𝑭𝒊𝟒𝒊  
hPIV1 87% 26% 73% 
hPIV2 25% 9% 
hPIV3 79% 52% 
hPIV4 55% 12% 
 
* Input OR was the median value of ORs in published multi-country studies.  
† The AFs for each hPIV type are in Table A15-1.  
‡ The estimation of the prevalence of each hPIV type is in Appendix A13. 
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A17. Yearly variation in hospitalisation rates of virus–associated 
ALRI 
 
Figure A17–1. Annual hospitalisation rates of IFV–ALRI in multi–year studies 
 
 
Figure A17–2. Annual hospitalisation rates of hMPV–ALRI in multi–year studies
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Figure A17–3. Annual hospitalisation rates of hPIV–ALRI in multi–year studies
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Figure A18–1. The location of included studies on IFV burden. This figure shows all studies with data on incidence rates, hospitalisation rates, and in–
hospital case–fatality ratios for IFV. 
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Figure A18–2. The location of included studies on hMPV burden. This figure shows all studies with data on incidence rates, 
hospitalisation rates, in–hospital case–fatality ratios, and proportions for hMPV. 
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